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a.u. Arbitrary unit
ACh Acetylcholine
AGS Activator of G protein signaling
Ang II Angiotensin II
APS Ammonium persulfate
AT 1-R Angiotensin 1 receptor
AUC Area under the curve
BRET Bioluminescence resonance energy transfer
BSA Bovine serum albumin
CaMKII Ca2+/calmodulin-dependent kinase II
CCD Charge coupled device
CR Conserved region
CRE cAMP responsive element
DAG Diacylglycerol
Dbl Diffuse B cell lymphoma
DH Dbl homology
ERK5 Extracellular signal regulated kinase  5
ET-1 Endothelin 1
FAK Focal adhesion kinase
FCS Fetal calf serum
FRAP Fluorescence recovery after photobleaching
FRET Fluorescence resonance energy transfer
GAP GTPase activating protein
GDI Guanine nucleotide dissociation inhibitor
GDP Guanosine diphosphate
GEF Guanine nucleotide exchange factor
GFP Green fluorescent protein
GPCR G protein coupled receptor
GRK G protein coupled receptor kinase
GST Glutathione-S-transferase
3Abbreviations
GTP Guanosine-5´-triphosphate
HEK Human embryonic kidney
His Histamine
HRP Horse radish peroxidase
IP3 Inositol 1,4,5 triphosphate
IPTG Isopropyl-β-D-1-thiogalactopyranoside
JNK c-Jun N-terminal kinase
Kir Inward rectifier K+ channel
LARG Leukemia-associated RhoGEF or ARHGEF12 or KIAA0382
M3-R Muscarinic M3 receptor
mDia Mammalian Dia protein or mammalian homolog of Drosophila Diaphanous
MEF Mouse embryonic fibroblast
MLC Myosin light chain
MLCK MLC kinase
MLCP MLC phosphatase
MLK3 Mitogen-activated kinase
MLL Mixed lineage leukemia
mTur2 mTurquoise2
NA Noradrenaline
NFκB Nuclear factor κB
NLS Nuclear localization sequence
NMR Nuclear magnetic resonance spectroscopy
NO Nitric oxide
p115RhoGEF Lymphoid blast crisis like 2 (LSC) or Lip or LBCL2 or ARHGEF1 or SUB1.5
p63RhoGEF GEFT or ARHGEF25
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PDZ Post synaptic density protein, Drosophila disc large tumor suppressor, zonula
occludens-1 protein
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PIP Phosphatidylinositol phosphate
PKC Protein kinase C
PKN Protein Kinase N
PLCβ Phospholipase C β
PVDF Polyvinylidene fluoride
RBD Rho binding domain
RFP Red fluorescent protein
RGS Regulator of G protein signaling
RH RGS homology
Rho Ras homologous
RhoGDI Rho guanine nucleotide dissociation inhibitor
RNAse A Ribonuclease A
ROCK Rho-associated coiled-coil kinase
ROI Region of interest
S1P Sphingosine 1 phosphate
SDS Sodium dodecyl sulfate
SFK Src family kinase
SNP Single nucleotide polymorphism
SRE Serum response element
SRF Serum response factor
t1/2 Half time
Txa2 Thromboxane A2
Txa2-R Thromboxane A2 receptor
V-p63 Venus-p63RhoGEF
VSMC Vascular smooth muscle cell
YFP Yellow fluorescent protein
α1-AR α1 adrenergic receptor
α2A-AR α2A adrenergic receptor
β2-AR β2 adrenergic receptor
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3 Summary
Activation of RhoGTPases downstream of G protein coupled receptors is important for many
physiological functions, such as blood pressure regulation. The subfamilies Rho, Rac and Cdc42 are
the best understood RhoGTPases and the present study focused on signaling towards the Rho
subfamily member RhoA. In its active state RhoA regulates the cytoskeleton by its influence on actin
dynamics, activates important signal transducers such as Rho-associated coiled-coil kinase, which
phosphorylates and thereby inactivates myosin light chain phosphatase and induces gene transcription
via serum response factor.
Most RhoGTPases cycle between a GDP-bound inactive and a GTP-bound active state. The
exchange of GTP for GDP and therefore activation is mediated through Rho guanine nucleotide
exchange factors (RhoGEFs). In the case of RhoA the largest family of RhoGEFs is functionally and
structurally characterized by a DH domain adjunct to a PH domain. The DH domain holds GEF
activity and the PH domain has mainly regulatory functions. Some of these RhoGEFs can be
activated by Gαq/11 and/or Gα12/13 and the present work focused on their regulation: Downstream of
Gα13 RH-RhoGEFs are activated. This group of RhoGEFs shares a regulator of G protein signaling
homology domain (RH) in addition to the DH-PH domain, which is also present in the Gαq-activated
p63RhoGEF. Knock-out of the RH-RhoGEF leukemia-associated RhoGEF (LARG) protects against
salt-induced hypertension in mice and the acute response of vascular smooth muscle cells to
angiotensin II treatment is mediated mainly by p63RhoGEF. For both proteins several other
physiological functions have been described. Nevertheless, little had been known about why
RhoGEFs are activated downstream of two Gα subfamilies and the temporal as well as spatial
dynamics of their receptor-mediated activation. Therefore we developed FRET-based assays
monitoring RhoGEF activation in living cells for the first time.
The Förster resonance energy transfer (FRET) occurs between two fluorophores - in the present study
fused to the proteins of interest - with a distance of less than 10nm. Thus an increase in FRET upon
stimulation with the agonist reflects convergence of the proteins of interest. Changes in FRET were
recorded in single, living cells with a high-speed CCD-camera.
The interaction between LARG and Gα13 was monitored in cells transfected with Gα13-mTur2 and
YFP-LARG. The stimulation of thromboxane A2 receptor induced a robust increase in FRET.
Surprisingly, as shown by the slow decrease in FRET between LARG and Gα13, the interaction of
LARG and Gα13 dissociated very slowly (estimated t1/2>5min) compared to the Gα13 inactivation
(t1/2=17.50s). This observation was also reflected in the kinetics of LARG translocation to the
plasma membrane. Thus LARG and Gα13 interact rapidly upon activation of Gα13, but either LARG
inhibits Gα13 inactivation or stays in a complex with Gα13 after inactivation of the same. In our
opinion the prolonged interaction is most likely the reason for the almost 100-fold higher
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sensitivity towards stimulation with a thromboxane agonist of the Gα13 LARG interaction
compared with the Gα13 activation.
The p63RhoGEF activation was studied by monitoring the interaction of Gαq-CFP and
Venus-p63RhoGEF. A robust increase in FRET was observed upon stimulation of Gαq coupled
receptors. In contrast to the LARG Gα13 interaction, the p63RhoGEF Gαq interaction mirrored closely
the Gαq activation as well as inactivation. In addition also the sensitivity of p63RhoGEF Gαq
interaction and Gαq activation was in the same range (EC50 of 500nM histamine). Both observations
were also true in a trimeric complex of p63RhoGEF and Gαq with the regulator of G protein signaling
RGS2. RGS2 was previously shown to accelerate Gαq inactivation in vitro and consequently we
observed an accelerated dissociation of p63RhoGEF and Gαq in the presence of RGS2. Additionally,
we could monitor an increase in FRET between p63RhoGEF and RGS2, which is the first evidence for
such a trimeric complex in living cells. Thus our data strongly support the concept of a functional
activation-dependent p63RhoGEF Gαq RGS2 complex. In this complex RGS2 inhibits downstream
signaling. This could be an explanation for severe hypertension, which has been observed in RGS2
knock-out mice (Tang et al., 2003).
In summary, LARG as well as p63RhoGEF are both activated upon stimulation of G protein coupled
receptors. Nevertheless LARG´s sensitivity towards receptor activation and duration of signaling
seems to be remarkably higher and longer than p63RhoGEF´s. The inactivation of p63RhoGEF is
further accelerated by RGS2, which also decreases downstream signaling.
Keywords: Förster resonance energy transfer (FRET), Gαq, Gα13, G protein coupled receptor (GPCR),
histaminergic receptor, thromboxane A2 receptor, p63RhoGEF, leukemia-associated RhoGEF
(LARG), regulator of G protein signaling 2 (RGS2)
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Zusammenfassung
Die Aktivierung der RhoGTPasen durch G-Protein gekoppelte Rezeptoren ist wichtig für viele
physiologische Funktionen wie zum Beispiel die Blutdruckregulation. Am besten sind die Unterfamilien
Rho, Rac und Cdc42 der RhoGTPasen verstanden. In der vorliegenden Arbeit liegt der Fokus auf
Signaltransduktions-Mechanismen, welche RhoA - ein Mitglied der Rho Unterfamlie - aktivieren. Aktives
RhoA reguliert zum Beispiel das Zytoskelett durch seinen Einfluss auf die Aktin-Dynamik und reguliert
die Rho-Kinase ROCK, welche die Myosin-Leichtketten-Phosphatase durch Phosphorylierung inaktiviert.
RhoA induziert weiterhin mittels des Serum responsiven Faktors Gentranskription.
Die meisten RhoGTPasen wechseln zwischen einem GDP-gebunden inaktiven und einem
GTP-gebunden aktiven Zustand hin und her. Der Austausch von GDP durch GTP und somit die
Aktivierung wird durch Rho Guanin Austausch Faktoren (RhoGEFs) vermittelt. Die größte Familie
der RhoA-aktivierenden RhoGEFs ist funktionell und strukturell durch eine DH Domäne und eine
direkt anschließenden PH Domäne charakterisiert. Die DH Domäne stellt die GEF Aktivität bereit, die
PH Domäne hat vor allem regulatorische Funktionen. Manche dieser RhoGEFs werden durch Gαq/11
und/oder Gα12/13 aktiviert. Die vorliegende Arbeit beschäftigt sich mit der Regulation dieser RhoGEFs.
Unterhalb von Gα13 werden RH-RhoGEFs aktiviert. Alle RH-RhoGEFs besitzen eine Regulator of
G protein signaling homologe (RH) Domäne zusätzlich zur DH-PH Domäne, welche auch das
Gαq-aktivierte p63RhoGEF besitzt. Nach genetischer Depletion des RH-RhoGEFs LARG sind Mäuse
gegen Salz-induzierten Bluthochdruck geschützt und die akute Reaktion auf Behandlung mit
Angiotensin II fehlt den p63RhoGEF defizienten Mäusen. Für beide Proteine sind weitere
physiologische Funktionen beschrieben. Trotzdem war bisher unklar, warum RhoGEFs durch zwei
Gα-Unterfamilien aktiviert werden. Auch über die zeitliche und räumliche Dynamik der
Rezeptor-vermittelten Aktivierung war wenig bekannt. Deshalb entwickelten wir FRET-basierte
Messmethoden, welche es ermöglichen, die RhoGEF Aktivierung zum ersten Mal in lebenden Zellen
zu beobachten. Förster Resonanz Energie Transfer (FRET) findet zwischen zwei Fluorophoren
statt - in dieser Studie sind die Fluorophore an interessierende Proteine fusioniert –, welche einen
Abstand von höchsten 10nm besitzen. Daher reflektiert ein Anstieg im FRET nach Stimulation mit
dem Agonisten die Annäherung der interessierenden Proteine. In einzelnen, lebenden Zellen wurden
Änderungen in FRET mit einer Hochgeschwindigkeitskamera detektiert.
Die Interaktion zwischen LARG und Gα13 wurde in Zellen beobachtet, welche mit Gα13-mTur2 und
YFP-LARG transfiziert waren. Die Stimulation des Thromboxan A2 Rezeptors führte zu einem
robusten Anstieg des FRET Signals. Wie sich in der langsamen Abnahme des FRET Signals zwischen
LARG und Gα13 zeigte, dissoziierten LARG und Gα13 überraschenderweise deutlich langsamer
(t1/2>5min) als Gα13 inaktivierte (t1/2=17,50s). Dies konnte auch in der Kinetik der LARG
Translokation zur Plasmamembrane beobachtet werden. Somit verursacht die Aktivierung des Gα13,
dessen schnelle Interaktion mit LARG. Bemerkenswerterweise inhibiert LARG entweder die Gα13´s
8Summary
Inaktivierung oder es bindet an Gα13 auch nach dessen Inaktivierung. Wir gehen davon aus, dass die
verlängerte Interaktion die Ursache für die fast 100fach erhöhte Sensitivität der
LARG-Gα13-Interaktion für die Stimulation mit einem Thromboxan Agonisten im Vergleich zur
Gα13-Aktivierung ist.
Die Aktivierung von p63RhoGEF wurde durch Beobachtung der Interaktion von Gαq-CFP und
Venus-p63RhoGEF untersucht. Ein robuster Anstieg im FRET wurde nach Stimulation von
Gαq-gekoppelten Rezeptoren detektiert. Im Gegensatz zur LARG-Gα13-Interaktion reflektiert die
p63RhoGEF-Gαq-Interaktion zeitlich sehr genau sowohl die Gαq-Aktivierung als auch seine
Inaktivierung. Außerdem zeigen die p63RhoGEF-Gαq-Interaktion und die Gαq-Aktivierung eine
ähnliche Sensitivität (EC50 von 500nM Histamin). Beide Beobachtungen wurden auch in einem
trimären Komplex aus p63RhoGEF, Gαq und dem Regulator of G protein signaling RGS2 bestätigt. In
der Vergangenheit wurde eine beschleunigte Gαq-Inaktivierung durch RGS2 in vitro beschrieben und
folgerichtig beobachteten wir eine beschleunigte Dissoziation von p63RhoGEF und Gαq in
Anwesenheit von RGS2. Zusätzlich konnten wir einen Anstieg im FRET zwischen p63RhoGEF und
RGS2 beobachten. Diese Beobachtung war der erste Beweis für diesen trimären Komplex in lebenden
Zellen und unterstützt das Konzept eines funktionalen, aktivierungsabhängigen p63RhoGEF-
Gαq-RGS2-Komplexes. In diesem Komplex inhibiert RGS2 die nachgeordnete Signalweiterleitung.
Dies könnte den deutlichen Bluthochdruck erklären, welcher für Mäuse ohne RGS2 beschrieben
wurde (Tang et al., 2003).
Zusammenfassend werden sowohl LARG als auch p63RhoGEF durch die Stimulation der G-Protein
gekoppelter Rezeptoren aktiviert. Trotzdem ist LARGs Sensitivität für die Rezeptoraktivierung
deutlich höher und die Dauer der Signalweiterleitung länger als es für p63RhoGEF gezeigt wurde. Die
Inaktivierung von p63RhoGEF wird zudem durch RGS2 weiter beschleunigt. Dies hat eine Abnahme
der nachgeordneten Signalweiterleitung zur Folge.
Schlüsselworte: Förster Resonanz Energie Transfer (FRET), Gαq, Gα13, G-Protein gekoppelter 
Rezeptor (GPCR), Histamin Rezeptor, Thromboxan A2 Rezeptor, p63RhoGEF, Leukämie assoziiertes 
RhoGEF (LARG), Regulator of G protein signaling 2 (RGS2)
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4 Introduction
4.1 The GPCR Gα RhoGEF RhoGTPase signaling axis mediates signal
transduction into and within cells
The human body consists of roughly 3.72*1013 cells (Bianconi et al., 2013). Inter- and intracellular
signaling is essential for all physiological functions of the human body and is tightly regulated.
Control of the signaling is achieved through changes in and detection of e.g. hormone levels within the
body as well as by proteins, which function as cellular switches by cycling between an active and an
inactive state.
An omnipresent class of cellular switches are guanine nucleotide binding proteins (G proteins) and
their regulation were in the focus of the present study (McCudden et al., 2005). These proteins exist in
a guanosine-5´-triphosphate (GTP)-bound active conformation and a guanosine diphosphate
(GDP)-bound inactive conformation (fig. 1A and (McCudden et al., 2005)). G proteins get inactivated
by their intrinsic ability to hydrolyze GTP to GDP and inorganic phosphate (Gilman, 1987; Kaziro et
al., 1991). The hydrolysis rate and the exchange of GDP for GTP are regulated processes (fig. 1A,
(Kaziro et al., 1991)). GTPase activating proteins (GAPs) increase the hydrolysis rate and thus
accelerate G protein inactivation (Siderovski and Willard, 2005). The binding of GDP to G proteins is
regulated by guanine nucleotide exchange factors (GEFs) and guanine nucleotide dissociation
inhibitors (GDIs). GDIs keep the G protein inactive by keeping GDP whereas GEFs activate the
G protein by promoting GDP release and GTP binding (Goss et al., 1984). The G protein´s affinity is
in the same range for GDP and GTP. Nevertheless GTP binds, because it is present in a
10 GTP:1 GDP stoichiometry in the cytosol (Bos et al., 2007).
Fig. 1 The activation and inactivation of G proteins by GEFs, GAPs and GDIs
A G proteins exist in an active GTP-bound and in an inactive GDP-bound state. The proteins can cycle between the two
states by hydrolysis of GTP and exchange of GDP for GTP. GTP exchange factors (GEFs) facilitate the latter, whereas
GTPase activating proteins (GAPs) accelerate the intrinsic GTPase activity of the G protein. The GTP dissociation
inhibitors (GDI) negatively regulate GTP binding. In B the G protein cycle is shown for trimeric G proteins and further
Gβγ signaling was neglected for simplicity. In C the G protein cycle is shown for the small GTPase RhoA.
10
Introduction
The family of G proteins is subdivided into trimeric and small G proteins (fig. 1B, C and for further
information see 4.3 and 4.4, respectively). Chapter 4.3 focuses on the trimeric G protein, the Gα
subunit first and then on Gα´s GDI Gβγ. The trimeric G proteins are activated by their GEFs
G protein coupled receptors (GPCRs, see also 4.2). These proteins build the largest receptor class
and mediate a good portion of communication from the cell environment into the cell (Rosenbaum
et al., 2009). The inactivation of trimeric G proteins is accelerated by GAPs, like the regulator of
G protein signaling (RGS) protein family. They are discussed later (see 4.6) and one member of the
family, RGS2, was studied in respect to regulation of Gαq in the present work. A multitude of
effectors are activated by trimeric G proteins including GEFs for small G proteins. The RhoGEFs
are discussed in more detail later on (see 4.5). The aim of this study was to gain further insights into
the interaction of the RhoGEFs LARG and p63RhoGEF with their activators Gαq and Gα13,
respectively. Finally the RhoGEFs activate the small GTPase RhoA and this leads to further
downstream signaling (see 4.4). The effect of the two mentioned RhoGEFs on the downstream
signaling was also investigated in the present thesis. In summary, the present thesis investigated the
temporal as well as spatial regulation of the GPCR Gα RhoGEF RhoGTPase signaling axis (see red
arrows in fig. 2), with p63RhoGEF and LARG as model RhoGEFs. By this we aimed to supply
missing information on the temporal as well as spatial regulation of this axis in living cells. Since
this signaling axis is implicated in many physiological processes, as for example regulation of
vascular tone (see 4.7).
4.2 GPCRs transduce extracellular signals into intracellular signaling cascades
Approximately 800 GPCRs are encoded in the human genome and roughly 36% of the established
drugs as listed in drug bank target GPCRs (Ma and Zemmel, 2002; Fredriksson et al., 2003; Rask-
Andersen et al., 2011). GPCRs generally transmit environmental signals into the cell, but some can
also signal from intracellular membranes (Calebiro et al., 2010; Irannejad et al., 2013). They link the
extra and intracellular space by seven membrane-spanning α-helices, a ligand binding site, which is
accessible from the extracellular lumen and the binding site for downstream signaling partners at the
intracellular face of the GPCR (Pogozheva et al., 1997).
An agonist binds to the ligand binding site and induces a conformational change of the agonist
binding site within a few microseconds as assessed by simulation and nuclear magnetic resonance
spectroscopy (NMR, (Dror et al., 2011a, 2011b; Nygaard et al., 2013)). This leads to changes in the
transmembrane domains, mainly transmembrane helices III and VI. These changes are proceeded
into the intracellular parts of the receptor, which recruits downstream signaling partners
(Rosenbaum et al., 2009; Kahsai et al., 2011; Kobilka, 2013). The exact changes in conformation
differ between receptors and may even differ at the same receptor according to various agonists
(Kobilka and Deupi, 2007; Bhattacharya and Vaidehi, 2010). In general these major conformational
changes were observed with rate constants of 30 to 50 ms for various GPCRs by means of
11
Introduction
intramolecular fluorescence resonance energy transfer (FRET, (Vilardaga et al., 2003; Hoffmann et
al., 2005, 2012; Hein et al., 2006; Maier-Peuschel et al., 2010; Ziegler et al., 2011)).
Mainly three protein families execute further downstream signaling: trimeric G proteins, G protein
coupled receptor kinases (GRKs) and β-arrestins (Reiter et al., 2012). The active receptor serves as
GEF for the recruited trimeric G protein and induces further signaling of the G protein subunits (see
4.3, (Tuteja, 2009)). GPCRs are entitled as G protein coupled receptors due to this mechanism. In
contrast, GRKs and β–arrestin mediate a signaling pathway independent of G proteins.
β-arrestin is recruited by the active GPCR conformation and the GRK-dependent phosphorylation of
the same. The interaction of β-arrestin with the GPCR competes with G proteins for binding to the
GPCR, and thus antagonizes G protein dependent GPCR signaling (Lefkowitz, 1998). Furthermore
β-arrestin binding triggers internalization of the receptor via clathrin-coated pits and thereby
desensitizes the cellular response towards the agonist (Lefkowitz, 1998). Moreover, it became
evident that GRK β-arrestin recruitment does not only induce desensitization, but in fact gives rise
to a number of spatially and temporally G protein-independent signaling pathways, mainly by
β-arrestin’s function as scaffold protein (Reiter et al., 2012). Noteworthy, the signaling within the
GPCRs can be modified by lipids, ions, allosteric modulators and voltage changes in close
proximity to the receptor as well as homo- and heterooligomerization of receptors (Ponimaskin et
al., 2002; Papoucheva et al., 2004; Terrillon and Bouvier, 2004; Ben-Chaim et al., 2006; Rinne et
al., 2013; Katritch et al., 2014; Langmead and Christopoulos, 2014).
4.3 Trimeric G proteins are activated by GPCRs and regulate intracellular effectors
Heterotrimers are built by GDP-bound Gα and the obligate heterodimer Gβγ and are localized at the
plasma membrane (McCudden et al., 2005). The trimeric G protein is recruited to a GPCR upon its
activation (see 4.2). This leads to release of GDP from the Gα subunit, followed by GTP binding and
subsequent severe conformational changes of Gα and Gβγ (see 4.3.1.1.) After activation, the G protein
subunits transfer the signal to a distinct set of effector proteins (see fig 2, (Oldham and Hamm, 2008)).
This is also the case if the G protein is already bound to an inactive GPCR, which is known as
precoupling and may have some impact on activation-kinetics (Galés et al., 2006; Qin et al., 2008,
2011). The activation cycle is completed by hydrolysis of GTP to GDP (Oldham and Hamm, 2008).
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4.3.1 The Gα subunit is the switch within the trimeric G protein
In mammals, 16 genes encoding Gα subunits have been identified (McCudden et al., 2005). These
subunits can be sorted into four classes (Gαs, Gαi, Gαq and Gα12) based on their primary sequence
similarity (Simon et al., 1991).
Recently, a fifth Gα class was
identified, which is conserved across
kingdoms including vertebrates, but
is not found in the human genome
(Oka et al., 2009). The classes are
activated by different receptors and
couple to different effectors (for
some examples see fig 2). But until
now it is not fully clear how
specificity between receptors and
G protein families is obtained, even
though many contact sites are
described between GPCR and
G protein (Moreira, 2014). In 4.3.3
and 4.3.2 the Gαq and Gα12 families
will be described in more detail, as
these two are the most important for
the work presented in this thesis.
4.3.1.1 Structure and activation
The Gα subunit consists of a GTPase domain and a α-helical domain (see fig. 3). The GTPase
domain is conserved in the entire G protein superfamily and the switch regions show significant
conformational differences whether GTP or GDP is bound (Oldham and Hamm, 2008). The
nucleotide binding pocket is hidden and further surrounded by the GTPase domain´s p-loop,
switch I, II and III (Chung et al., 2011). Functionally, the GTPase domain is important for Gβγ
binding and GTP hydrolysis. The helical domain is unique for the Gα subunits of the trimeric
G proteins and consists of six α-helices, which form a lid over the nucleotide binding pocket
(Oldham and Hamm, 2008). This domain increases affinity towards GTP and the GTP hydrolysis
rate (Echeverría et al., 2000). All Gα subunits are lipid-modified at their N-terminus, mainly
palmitylated. The lipid-modifications are crucial for structure and function of the Gα subunit and
support its membrane localization (Degtyarev et al., 1994; Franco et al., 1996; Bhattacharyya and
Wedegaertner, 2000; Preininger et al., 2003). The membrane localization of Gα is additionally
supported by the Gβγ dimer (Sánchez-Fernández et al., 2014).
Fig. 2 The four Gα classes and their canonical effectors
Many different G protein coupled receptors (GPCRs) activate one or
more classes of Ga subunits. Subsequently each class activates a distinct
subset of effectors. This scheme shows the most prominent effector for
each class as mentioned by McCudden et al. plus the more recently
established link between Gαq and RhoGEFs (McCudden et al., 2005).This selection might not reflect physiological relevance. Further the
activation of Gβγ and their effectors are neglected in the interest of
simplicity. The red arrows indicate the two GPCR Gα RhoGEF Rho
axes, which were the focus of the present study.
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Scientists have been investigating the
binding of the Gα subunit to the GPCR
and subsequent conformational changes
within the G protein for a long time.
Already in 1988 the Gα´s C-terminus
was described as a binding site for
GPCRs (Hamm et al., 1988). The
crystal structure resolved the
nucleotide-free Gαs subunit in complex
with the β2 adrenergic receptor (β2-AR)
(Rasmussen et al., 2011). In this
structure the Gα´s C-terminus interacts
indeed with the GPCR and additionally
the Gα´s αN-β1 hinge and the α4/β6
region (Chung, 2013). However, as a
basic rule dynamic movements in a
protein in vivo should be considered,
which may not be reflected in crystal
structures of the protein. This is true for the Gα´s α-helical domain. Here, conformational plasticity was
observed by NMR studies and electron microscopy experiments and is not represented in the crystal
structure (Abdulaev et al., 2006; Rasmussen et al., 2011; Westfield et al., 2011). The helical domain of
Gα has to move substantially in order to bind to the active GPCR as suggested by the crystal structure
(Chung, 2013). The nucleotide binding pocket opens by this movement (Chung, 2013). No further
changes are observed within Gα´s core. Nevertheless also the C-terminus and the neighboring α5 helix of
the Gα subunit move upon activation (Chung, 2013). The described changes in Gα structure occur
probably simultaneously with GDP release. Sequentially GTP binds and the trimeric G protein
undergoes severe conformational changes. Upon hydrolysis of GTP to GDP the activation cycle
terminates. Gα itself hydrolyzes GTP rather slowly, but Gα is a faster GTPase than RhoGTPases. This
step can be accelerated by RGS proteins (see 4.6, (Sánchez-Fernández et al., 2014)).
Whether the rearrangement within the Gα subunit leads to dissociation of the trimeric complex or not
is still under debate and may be subtype specific (Oldham and Hamm, 2008; Vilardaga et al., 2009;
Bondar and Lazar, 2014): In vitro experiments initially introduced the idea of subunit dissociation
(Hamm, 1998). But with this working model Gα subtype specific Gβγ effects could not be explained
(Sadja et al., 2003). In line with this an increase in FRET for Gαi activation was found in living cells,
which also contradicted subunit dissociation ((Bünemann et al., 2003; Frank et al., 2005), for details
on FRET see 5.2.6.1, please). This finding was reproduced by bioluminescence resonance energy
transfer (BRET, (Galés et al., 2006)). Additionally, Gβγ was less mobile when Gαi and Gαs were
Fig. 3 Domains of the Gα subunit
Inactive Gβγ bound Gαi1 structure as annotated by Baltoumas andcolleagues ((Baltoumas et al., 2013), (PDB 1GP2)). The Gα subunit
consists of the GTPase domain with the three switch (Sw.) regions,
which bind GTP/GDP and a α-helical domain, which is unique for Gα
subunits. The Gα subunits are lipid modified at their N-terminus
(N-term.), which is crucial for localization at the plasma membrane.
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activated than if Gαo was activated as measured by fluorescence recovery after photobleaching
(FRAP) and also this data favor the idea of rearrangement for some Gα subtypes (Digby et al., 2006).
A recent study investigated G protein dissociation by two-photon polarization microscopy and instead
of fluorophore insertion this workgroup used N-terminally fluorophore-labeled Gα subunits, but to the
author´s knowledge for such Gα constructs functionality in terms of inactivation kinetics has not been
evaluated in detail (Bondar and Lazar, 2014). Bondar and Lazar postulated the rearrangement seen in
FRET is due to the site of fluorophore insertion into the Gα subunit. Nevertheless, also this workgroup
does not describe dissociation as a mandatory step for effector activation (Bondar and Lazar, 2014).
All these studies were done under G protein overexpression conditions and ratio of effectors to
G proteins is thus greatly reduced compared to untransfected cells. Therefore in overexpression the
low affinity within the trimeric G protein might be sufficient for their further interaction after Gα
activation, whereas under endogenous conditions the presence of effector with high affinity for the
G protein subunits might force the trimeric G protein to dissociate (M. Bünemann, personal
communication).
4.3.1.2 Effector recognition and activation, a mainly indirectly studied process
The effector recognition of active Gα is maintained by the GTPase domain, precisely switch II and
α3 helix and its junction with β5 strand (fig. 3). This junction, also known as α3-β5 loop, differs both
in sequence and in structure between Gα subtypes and thereby maintains effector specificity (Sprang et
al., 2007; Baltoumas et al., 2013). Nevertheless, the GTPase domain structure is conserved between
the four Gα families (Baltoumas et al., 2013). But structural similarity does not include electrostatic
similarity and Baltoumas et al. suggest electrostatic differences as important determinate of specificity
for both Gα effector and Gα RGS interactions (Baltoumas et al., 2013). In the GTPase domain a
hydrophobic canyon opens upon GTP binding (Aittaleb et al., 2010). The recognized effector binds to
Gα by a hydrophobic chain, which inserts into the N-terminal part of α2 helix (SwichII) and α3 helix
(Sánchez-Fernández et al., 2014). For Gαq the same was observed in crystal structures with three
different effectors, namely phospholipase C (PLC) β3, p63RhoGEF and GRK2 (Tesmer et al., 2005;
Lutz et al., 2007; Waldo et al., 2010). All three effectors bind alike to Gαq.
Binding to Gα influences effectors in many fashions: Gαi is an allosteric inhibitor of adenylyl
cyclase, whereas Gαs allosterically activates and inhibits this enzyme. In case of guanosine
monophosphate phosphodiesterase (PDE) Gαt (Transducin) sequesters an autoinhibitory subunit and
thereby activates the enzyme (Sprang et al., 2007). Also the Gαq effectors PLCβ and p63RhoGEF
are released from autoinhibition (Sánchez-Fernández et al., 2014). Further Gαq seems to work as a
scaffold in case of extracellular signal-regulated kinase 5 (ERK5) and protein kinase C (PKC) ζ
(García-Hoz et al., 2010).
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The authors of this study mainly investigated effects on ERK5 phosphorylation and extrapolated from
this to PKC activation. Notably, such a study design is rather common for investigations on regulation
of effectors by G protein. To our knowledge in all early studies on adenylyl cyclase regulation by Gαs
and Gαi and PLCβ3 regulation by Gαq cAMP and either PIP2 or IP3 levels were measured as surrogate
for effector activation, respectively. Furthermore in some cases, like LARG activation by Gαq, reporter
gene activity far downstream of the effector was used as read-out (Pfreimer et al., 2011). The direct
interaction between effector and G protein was shown by pull down experiments and later crystal
structures were resolved for several effector G protein interactions, which gave direct but static insight
into their interaction mode. Hence, the information on the kinetic of regulation was rather limited.
Nevertheless already in 1989 the immediate inactivation of PDE upon Gαt inactivation was elucidated
by measurement of free Pi due to GTP hydrolysis and pH change due to cGMP hydrolysis in the same
sample (Arshavsky V. Yu. et al., 1989). Noteworthy, in earlier studies deactivation of the signaling
cascade was found considerably slower than observed in vivo which was caused by non-physiological
stoichiometry of signaling partners. In the mentioned study they increased concentrations and
temperature and could than measure kinetics close to in vivo. This shows the limitations of
biochemical approaches, since kinetics may be differ between in vitro and in cells due to different
conditions of the interaction partners.
The first dynamic studies in living cells investigated channel opening and closing upon stimulation of
GPCRs by electrophysiological methods, like for example GIRK activation by Gβγ (Dascal, 1997).
The kinetics of GIRK currents upon receptor stimulation were closely resembled by activation and
inactivation of Gαi, which were determined by FRET (Bünemann et al., 2003). Also the inhibition of
N-type Ca2+ channels by Gβγ was studied in detail by electrophysiological recordings and with
regulation-block by site-specific peptides also the interaction sites were mapped (as reviewed in
(Zamponi and Snutch, 1998; Zamponi and Currie, 2013)). Investigation of other effectors in living
cells was hindered by the lack of electrophysiological read-outs. Hence, another method had to be
applied. Therefore first FRET-based assays were developed, which monitored fluorophore labeled
G protein subunits and fluorophore labeled effectors in living cells (Zhou et al., 2003). To date, such
assays have been invented for effectors of different G protein families, like the interaction of adenylyl
cyclase V with Gαi, Gαs and Gβγ (Milde et al., 2013) or PLCβ3 and GRK2 with Gαq ((Pollinger, 2012)
and Wolters et al., under revision). As shown in the present study and by T. Pollinger (Pollinger, 2012)
the interaction of PLCβ3 with Gαq resembled closely Gαq activity, whereas Milde and coworkers
found a prolonged interaction between Gαi and adenylyl cyclase V compared to Gαi activation (Milde
et al., 2013). They suggested, that this prolonged interaction might explain earlier findings of higher
sensitivity of cAMP production compared with activation of the Gα subunit. Nevertheless, many other
important effectors of trimeric G proteins have not been studied in such depth yet, like any of the
Gα12/13 effectors. The present study provided the first data on dynamics of interaction of the effector
LARG with Gα13 and on the interaction of p63RhoGEF with Gαq.
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4.3.2 The Gα12 family activates RhoGEFs and other effectors
The Gα12 family consists of Gα12 and Gα13, which are both conserved among species and their mRNAs
are shown to be expressed ubiquitously (Simon et al., 1991; Strathmann and Simon, 1991; Wilkie and
Yokoyama, 1994). Both proteins are palmitylated at their N-terminus and thereby are directed to the
plasma membrane (Bhattacharyya and Wedegaertner, 2000; Waheed and Jones, 2002). Gα12 was found
in lipid-rafts whereas Gα13 did not localize to this microdomain (Waheed and Jones, 2002). The
differences in localization and structure might explain functional differences between Gα12 and Gα13.
The structural differences have been observed in chimeric crystal structures of both family members with
Gαi (Kreutz et al., 2006). One example is the enlarged αB-αC loop in Gα13, which is suggested to be
responsible for different GAP activities of the same effector towards the two Gα subunits (Kreutz et al.,
2006). Besides these differences Gα12 and Gα13 behave rather similar in regard to slow intrinsic rates of
GTP hydrolysis and GDP GTP exchange (Singer et al., 1994; Kozasa and Gilman, 1995).
Many GPCRs activate Gα12/13, but to find and conform GPCRs with Gα12/13-selectivity is challenging
(Riobo and Manning, 2005). Most GPCRs, which couple to Gα12/13, couple also to other G proteins, in
particular to Gαq. In this study the thromboxane A2 receptor was used to activate Gα13, which coupled
to Gα12/13 and Gαq in platelets (Offermanns et al., 1994). Additionally, different G protein families may
converge on the same downstream target.
Effectors
The best characterized downstream target of the Gα12 family is RhoA (4.4.1, (Worzfeld et al., 2008)).
Like for Gαq and its effector p63RhoGEF (4.5.2), RhoA is not activated directly by the G protein.
Instead Gα12/13 activates RhoGEFs, which then activate RhoA (4.5.1). Vogt et al. showed Rho
activation in pertussis toxin treated, Gαq/11 deficient cells as well as Gα12/13 deficient cells (Vogt et al.,
2003). Additionally, Gα12 and Gα13 interact with type I and type II classical cadherins. The cadherin´s
adhesive function is blocked by Gα12/13 binding and subsequently the transcriptional activator
β-catenin is released. This affects cell migration independent of RhoA (Meigs et al., 2001, 2002).
Interestingly, the interaction between cadherins and Gα13 relies on different amino acids than RhoGEF
binding (Meigs et al., 2005). Since this information was gained in the context of constitutive active Gα
subunits, the physiological relevance of this signaling pathway is not yet known (Kelly et al., 2007).
Furthermore interactions of Gα13 with radixin have been described, which might activate the
Ca2+/calmodulin-dependent kinase II (CaMKII) and might have some impact on Gα13-mediated Rac
activation (Liu and Voyno-Yasenetskaya, 2005). Radixin might also be indirectly activated
down-stream of Rho (Kelly et al., 2007).
Additional interactions have been described between the Gα12 family A-kinase anchoring proteins,
non-receptor tyrosine kinases and protein phosphatases, even though the physiological relevance is not
yet fully understood for these interactions (Kelly et al., 2007; Worzfeld et al., 2008).
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Regulation of the Gα12/13 family
Regulation of Gα12/13 occurs by the GAP activity of the RhoGEFs described before (see 4.5.1) and by
phosphorylation (Kozasa et al., 2011). Phosphorylation of Gα13 blocks its activation and is mediated
by protein kinase A (PKA) (Manganello et al., 2003). Whereas Gα12 is phosphorylated by PKC, which
decreases the affinity of Gα12 for Gβγ (Kozasa and Gilman, 1996).
Physiology and pathology
Knock-out studies revealed non-redundant functions for Gα12 and Gα13, as Gα12 knock-out mice
showed no apparent abnormalities and Gα13 knock-out was embryonic lethal (Offermanns et al., 1997;
Gu et al., 2002). In endothelial cells Gα13 was found essential for proper angiogenesis and in platelets
for cell shape changes upon activation and aggregation (Moers et al., 2003). These phenotypes were
probably caused by loss of cell shape regulation, cell movement, cell cell or cell matrix interactions as
well as cell polarization (Worzfeld et al., 2008). Many other physiological phenotypes of Gα12/13 rely
on these effects, as for example regulated neuronal and B-cell migration and leukocyte adhesion
(Moers et al., 2003, 2008; Francis et al., 2006; Rieken et al., 2006).
In regard to cancer the Gα12 family is of special interest as their wild type genes are considered
oncogenes in contrast to the members of all other Gα families due to their transforming ability (Xu et
al., 1993, 1994). Furthermore, Gα12 was found upregulated in human breast and prostate
adenocarcinoma tissue (Kelly et al., 2006a, 2006b). Interestingly, metastatic spread was reduced in a
xenograft model by blockade of Gα12 and Gα13 signaling in murine breast cancer cells. But this
blockade did not influence either tumor growth or metastasis rate, if cells were injected into the blood
stream (Kelly et al., 2006a, 2007).
Gα13 is not required to maintain basal heart function, but seems to be essential for α1 adrenergic
receptor induced hypertrophic response, pressure-overload induced hypertrophy and heart failure in
vivo, as studied in mice with a conditional, heart-specific Gα13 knock-out (Maruyama et al., 2002;
Takefuji et al., 2012). Further the pathological progression of pressure-overload induced hypertrophy
seems to depend on LARG activation by Gα13 (4.5, (Takefuji et al., 2013)). Gα12 and Gα13 are together
with Gαq of crucial importance for vascular tone (4.7, (Schoner, 2008)). Several examples are
described for crosstalk between Gα12/13 and other G proteins, mainly Gαq (as reviewed by (Suzuki et
al., 2009a)).
4.3.3 The Gαq family activates p63RhoGEF besides its canonical effector PLCβ
The Gαq family is composed of four members and conserved among species (Wilkie and Yokoyama,
1994): Gαq is ubiquitously expressed, Gα11 is found everywhere except platelets, whereas Gα14 is
mainly found in kidney, liver and lung and Gα16 in the hematopoietic system (Hubbard and Hepler,
2006). The human Gα16 is considered to be an orthologue of mouse Gα15 (Wilkie et al., 1992).
Noteworthy, the amino acid sequence is conserved the least among this family compared to the other
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Gα families and the differences occur within the nucleotide binding pocket as well as in the N- and
C-terminus (Wilkie et al., 1991). Maybe, due to this Gα15/16, and to a lesser extent Gα14, were shown to
be activated by Gαs and Gαi/o coupled GPCR (Hubbard and Hepler, 2006).
The Gαq effectors: PLCβ and p63RhoGEF
Far more research has been done on Gαq and Gα11 than on the other two members. However in the
following comparative knowledge is reviewed about effector binding by all family members:
PLCβ isoforms are the classic effectors of Gαq family members (Rebecchi and Pentyala, 2000; Rhee,
2001). Additionally, PLCβ 2 and 3 can be activated by Gβγ (Camps et al., 1992; Park et al., 1993). In
general all active PLCβ isoforms cleave phosphatidylinositol 4,5 bisphosphate (PIP2) into the two
second messengers inositol 1,4,5 trisphosphate (IP3) and diacylglycerol (DAG, (Rhee, 2001)).
Subsequently Ca2+ is released from intracellular stores and PKC is activated (Sánchez-Fernández et
al., 2014). Consequently, the determination of IP3 production by cell lysates is the commonly used
method to investigate PLC activity (e.g. (Camps et al., 1992; Park et al., 1993; Lyon et al., 2011)).
Recently, T. Pollinger established a FRET-based assay to study PLCβ3 Gαq as well as PLCβ3 Gβγ
interaction in single living cells (Pollinger, 2012).
Activation of all Gαq family members potentially leads to activation of all PLCβ isoforms by relief of
PLCβ from autoinhibition (Hubbard and Hepler, 2006; Lyon et al., 2011). However, the family
members differ in their activation efficacy towards PLCβ isoforms and the PLCβ isoforms show
varying expression patterns. Taken together this may lead to isoform-specific PLCβ signaling under
physiological conditions (Hubbard and Hepler, 2006).
p63RhoGEF is the second best described Gαq effector besides PLCβ, which is Gαq family specific (Lutz
et al., 2005; Sánchez-Fernández et al., 2014). This protein activates Rho signaling by exchange of GDP
for GTP on RhoA and was shown to compete with PLCβ for Gαq binding by biochemical assays (Lutz et
al., 2005). RhoGEF activation downstream of Gαq seems to be a conserved mechanism like signaling
from Gαq to PLCβ, as UNC-73 (homolog of Trio RhoGEF) was found in C. elegans (Williams et al.,
2007). In general activation of RhoA induces stress fiber formation, is involved in cell contraction and
during cell movement it is important for following of body and tail behind the leading edge (for details
4.4.1, (Etienne-Manneville and Hall, 2002)). p63RhoGEF binds also to Gα16 and blocks its PLCβ
activation, but surprisingly this binding does not result in Rho signaling (Yeung and Wong, 2009). This
indicates yet another level of signaling differences between the Gαq family members, as effectors may
change their function from real effectors towards a role as effector antagonist at certain Gαq family
members. The competitive behavior of p63RhoGEF and PLCβ3 towards Gαq will be discussed in more
detail later on (see 4.5.2.1 PLCβ3 overlaps with p63RhoGEF and RGS2 binding to Gαq). Trio is another
RhoGEF activated by Gαq and this one activates Rac in addition to Rho (see 4.5.2.1 Trio and Kalirin, the
complex siblings of p63RhoGEF, (Vaqué et al., 2013)).
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RGSs and GRKs regulate Gαq signaling
Gα14 and Gα15/16 are even less studied in terms of regulation by RGS proteins (see 4.6). Only one study
focused on this topic in regard to Gα14 and Gα15/16 and showed blockade of Gα16 signaling by RGS2
(Day et al., 2003). RGS2 is a member of the B/R4 subfamily of RGS proteins and as most of the
subfamilies’ members RGS2 negatively regulates Gαq and Gα11 by its GTPase activity (Hubbard and
Hepler, 2006). Additionally some RGS proteins work as effector antagonists for PLCβ by overlap of
their and PLCβs binding sites (Hepler et al., 1997; Anger et al., 2004).
The previously described GRKs not only bind and phosphorylate GPCRs, but some of them bind also
specifically to Gαq family members and block their signaling again as effector antagonists. Binding
was described for active Gαq and Gα11 with GRK2 and GRK3 (Carman et al., 1999). GRK2 blocks
signaling by all Gαq family members besides Gα16, probably by occupation of the effector binding site
(Day et al., 2003). So signal attenuation is induced by GRK2 via GPCR internalization, as described
earlier (see 4.2), and blockade of the effector binding site at Gαq.
Physiology
Gαq mediates a wide variety of physiological and pathological functions, like hormone release, innate
and adaptive immunity, hepatic glucose fluxes, long-term depression, platelet activation and induces
either apoptosis or proliferation (Sánchez-Fernández et al., 2014). A somatic gain of function mutation
within the Gαq encoding GNAQ gene results in port-wine stains and the Struge-Weber syndrome, a
sporadic congenital neurocutanous disorder (Shirley et al., 2013). Similarly activating mutations were
found in the Gαq and Gα11 in approximately 80% of all uveal melanomas (van Raamsdonk et al.,
2010). Also in the heart, Gαq/11 signaling is crucial, as double knock-out mice died at embryonic
day 11 due to heart malformation and overexpression of Gαq induced heart hypertrophy (Offermanns
et al., 1998; Fan et al., 2005). In addition the double knock-out mice showed craniofacial defects. As
described in detail later (4.7) Gαq together with Gα12/13 plays an important role in vascular tone
(Schoner, 2008).
4.3.4 The Gβγ subunits activate their own set of effectors
The second part of the trimeric G protein is the obligate heterodimer Gβγ. In human, five Gβ subunits
and twelve Gγ subunits have been identified. All Gβ subunits show high sequence similarity except
Gβ5 and also Gγ subunits are more diverse (Khan et al., 2013). Some specificity in Gβ Gγ association
is described, as for example Gβ2 cannot pair with Gγ1 (Schmidt et al., 1992). The Gβ subunit forms a
propeller of seven blades and an α-helical N-terminus (Oldham and Hamm, 2008). The blades are
formed by seven WD40 sequence repeats, which are tryptophan-aspartic acid sequences that repeat
about every 40 amino acids and form small antiparallel β strands (Neer et al., 1994). Gβ interacts by
its N-terminus as well as the fifth and sixth bladder with the two α-helices, which form Gγ (Wall et al.,
1995; Sondek et al., 1996). The dimer is localized at the plasma membrane due to a C-terminal
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prenylation of the Gγ subunit, which is either a 15-carbon farnesyl moiety or a 20-carbon
geranylgeranyl group (Wedegaertner et al., 1995).
Upon activation of the trimeric G protein, the structure of Gβγ changes only minutely but an
extensive, relatively hydrophobic surface becomes accessible for effectors (Sondek et al., 1996;
Aittaleb et al., 2010). This surface is a part of the effector recognition site (Davis et al., 2005). Upon
GTP hydrolysis Gα reassociates with Gβγ and this terminates Gβγ´s signaling to effectors (Ford et
al., 1998; Li et al., 1998).
Gβγ activates a variety of effectors
The first effector described for Gβγ was the G protein regulated inward rectifier K+ channel (Kir,
(Logothetis et al., 1987)). In the next years other effectors were found, like voltage-dependent N- and
P/Q-type Ca2+ channels, Erk1/2 (extracellular signal-related kinase), c-Jun N-terminal kinase,
mitogen-activated protein kinase, various adenylyl cyclase isoforms, PLCβ3, GRK2 and 3 and the
RacGEF P-Rex1 (McCudden et al., 2005). The regulation of adenylyl cyclase is an example for
regulation of a single protein by Gα subunits as well as Gβγ at the same time (Tang and Gilman,
1991). The interaction with all effectors, which have been mentioned, occurs at the plasma membrane.
In addition Gβγ signaling was described also in other cellular compartments, like mitochondria,
endoplasmic reticulum and nucleus (Khan et al., 2013). It´s not clear whether all of these interactions
depend on activation of the trimeric G protein.
Physiology
The physiological role of Gβγ was clarified in several knock-out studies and also a polymorphism was
described for Gβ3. This polymorphism caused a truncated splice variant, which is unable to modulate
Kir3 and calcium channels (Ruiz-Velasco and Ikeda, 2003). Additionally, the polymorphism was
associated with a wide variety of pathologies, like hypertension, gastrointestinal disease, depression,
obesity and therapy complications, like increased bleeding time (Khan et al., 2013).
4.4 The Rho family of small G proteins regulates mainly the cytoskeleton
The largest family within the Ras superfamily of small GTPases is the Ras homologous (Rho) family
with 23 genes in human (Jaffe and Hall, 2005; Bustelo et al., 2007). The best characterized
RhoGTPases RhoA, Rac and Cdc42 control the actin cytoskeleton and transcription factors, like
Serum response factor (SRF) and nuclear factor κB (NFκB, (Ridley, 2006)). In addition, more than
90 other Rho effectors are described, like protein kinases, phospholipases, actin regulators and adaptor
proteins (Jaffe and Hall, 2005; Ridley, 2011). It´s challenging to identify, yet unknown Rho effectors
in the genome, since the RhoGTPases´ effectors lack a common well-defined RhoGTPase recognition
site (Cook et al., 2014). The present study focused on regulatory processes, which tightly control
RhoA activation.
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RhoGTPases are regulated by RhoGEFs, GAPs and GDIs
Most small G proteins cycle between active GTP-bound and inactive GDP-bound state, alike the Gα
subunits of trimeric G proteins (fig. 1C, 4.1). The intrinsic GTPase rate of RhoGTPases is rather low
and can be accelerated by RhoGAPs (Ridley, 2013). Additionally, their affinity is high for GDP and
GTP and this results in a dissociation half life of one or more hours (Bos et al., 2007). The exchange
of the nucleotides and therefore the activation is mediated by RhoGEFs (4.5). The GTP hydrolysis is
accelerated by RhoGAPs and additionally, Rho guanine nucleotide dissociation inhibitors (RhoGDIs)
negatively regulate some RhoGTPases. They bind to Rho-GDP and sequester it into the cytosol
(Garcia-Mata et al., 2011). In the absence of RhoGDIs most RhoGTPases are localized at the cell
membrane due to post-translational modifications (Cook et al., 2014). The post-translational
modifications are one or two lipid groups at their C-terminus. These lipid groups are prenyl groups,
either farnesyl and geranylgeranyl, or a palmitoyl group (Wennerberg and Der, 2004). RhoGDIs can
only bind the prenyl group into a hydrophobic pocket and additionally, hide the RhoGTPase´s effector
binding site (Garcia-Mata et al., 2011). For some RhoGTPases, like RhoA, further post-translational
modifications are described.
Physiology
Cellular processes such as cell shape, cell migration, cell cycle progression and gene transcription are
regulated by RhoGTPases (Etienne-Manneville and Hall, 2002). These effects occur mainly by the
Rho family´s effect on actin and microtubule dynamics (Ridley, 2011).
The three Ras proteins are commonly mutated in cancer. In contrast, until now RhoGTPases were
not found mutated in cancer, with the exception of an activating Rac1 mutant in melanoma (Cook et
al., 2014). But nevertheless RhoGTPases are often more active in cancer tissue than in healthy
tissue. This is due to indirect activation by changes in their expression or in the activity of their
regulators (Cook et al., 2014).
4.4.1 The Rho subfamily
In 1985, the members of the Rho subfamily RhoA, RhoB and RhoC were the first RhoGTPases
discovered in humans (Madaule and Axel, 1985). They show a sequence homology of 88% and differ
only in their C-terminal last nine to twelve amino acids and in their post-translational modification
(Wheeler and Ridley, 2004; Ridley, 2013). RhoB is prenylated and palmitylated, whereas RhoA and
RhoC are only prenylated (Wennerberg and Der, 2004). Further RhoA can be phosphorylated and
ubiquitinated, which then leads to either its translocation into the cytosol or its degradation,
respectively (Lang et al., 1996; Nethe and Hordijk, 2010). In general RhoA and RhoC localize at the
plasma membrane and in the cytoplasm, whereas RhoB is mainly localized in endosomes (Adamson et
al., 1992; Zalcman et al., 1995). The RhoA subfamily is activated by RhoGEFs (4.5) and also
β-arrestin 1 was described to activate RhoA (Barnes et al., 2005). The activation of RhoA leads to
stress fiber and focal adhesion formation as shown in early studies with murine fibroblasts, which is a
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phenotype distinct from the one caused by Rac and Cdc42 activation (Ridley and Hall, 1992; Ridley et
al., 1992; Nobes and Hall, 1995).
The diverse physiological functions of the RhoA subfamily
In 1993, RhoA, RhoB, RhoC were shown to be essential for cytokinesis with the help of the C3
exoenzyme (Kishi et al., 1993). In the following years the RhoA subfamily was found important in
many cellular functions, like transcription, cell transformation or cell cycle progression in cell culture
(Jaffe and Hall, 2005). Complete RhoA knock-out is embryonic lethal at early developmental stages
(Pedersen and Brakebusch, 2012). Therefore, several conditional RhoA knock-outs were introduced in
different cell types of the nervous and the hematopoetic system as well as keratinocytes, lens
epithelium and cardiomyocytes (Chauhan et al., 2011; Herzog et al., 2011; Jackson et al., 2011;
Katayama et al., 2011, 2012; Xiang et al., 2011; Cappello et al., 2012; Pleines et al., 2012; Zhang et
al., 2012). For example RhoA knock-out in the hematopoetic system resulted in impaired platelet
formation, blood clotting and inhibition of B cell development (Zhou and Zheng, 2013). The
consequence of RhoA knock-out in a tissue is probably influenced by expression of RhoB and RhoC
and their compensatory upregulation. Such a compensatory upregulation of RhoB and RhoC was
described in RhoA knock-out fibroblasts for example (Melendez et al., 2011).
The endosome localized RhoB was shown to be involved in endocytosis and vesicle trafficking in
vitro (Mellor et al., 1998; Sandilands et al., 2004). RhoB knock-out mice were viable, but suffered
from retarded retinal vascularization, caspase-3 dependent neuronal apoptosis, thymus atrophy,
impaired neuronal morphology and synaptic plasticity and were prone to develop carcinogen induced
skin cancer (Liu et al., 2001; Adini et al., 2003; McNair et al., 2010; Barberan et al., 2011; Bravo-
Nuevo et al., 2011). RhoA was shown to stimulate cell cycle progression and cytokinesis, regulate cell
migration and to be upregulated in many different tumor types (Vega and Ridley, 2007; Ridley, 2013).
Also RhoC is over expressed in a variety of cancers and additionally, the number of metastases seems
to correlate positively with its expression (Karlsson et al., 2009; Thumkeo et al., 2013). In line with
this RhoC knock-out mice did not show any metastasis in a lung cancer model (Hakem et al., 2005).
Amongst others, ROCK is activated by the Rho subfamily
During the mid-90s multiple Rho effectors were cloned including Rhotekin, Rhophilin, PKN, Citron,
Rho-associated coiled-coil kinase (ROCK) and mDia (Leung et al., 1995; Madaule et al., 1995; Reid
et al., 1996; Watanabe et al., 1996, 1997). RhoC was shown to activate the formin FMNL3, which is
not activated by RhoA (Vega et al., 2011). Details on the effectors ROCK, Rhotekin and
transcriptional activation downstream of the RhoA subfamily can be found below:
RhoA activates the serine/threonine kinase ROCK, which in turn phosphorylates and activates myosin
light chain (MLC) and inactivates MLC phosphatase (MLCP, fig. 4 ,(Amano et al., 1996; Kimura et
al., 1996)). Additionally, ROCK activates LIMK, which leads to inactivation of the actin
depolymerisation factor cofilin (Maekawa et al., 1999; Ohashi et al., 2000). By these two mechanisms
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ROCK regulates myosin and actin dynamics downstream of RhoA. Noteworthy, ROCK is also
activated independent of RhoA for example by Caspase-3 and granzyme B (Sebbagh et al., 2005).
ROCK is important in cell migration, cell cell adhesion, transcription, apoptosis, axonogenesis and
T cell function (Hirose et al., 1998; Itoh et al., 1999; Sahai et al., 1999; Coleman et al., 2001; Sahai
and Marshall, 2002; Heasman et al., 2010). Furthermore, as shown in rats ROCK is important in blood
pressure regulation (see also 4.7) and cancer cell invasion (Uehata et al., 1997; Itoh et al., 1999).
Knock-out of either one of the two ROCK isoforms resulted in intrauterine growth retardation and
defects in eyelid as well as ventral body wall closure (Thumkeo et al., 2003, 2005). The double
knock-out was lethal (Thumkeo et al., 2005). In Japan the ROCK inhibitor Fasudil is used in the
treatment of cerebral vasospasm since many years (Morgan-Fisher et al., 2013).
Not much is known about Rhotekin´s cellular function (Thumkeo et al., 2013). But the Rho binding
domain (RBD) of Rhotekin has been of great interest for the Rho GTPase researchers in the last fifteen
years. They used it to extract active RhoA from full cell lysates, which is facilitated by RBD´s high
affinity for active, GTP-bound RhoA (Ren et al., 1999; Ren and Schwartz, 2000).
Downstream of RhoA c-Jun, serum response factor (SRF) and MEF2 are activated via diverse
mechanisms (Marinissen and Gutkind, 2005). A SRF reporter gene assay, SRE.L, is widely used to
indirectly determine Rho activity (Siehler, 2009). The serum response element (SRE) is activated by
SRF together with either TCF or MRTF, which are transcriptional co-factors (Olson and Nordheim,
Fig. 4 The RhoA ROCK signaling in vascular smooth muscle cells
RhoA can be kept in the cytosol by RhoGDIs and GTP hydrolysis is accelerated by RhoGAPs. Therefore these two
protein families inhibit RhoA signaling. In contrast RhoGEFs induce the exchange of GDP for GTP on RhoA, upon their
activation by Gαq or Gα12/13. Subsequently RhoA activates downstream effectors. One of those effectors is ROCK, whichphosphorylates myosin light chain phosphatase (MLCP), beside other effectors. This process is also called Ca2+
sensitization in vascular smooth muscle cells. As upon inactivation of MLCP myosin light chain (MLC) is more sensitive
towards phosphorylation by myosin light chain kinase (MLCK), which is a Ca2+ calmodulin dependent enzyme. This
scheme is based on Satoh et al., but modified towards the scope of this thesis (Satoh et al., 2011). The Gβγ subunit is
neglected in the interest of simplicity.
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2010). The target genes are immediate-early as well as muscle specific genes, like β-actin and vinculin
(Siehler, 2009). Selectivity between these genes is maintained by coactivation of SRF together with
either TCF or MRTF (Jaffe and Hall, 2005). For the SRE.L reporter gene assay the serum response
element (SRE) was mutated to exclude TCF binding (Hill et al., 1995). MRTFs are activated
downstream of RhoA upon dissociation from monomeric actin (Olson and Nordheim, 2010). RhoA
decreases the amount of monomeric actin in the cytosol by two mechanism and thus activates SRE.L:
(A) minimized actin depolymerisation due to inactivation of cofilin by ROCK and (B) increased actin
filament assembly due to mDia activation (Siehler, 2009).
4.5 Most RhoGEFs contain a DH-PH domain
The activation of RhoGTPases is the primary function of RhoGEFs, which are divided into dedicator of
cytokinesis (DOCK) RhoGEFs and the B-cell lymphoma (Dbl) RhoGEFs (Cook et al., 2014). The
DOCK RhoGEFs act solely on Rac and/or CDC42 and are therefore neglected in the following (Pakes et
al., 2013). The Dbl RhoGEFs consists of 70 members with 28 acting on RhoA in human and are
activated by integrins, receptor tyrosine kinases and heterotrimeric G proteins of the Gαq/11 and Gα12/13
family (Burridge et al., 2004; Cook et al., 2014). Upon the Dbl RhoGEFs all members share a catalytic
Dbl homology (DH, ≈200 amino acids) domain and almost all a regulatory pleckstrin homology (PH,
≈100 amino acids) domain, which is located C-terminal of the DH domain (Rossman et al., 2005; Cook
et al., 2014). Besides these domains the Dbl RhoGEFs vary in their structure. For example two RhoGEF
proteins (Trio and Kalirin) possess two DH-PH domains each and in addition many other domains
(4.5.2.1 Trio and Kalirin, the complex siblings of p63RhoGEF, (Rossman et al., 2005)).
Mechanistically the activation of RhoGTPases by RhoGEFs is a highly conserved process, even
though the sequence homology is low between DH domains (Rossman et al., 2005). Upon RhoGEF
binding the nucleotide binding pocket (the three switch regions and p-loop of the RhoGTPase,
(2.3.1.1)) undergo conformational changes and GDP dissociates. Additionally the RhoGEF sterically
displaces the cofactor Mg2+, which is necessary for high affinity binding of the nucleotide (Rossman et
al., 2005). Afterwards GTP and Mg2+ are able to bind to the GTPase, which leads again to changes in
the switch region and dissociation of the complex (Rossman et al., 2005).
Significantly, the system of RhoGTPase activation by RhoGEFs was hijacked by many pathogenic
bacteria, like a serovar of Salmonella enterica or an enteropathogenic Escherichia coli. The
pathogenicity is mediated by the bacterial type three exotoxins, which mimic or antagonize the
function of human RhoGEFs (Orchard and Alto, 2012).
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DH domains have GEF activity and PH domains have more heterogeneous functions
The DH domain consists of three conserved regions (CR1 to CR3) and an only partially conserved
C-terminus (helix α6), which varies in its length and orientation (Rossman et al., 2005). CR1 and
CR3 interact with switch I of the GTPase and CR3 and parts of the C-terminus with switch II.
Mutations in these regions interfere with GTPase binding (Aghazadeh et al., 1998; Liu et al., 1998;
Rossman et al., 2005). The selectivity of Dbl RhoGEFs towards differing RhoGTPase families is
maintained by the highly variable interaction site between GTPases’ β2 and β3 strands and the DH’s
back rest (Rossman et al., 2005).
In general PH domains are found in many peripheral proteins and are known as phosphatidylinositol
phosphate (PIP) binding domains and mediators of protein protein interaction (Bos et al., 2007;
Shankaranarayanan et al., 2010). The PH domains of DH-PH domains are surprisingly divergent in
their function (Bos et al., 2007): In some RhoGEFs the PH domain seems to increase the DH domain´s
GEF activity as shown by truncation studies (Liu et al., 1998; Rossman and Campbell, 2000). For
example, in leukemiaassociated RhoGEF (LARG), Dbs and PDZ-RhoGEF the PH domain builds
direct contacts to RhoA and is important for full nucleotide exchange activity (Kristelly et al., 2004;
Bos et al., 2007). For other RhoGEFs an inhibition of the DH domain by the PH domain is described.
Examples for this are the DH domains of Son of sevenless, Trio and p63RhoGEF (Soisson et al., 1998;
Bellanger et al., 2003; Lutz et al., 2007). Finally in Tiam1, intersectin and collybistin for the
PH domain neither influence on in vitro GEF activity nor contacts to the bound GTPase were
described (Worthylake et al., 2000; Snyder et al., 2002; Xiang et al., 2006).
Diverse regulatory mechanisms for Dbl RhoGEFs
Many RhoGEFs are constitutively activated by truncation of the protein N-terminal of the DH domain
or by phosphorylation, which both releases the DH domain from autoinhibition (Aghazadeh et al.,
2000; Schmidt and Hall, 2002). Also regulation by homo- as well as heterodimerization (4.5.1.1,
Regulation by dimerization and phosphorylation) and subcellular sequestration was described
(Rossman et al., 2005). Further and most crucial for the present thesis some RhoGEFs are activated by
trimeric G proteins. Especially Gαq/11 and Gα12/13 activate certain RhoGEFs (4.5.1 and 4.5.2). For the
RhoGEF P-Rex1 activation by Gβγ was described (Welch et al., 2002).
Pharmacologically targeting RhoGEFs
Until now, neither highly specific nor potent inhibitors were found for RhoGEFs, besides the natural
product brefeldin A, which inhibits Arf activation by ArfGEF (Mossessova et al., 2003; Vigil et al.,
2010). But the interaction between Arf and ArfGEF is distinct from the interaction between
RhoGTPases and RhoGEFs. Recently a high throughput study was published on a direct blocker of the
LARG RhoA complex, which showed an affinity of 110 µM towards RhoA in vitro (Gao et al., 2014).
However data on the effect of this blocker in living cells or even in vivo are pending. Further
RhoGEFs could be modulated indirectly by targeting kinases up- and downstream of RhoGEFs (Cook
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et al., 2014). Like PKA upstream of LARG or Rho-associated serine/threonine kinase (ROCK)
downstream of RhoA (see 4.4.1). The blocker for ROCK, Fasudil, is already in clinical use in Japan
(Morgan-Fisher et al., 2013).
4.5.1 Gα13-activated RhoGEFs
The Gα12/13 RhoGEF Rho signaling pathway is conserved from C. elegans and D. melanogaster to
mammals, with Concertina as single orthologue for Gα12/13 in D. melanogaster (Barrett et al., 1997;
Hiley et al., 2006).
In human Gα12 and Gα13 activate PDZ-RhoGEF1 and leukemia-associated RhoGEF (LARG,
1544 amino acids), whereas p115RhoGEF is only activated by Gα13 (Hart et al., 1998; Kozasa et al.,
1998; Fukuhara et al., 1999, 2001). The activation of LARG by Gα12 relies on a phosphorylation by
the non-receptor tyrosine kinase Tec (Suzuki et al., 2003). Lbc RhoGEF is the fourth RhoGEF
activated by this Gα subfamily and is expressed in many different splice variants (Aittaleb et al.,
2010). The activation of this RhoGEF depends on Gα12, but a direct interaction has not yet been shown
(Aittaleb et al., 2010; Cavin et al., 2014). Due to the RH domain shared by LARG, p115RhoGEF and
PDZ-RhoGEF, they are also referred to as RH-RhoGEFs (see 4.5.1.1 and fig. 4, (Aittaleb et al.,
2010)). Together with Lbc RhoGEF they are additionally referred to as Lbc RhoGEFs. All of them are
widely expressed in mammals, with emphasis on the hematopoetic system for p115RhoGEF and on
the central nervous system for PDZ-RhoGEF (Hart et al., 1998; Fukuhara et al., 1999; Kourlas et al.,
2000; Kuner et al., 2002).
4.5.1.1 RH-RhoGEFs: LARG, p115RhoGEF and PDZ-RhoGEF
LARG and p115RhoGEF have weak GAP activity
In contrast to RGS proteins (4.6) the GAP activity of p115RhoGEF is not maintained by the RH
domain, but by a sequence directly N-terminal of the RH domain (Chen et al., 2003). Together the RH
1 Most RhoGEFs have more than one name. For RhoGEFs relevant for this thesis the different names can be
found in the abbreviations section as listed by Cook et al. (Cook et al., 2014).
Fig. 5 Domain structure of RH-RhoGEFs
As visible all RH-RhoGEFs share the DH-PH domain and the rgRGS domain. In addition LARG shares a PDZ domain
with PDZ-RhoGEF and a coiled-coil oligomerization domain with p115-RhoGEF. The scheme was adopted from
Aittaleb et al. (Aittaleb et al., 2010).
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domain and this N-terminally region build the rgRGS domain (fig. 5, (Aittaleb et al., 2010)). Gα12/13
binding to the rgRGS domain of RhoGEFs and the RH domain of RGS proteins differ and this might
be the reason for the rather weak GAP activity of LARG and p115RhoGEF (Aittaleb et al., 2010).
Both proteins exhibit GAP activity against Gα12 as well as Gα13, even though p115RhoGEF was not
demonstrated to be activated by Gα12 (Hart et al., 1998; Kozasa et al., 1998; Chen et al., 2003; Suzuki
et al., 2003). Since the trimeric G protein activates the RhoGEF and the RhoGEF accelerates the
G protein’s inactivation, p115RhoGEF and LARG are neither pure effectors nor pure regulators. But
they are rather part of a so called “kinetic scaffolding”, which transduced probably only rapid and
robust activation of Gα12/13 to Rho activation (Rossman et al., 2005). For PDZ-RhoGEF no GAP
activity was found towards Gα12/13, as Wells et al. stated referring to unpublished work by T. Kozasa
and P. Steinweis (Wells et al., 2002).
RhoGEFs bind Gα12/13 by their RH domain
In a crystallography study of p115RhoGEF with a Gα13/i chimera, the RH domain was shown to bind
to the canonical effector docking site of Gα and to be important for G protein binding together with a
C-terminal extension of this region (Chen et al., 2005). Three years later the structure was published of
the rgRGS domain of PDZ-RhoGEF with another Gα13 chimera, which was relatively similar to the
one observed for p115RhoGEF (Chen et al., 2008). The structures differed in the amino acids involved
in GAP activity for p115RhoGEF and this may explain PDZ-RhoGEF´s lack in GAP activity (Chen et
al., 2008). In the same study a complex was found of GDP bound Gα13 in close-to active conformation
together with PDZ-RhoGEF, which may suggests the interaction of RH-RhoGEF with Gα12/13 after
GTP hydrolysis. Aittaleb and colleges suggested a competition of Gβγ with the RH-RhoGEF for
Gα12/13-GDP binding (Aittaleb et al., 2010).
Fig. 6 Activation of LARG by Gα13Upon stimulation of a G protein coupled receptor with an agonist, Gα13 becomesactive. The active Gα13 binds LARG by its RH domain and subsequently theC-terminus and the DH-PH domain bind. During this activation process LARG
translocates from the cytosol to the plasma membrane. The scheme is based on
Suzuki et al.´s hypothesis about LARG activation by Gα13 (Suzuki et al., 2009b).Gβγ were neglected in interest of simplicity.
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In a surface plasmon resonance study Gα13 interacted with the RH domain, the DH-PH domain and
with C-terminal regions of LARG (fig. 6, (Suzuki et al., 2009b). The authors discuss an induced fit
mechanism: First the RH domain binds the active Gα13 and upon subsequent intraprotein
rearrangements the DH-PH domain binds together with the C-terminal regions to Gα13. This second
step is probably independent of Gα13´s activation state and Aittaleb et al. link it to the C-terminal
region of the GTPase domain of Gα13 (Aittaleb et al., 2010). The high affinity complex depends on all
three interactions and a mutation was described within Gα13, which abolished RH but not DH-PH
domain binding (Nakamura et al., 2004; Grabocka and Wedegaertner, 2007).
Already 2007 Kreutz and colleagues showed the C-terminal 100 amino acids of Gα13 to be important
for activation of the GEF activity of p115RhoGEF and LARG, whereas the N-terminal α-helical
domain and the switch regions are crucial for GAP activity. The Gα subunit binds the RH domain
and facilitates Gα13´s binding to the DH domain by this, which then leads to GEF activation (Chen
et al., 2012).
For PDZ-RhoGEF a NMR study showed autoinhibition of GEF activity by the PDZ domain, the RH
domain and a short acidic motive immediately N-terminal of the DH domain (Zheng et al., 2009).
Regulation by dimerization and phosphorylation
Another type of regulation was described for all three RH-RhoGEFs, which is dimerization. They can
form homo- and heterodimers, which might have a negative regulatory effect. Since dimerization
occurs through their C-termini and deletion of the C-terminus leads to higher SRE.L transcription
(Chikumi et al., 2004). For LARG a single point mutation inhibited dimerization and led to nuclear
localization of LARG (Grabocka and Wedegaertner, 2007). In this study SRE.L transcription was
unchanged. Notably, GEF activity is potentiated by the binding of the Rho effector mDia1 to the
C-terminus of LARG, which seems to be a positive feedback loop in the LARG Rho mDia1 axis
(Kitzing et al., 2007). The LARG Rho mDia1 axis is important for microtubule organization during
cell polarization (Goulimari et al., 2008).
The C-termini of PDZ-RhoGEF and LARG are phosphorylated by focal adhesion kinase (FAK),
which was shown to be important for sustained Rho activation upon thrombin receptor activation
(Chikumi et al., 2002a). FAK maybe initiates thereby also a positive feedback loop. LARG is
additionally phosphorylated by a set of other kinases like Burtons´s tyrosine kinase, Src family kinases
(SFKs) and Tec (Hamazaki et al., 1998; Mao et al., 1998; Guilluy et al., 2011). In vascular smooth
muscle cells PDZ-RhoGEF is tyrosine phosphorylated by PYK2 upon stimulation with angiotensin II,
which lead to enhanced GEF activity (Ying et al., 2009). Also for p115RhoGEF phosphorylation sites
are described, but their phosphorylation remains to be tested in living cells (Chow et al., 2013).
RH-RhoGEFs translocate to the plasma membrane
The RH-RhoGEFs translocate to the cell membrane upon activation of Gα12/13 coupled receptors or
coexpression of constitutive active Gα12/13 (Meyer et al., 2008). Bhattacharyya and Wedegaertner showed
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the translocation of p115RhoGEF from the cytosol to the plasma membrane for the first time
(Bhattacharyya and Wedegaertner, 2000). The translocation was induced by coexpression of constitutive
active Gα13 together with myc-tagged p115RhoGEF and depended on Gα13´s localization at the plasma
membrane. Further p115RhoGEF´s translocation was shown to be a reversible process upon activation
and inactivation of different Gα12/13 coupled receptors, with translocation within in one to two minutes
and redistribution upon antagonist application within a minute (Meyer et al., 2008).
For PDZ-RhoGEF colocalization with cortical actin and microtubules was described (Togashi et al.,
2000). In neurons LPA receptor activation translocates PDZ-RhoGEF to the tips of neurites and
overexpressed PDZ-RhoGEF is found partially at or close to the plasma membrane (Banerjee and
Wedegaertner, 2004). Recently, p115RhoGEF and PDZ-RhoGEF were artificially translocated to the
plasma membrane by a rapalog system and this led to an increase in GEF activity in the absence of
G protein activation (Carter et al., 2014). Thus the authors suggested GEF activity to be based on
colocalization of the RhoGEF with Rho at the plasma membrane, rather than on activation of the GEF
activity. Nevertheless biochemical experiments clearly show an increase in GEF activity for
p115RhoGEF and LARG by Gα13 in solution (Hart et al., 1998; Suzuki et al., 2003).
Endogenous and cotransfected LARG is found predominantly in the cytosol of COS7 cells (Banerjee
and Wedegaertner, 2004; Grabocka and Wedegaertner, 2007). In MDCKII cells LARG is localized at
the lateral cell membranes and a bit in the cytosol (Taya et al., 2001). In fibroblasts LARG is found in
the microtubule organizing center and along microtubule tracks (Siehler, 2009). The translocation of
LARG was monitored in living cells as part of this thesis.
Activation of PDZ containing RhoGEFs by non-GPCR receptors
PDZ containing RhoGEFs can be activated by binding of their PDZ domain to a PDZ binding motive
in the C-terminus of plexin B1, a semaphorin 4D receptor and this activation mechanism is implicated
in axonal growth cone collapse and angiogenesis (Swiercz et al., 2002; Basile et al., 2004).
Additionally, LARG binds directly and constitutive to IGF-1 receptor and is activated by IGF-1 (Taya
et al., 2001). LARG/PDZ-RhoGEF bind also to the GPCRs LPA-1 and LPA-2 via the receptor´s PDZ
binding motive (Yamada et al., 2005).
RhoA binding and GEF activity
LARG has the highest catalytic activity among the RH-RhoGEFs. They are specific GEFs for RhoA,
RhoB and RhoC and RhoA-GTP binds to the DH domain and forms also contacts with the PH domain
(Jaiswal et al., 2011). Autoinhibition of p115RhoGEF was mapped to its RH domain (Jaiswal et al.,
2011). Whereas mutations in the PH domain released LARG from autoinhibition to levels of DH
domain alone, which was not the case for PDZ-RhoGEF (Kristelly et al., 2004; Oleksy et al., 2006).
This difference could be due to the LARG´s relatively long linker, which allows a larger movement
between DH and PH domain of LARG compared to PDZ-RhoGEF (Aittaleb et al., 2010). For all
Lbc RhoGEFs a hydrophobic patch in the PH domain seemed to be important for RhoA activation in
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cells (Aittaleb et al., 2009). In case of LARG its implicated in proper localization of LARG, since
fusion of an unspecific plasma membrane targeting motive restored RhoA activation in the absence of
this domain (Aittaleb et al., 2009).
Interestingly RhoA-GTP was described to bind to the PH domain of Lbc RhoGEFs and to induce a
positive feedback loop by this (Medina et al., 2013).
Physiology and pathology
Lsc is the murine orthologue of p115RhoGEF. It was primarily characterized in hematopoetic cells
and is required in normal B- and T-lymphocyte function as shown by knock-out studies (Girkontaite et
al., 2001). Further knock-out mice suffered from gastrointestinal motor dysfunction (Zizer et al.,
2010). p115RhoGEF is inactivated by the cytoplasmic domain of the HIV-1 transmembrane
glycoprotein gp41 (Zhang et al., 1999).
In contrast PDZ-RhoGEF knock-out mice showed no obvious phenotype (Mikelis et al., 2013). LARG
knock-out mice showed reduced birthrate, but no developmental defects were observed after birth
(Mikelis et al., 2013). However knock-out of both PDZ-RhoGEF and LARG resulted in complex
developmental defects and early embryonic lethality, probably due to major vascular defects (Mikelis
et al., 2013). In LARG, PDZ-RhoGEF, p115RhoGEF triple knock-out MEFs (mouse embryonic
fibroblasts) no Rho activation was found by Gα12/13 coupled receptors, but stable Rho activation by
Gαq coupled receptors (Mikelis et al., 2013).
LARG was firstly described in a fusion protein of a patient with acute myeloid leukemia (Kourlas et al.,
2000; Kuner et al., 2002). This fusion protein consisted of mixed lineage leukemia (MLL) and LARG
without its nuclear localization sequence (NLS) and PDZ-domain, precisely everything C-terminal of
AS 308. In mice LARG mRNA was found widely expressed with higher expression in lung, liver, testis,
heart and hematopoetic progenitor cells (Zinovyeva et al., 2004). Also in human LARG is ubiquitously
expressed (Kourlas et al., 2000). LARG expression was found dramatically increased in bone marrow of
patients with the pre-leukemic disorder Shwachman-Diamond syndrome (Rujkijyanont et al., 2007).
Whereas low LARG expression levels have been found in solid tumors (Ong et al., 2009). In the heart
LARG is the most abundantly expressed RhoGEF and is the central player during pressure-overload
induced hypertrophy (Takefuji et al., 2013). Together with other RH-RhoGEFs and p63RhoGEF, LARG
was described to be involved in vascular smooth muscle tone (4.7).
4.5.2 Gαq-activated RhoGEFs
The hypotheses of Rho activation by Gαq in parallel to Gα12/13 was supported by detection of Rho
activation downstream of Gαq in Gα12/13 deficient MEFs (Sah et al., 1996; Chikumi et al., 2002b; Vogt
et al., 2003). Mainly three RhoGEFs were discussed to link Gαq activation and Rho signaling: LARG ,
Lbc RhoGEF and p63RhoGEF with its near relatives Trio and Kalirin (Sagi et al., 2001; Booden et al.,
2002; Chikumi et al., 2002b; Pi et al., 2002; Vogt et al., 2003; Lutz et al., 2005; Rojas et al., 2007;
Williams et al., 2007).
31
Introduction
LARG was previously described in detail as Gα12/13-activated RhoGEF. Whether LARG is also
activated by Gαq is a matter of debate: LARG´s RH domain was able to coimmunoprecipitate Gα12,
Gα13 and Gαq in one study (Booden et al., 2002). Two other groups were not able to
coimmunoprecipitate LARG with Gαq (Fukuhara et al., 2000; Chikumi et al., 2002b). Further in the
presence of LARG SRE.L activation was enhanced by stimulation of H1-R or cotransfection of
constitutive active Gαq. This could be abolished by PLCβ1 coexpression, which argued in favor of
LARG activation by Gαq (Pfreimer et al., 2011). Our laboratory could not detect interaction of Gαq
and LARG by means of FRET, which might point against a Gαq LARG complex (Bodmann, diploma
thesis). Additionally, the p115RhoGEF, PDZ-RhoGEF, LARG triple knock-out mice showed defects
in Gα12/13 mediated Rho activation, but did not show any effects on Gαq mediated Rho activation
(Mikelis et al., 2013).
Also Lbc RhoGEF could be precipitated with Gαq, but its activation in Gα12/13 knock-out mice has not
been shown (Sagi et al., 2001; Pi et al., 2002). p63RhoGEF is the most well-established link between
Gαq activation and RhoA signaling (Lutz et al., 2005). The next section discusses p63RhoGEF in
detail and gives some further information about Kalirin and Trio.
4.5.2.1 p63RhoGEF
Gαq binds mainly p63RhoGEF´s PH domain
p63RhoGEF lacks a RH domain in contrast to the previously described RH-RhoGEFs. Gαq binding
was localized to the C-terminal helix of the PH domain by truncation studies and releases
p63RhoGEF from autoinhibition (fig. 7, (Lutz et al., 2007; Rojas et al., 2007)). Active Gαq bound to
the same region of closely related Trio and Kalirin, as shown in the same studies. In 2007 a crystal
structure was published of a Gαi/q chimera in complex with p63RhoGEF´s DH-PH domain (amino
acid 149 to 502) and RhoA (fig. 30 (Lutz et al., 2007)). This structure proofed the C-terminal helix
of the PH domain to be unusually long and to bind directly into Gαq´s effector docking site. Several
Fig. 7 Activation of p63RhoGEF by GαqIn inactive p63RhoGEF the PH domain folds back onto the catalytic DH domain, which leads to
autoinhibition. Active Gαq interacts with the PH domain and this releases the DH domain fromautoinhibition. In addition, Gαq directly contacts the DH domain. Together both mechanisms enablefull RhoGEF activity towards RhoA. The scheme is based on a figure from a review by Aittaleb and
colleagues (Aittaleb et al., 2010). Gβγ were neglected here in interest of simplicity.
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mutations were introduced into this region, which diminished p63RhoGEF Gαq interaction and two
of these mutants, F471E and L475A, were used in the present work (6.2.2 and 6.2.6). Noteworthy,
also contacts are formed between p63RhoGEF´s DH-domain and its DH-PH interface with the
C-terminal region of Gαq. These interactions have mainly regulatory functions, as mutation of the
corresponding amino acids of p63RhoGEF or Gαq (Tyr356) prevented p63RhoGEF´s activation by
Gαq, but did not affect their interaction (Lutz et al., 2007; Shankaranarayanan et al., 2010).
Consequently, p63RhoGEF interacts with, but is not activated by Gα16, which exhibits an isoleucine
in the place of Gαq´s Tyr356 (Moepps et al., 2008; Yeung and Wong, 2009). Also active mitogen-
activated kinase (MLK3) might bind to p63RhoGEF and thereby might prevent binding to and
activation by Gαq (Swenson-Fields et al., 2008).
PLCβ3 overlaps with p63RhoGEF and RGS2 binding to Gαq
Similarly PLCβ1/4 and p63RhoGEF are located at the plasma membrane under basal conditions and
are activated by Gαq via relief of autoinhibition (Shankaranarayanan et al., 2010; Lyon et al., 2011;
Sánchez-Fernández et al., 2014). Both proteins bind very similar to Gαq´s effector binding site with
their helix turn helix domain and thus exclude each other from Gαq binding (fig 8, orange area, (Lutz
et al., 2005, 2007; Adjobo-Hermans et al., 2013; Lyon et al., 2013, 2014)).
Interestingly, PLCβ3 binds additionally to switch I and II of Gαq and exhibits GAP activity towards
Gαq through these interactions. Hence fast activation of PLCβ3 by Gαq is followed by fast
inactivation of Gαq by PLCβ, which was entitled as “kinetic scaffolding” (Berstein et al., 1992;
Waldo et al., 2010).
Fig. 8 Comparison of putative trimeric complex of Gαq, RGS2 and p63RhoGEF and dimeric complex of Gαqand PLCβ3
On Gαq the canonical effector binding site is shown in orange and the RGS binding site in purple. These models weregenerated by Lyon and colleagues. In A they superimposed the structure of Gαq p63RhoGEF (PDB 2RGN) with theGαq RGS2 (PDB 4EKC) structure (Lutz et al., 2007; Nance et al., 2013; Lyon et al., 2014). The crystal structure ofPLCβ3 in complex with Gαq is shown in B (PDB 4GNK (Lyon et al., 2013)). One can recognize the overlap of PLCβ3with RGS2 and p63RhoGEF binding to Gαq.
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This second binding site between Gαq and PLCβ overlapped almost completely with the classical RGS
binding site at Gαq (fig. 8B, purple area (Waldo et al., 2010)). Hence, the Gαq PLCβ3 interaction
blocks Gαq´s switch I, which is freely accessible for RGS in the Gαq p63RhoGEF interaction (Aittaleb
et al., 2010). Consequently, a trimeric complex between p63RhoGEF, Gαq and RGS2 was shown by
biochemical assays and modulations in 2008 (see fig. 8A for a structural model, (Lutz et al., 2007;
Shankaranarayanan et al., 2008; Nance et al., 2013; Lyon et al., 2014)). A part of the work presented
here focused on the interaction between PLCβ3, RGS2 and p63RhoGEF with Gαq in living cells (6.2).
Interestingly, proper signaling at the neuromuscular junction of C. elegans was linked to simultaneous
signaling by both effectors (Williams et al., 2007).
p63RhoGEF localizes at the plasma membrane
In contrast to RH-RhoGEFs p63RhoGEF was found localized to actin-rich structures and at the plasma
membrane upon overexpression (Souchet et al., 2002; Shankaranarayanan et al., 2010). The
localization at the plasma membrane depends on palmitoylation of three cysteine residues in the
N-terminal region of p63RhoGEF and was concluded important for p63RhoGEF`s full activity
(Aittaleb et al., 2011; Goedhart et al., 2013). Consequently GEFT, which lacks the N-terminal region,
appeared in the cytosol (Lutz et al., 2004; Goedhart et al., 2013). Upon Gαq activation GEFT
translocated to the plasma membrane as shown by confocal microscopy (Goedhart et al., 2013).
RhoA is activated upon relieve of p63RhoGEF´s autoinhibition
p63RhoGEF is a GEF for RhoA, RhoB and RhoC (Rojas et al., 2007). RhoA binds to p63RhoGEF´s
DH domain, which is autoinhibited by the PH domain in the absence of active Gαq (Lutz et al., 2007).
However the interaction is regulated by the whole DH-PH domain (Lutz et al., 2004, 2007; Rojas et
al., 2007; Shankaranarayanan et al., 2010): The PH domain autoinhibits the DH domain, if they are
covalently linked via their α6-N6 linker and Gαq is not bound. Upon Gαq binding the affinity is
enhanced between DH domain and Gαq. This is caused by loss of autoinhibition and additional
allosteric activation of the DH domain (fig. 7). The additional allosteric activation occurs through the
interaction of Gαq´s C-terminal region and the DH domain (Shankaranarayanan et al., 2010).
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Trio and Kalirin, the complex siblings of p63RhoGEF
These RhoGEFs are much more complex in structure than p63RhoGEF (fig. 9). They have two sets of
DH-PH and additional domains. The first DH-PH domain activates RhoG and Rac, whereas the
second one activates RhoA. The latter is closely related to p63RhoGEF and their autoinhibitory
PH domains were shown 100% identical in the amino acids important for Gαq binding (Liu et al.,
1998; Bellanger et al., 2003; Skowronek et al., 2004; Chhatriwala et al., 2007; Lutz et al., 2007; Rojas
et al., 2007). However they form complex crosstalk between their other domains, heterotrimeric
G proteins and their effectors (Aittaleb et al., 2010). Therefore p63RhoGEF was used as a model for
RhoGEFs activated exclusively by Gαq in the work presented here.
Physiology and pathology
In Cenorhabditis elegans UNC-73E is the homologue of Trio and is for example important in egg
laying and growth (Williams et al., 2007). In mammals p63RhoGEF is predominantly expressed in the
brain and heart (Souchet et al., 2002; Lutz et al., 2004). Nevertheless p63RhoGEF was shown to be
critically involved in angiotensin II-induced signaling in vascular smooth muscle cells and is discussed
to be the main switch in Gαq-mediated smooth muscle activation (see 2.7, (Wuertz et al., 2010;
Momotani and Somlyo, 2012)). In the pathology of cancer GEFT, which is a splice variant of
p63RhoGEF, was found overexpressed in rhabdomyosarcoma (Sun et al., 2014). In breast carcinoma
p63RhoGEF was described to be essential for chemotactic migration and to be activated downstream
of GPR116, which expression correlated with breast tumor progression, recurrence and poor prognosis
(Hayashi et al., 2013; Tang et al., 2013).
Interestingly the Gαq p63RhoGEF RhoA axis was recently identified as target for the Pasteurella
multocida toxin, which inhibits osteoblast genesis and causes progressive bone loss during atrophic
rhinitis in various animals (Siegert et al., 2013).
Fig. 9 Domain structure of p63RhoGEF, Trio and Kalirin
These Gαq-activated RhoGEFs have one very similar DH-PH domain. Interestingly, Trio and Kalirin share anotherDH-PH domain, which activates Rac and RhoG, and they have many additional domains, for example a kinase domain in
their C-terminus. For these two proteins the N-terminus is excluded from the scheme. This scheme is based on a figure
from a review by Aittaleb and co-workers (Aittaleb et al., 2010).
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4.6 RGS proteins
Function
Approximately half of all regulators of G protein signaling (RGSs) negatively regulate Gα proteins
(Heximer, 2013). In order to do so RGS accelerate GTP hydrolysis at least 40-fold by stabilizing the
transition state of the GTPase, which they bind with highest affinity by interaction with all three switch
regions of Gα (Berman et al., 1996a, 1996b; Tesmer et al., 1997; Baltoumas et al., 2013) In human
35 RGS proteins are expressed. The RGS domain is the feature common to all of them. This domain is
120-130 amino acids long, composed of a bundle of nine α-helices and can bind directly to the activated
Gα subunit (Hollinger and Hepler, 2002; Baltoumas et al., 2013). Of relevance for the present work are
the B/R4 and F/RL subfamilies. The B/R4 subfamily consists of RGS1 to 5, 8, 13, 16, 18 and 21 and the
F/RL subfamily, also known as RGS-like proteins, includes RhoGEFs (see 4.5), GRKs, AKAPs and
sorting nexins (Ross and Wilkie, 2000). Of the F/RL family only the RhoGEFs are relevant for the
present study and they were described elsewhere (see 4.5).
The B/R4 RGS proteins can exhibit GAP activity towards Gαi and/or Gαq. Heximer and colleagues found
the GAP activity of RGS2 towards Gαq-stimulated IP3 production 5-fold higher than the one of RGS4 and
vice versa RGS4´s GAP activity for Gαi-mediated signaling 8-fold higher than RGS2´s in vitro (Heximer
et al., 1999). The Gαq and Gαi selectivity can be exchanged between RGS2 and 4 by mutation of three
amino acids within the Gα binding pocket of the respective RGS protein into the corresponding amino
acids of the other one (Heximer et al., 1999). Nevertheless, RGS2 wild type has GAP activity for Gαi in
membrane-reconstituted system (Cladman and Chidiac, 2002). In 2013, the crystal structure was
elucidated for RGS2´s RGS domain in complex with constitutive active Gαq, which lacks its N-terminal
helix (Nance et al., 2013). RGS2 docks to Gαq in an overall similar manner compared to the previously
described RGS Gαi/o complexes, but is tilted by seven degrees (Nance et al., 2013). Also this interaction
allows for the conserved mechanism of acceleration of GTPase activity by RGS proteins. If the three
amino acids mentioned previously are mutated to the ones in RGS4, the interaction is more similar to the
one observed for RGS and Gαi/o. Nevertheless in ventricular myocytes RGS2, 3, 4 and 5 inhibited Gαq
signaling equally well (Hao et al., 2006). Hence, in a signaling pathway specific GAP activity has to
depend on additional aspects. One is the type of activated GPCR. Some GPCRs can be recognized by the
RGS´ N-terminal region (Zeng et al., 1998; Bernstein et al., 2004; Itoh et al., 2006). As for example RGS5
inhibits Gαq activation by angiotensin 1 and endothelin ETA receptor, but not by muscarinic M3 receptor
(Zhou et al., 2001). Some RGS proteins work as effector antagonists independent of the GAP activity. In
order to do so, they either bind the effector or a region overlapping with the effector binding site at the Gα
subunit, thus competing with the effector for binding (Cunningham et al., 2001; Salim et al., 2003; Anger
et al., 2004). The latter mechanism was discovered in cells treated with GTPγS. Under this condition
RGS2 could not hydrolyze Gαq, but signaling towards PLCβ was still abolished (Cunningham et al.,
2001). Other Gαq effectors are discussed to build high order complexes together with Gα and RGS
proteins (Tesmer et al., 2005). In these complexes RGS2 and 4 would not compete for the effector
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binding, but rather inhibit effector association and activation allosterically (Shankaranarayanan et al.,
2008; Nance et al., 2013). A part of this study aimed to characterize the allosteric effect of RGS2 on the
p63RhoGEF Gαq interaction and investigated downstream signaling in detail (see also 4.5.2.1 PLCβ3
overlaps with p63RhoGEF and RGS2 binding to Gαq). Also Gβγ was suggested to bind RGS proteins
directly, e.g. RGS3, and this interaction was discussed to directly blocked Gβγ signaling (Shi et al., 2001).
Additionally direct binding was described between different RGS proteins and mediators downstream of
trimeric G proteins (reviewed in (Bansal et al., 2007)).
RGS proteins are tightly regulated
RGS proteins were shown to be regulated by posttranslational modification, translocation as well as
changes in expression level:
The palmitoylation at the N-terminus of RGS proteins was discussed to be involved in plasma
membrane localization, whereas the lipid modification in the RGS domain are thought to either
potentiate or inhibit GAP activity (Hiol et al., 2003; Osterhout et al., 2003; Jones, 2004). In addition
phosphorylation can influence the GAP activity positively as well as negatively depending on the RGS
protein and kinase involved (Hendriks-Balk et al., 2008).
RGS mRNA levels are regulated tissue as well as receptor specific, for example quick upregulation of
RGS2 mRNA was found upon angiotensin II stimulation (Grant et al., 2000; Li et al., 2005). RGS4
mRNA was up and RGS2 mRNA downregulated in models of cardiac hypertrophy (Kach et al., 2012).
The protein levels could not be examined directly due to lack of good antibodies. But RGS4 was
shown to be ubiquitinated, which probably causes the described relatively short half life of less than an
hour (Lee et al., 2005).
Physiology
The first RGS protein described was Sst2p, which inhibits the pheromone-induced mating response in
Saccharomyces cerevisiae and exhibits GAP activity against the yeast Gα, Gpa1 (Dohlman et al.,
1998). In mammals R4 RGS proteins are involved in a wide variety of processes as reviewed
elsewhere (Hendriks-Balk et al., 2008). For example RGS2 was shown as a regulator of vascular tone
(see 4.7) and was found in almost every tissue investigated in mice and humans (Kehrl and Sinnarajah,
2002). Further mice deficient in RGS2 showed defects in immune response, synapse development and
increased anxiety response (Oliveira-dos-Santos et al., 2000). In the vascular pathology of
atherosclerosis RGS5 was found downregulated and decreased RGS5 mRNA levels were associated
with neointima formation (Geary, 2002; Li et al., 2004; Adams et al., 2006). The expression of
RGS1, 13 and 16 in B cells is important for adaptive immune response (Beadling et al., 1999; Han et
al., 2006). Almost every RGS protein was found expressed in the mammalian heart and cultured
cardiomyocytes, however the expression levels may differ between cell types and regions of the heart
(Hendriks-Balk et al., 2008; Zhang and Mende, 2011). For some the expression was really low and
others, like RGS2, RGS4 or p115RhoGEF, were highly expressed (Wieland and Mittmann, 2003).
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4.7 The GPCR G protein RhoGEF Rho axis in vascular tone
The arterial blood pressure is tightly regulated by many different mechanisms in order to prevent
persistent, elevated levels in systolic and/or diastolic blood pressure, known as hypertension (Loirand
and Pacaud, 2014). One of these mechanisms is regulation of the vascular tone, which is mainly
conducted by vascular smooth muscle cells (VSMC). Their contraction depends on the
phosphorylation status of 20kDa myosin light chain (MLC), which is phosphorylated by MLC kinase
(MLCK) and dephosphorylated by MLC phosphatase (MLCP, fig. 4, (Puetz et al., 2009)). In the
phosphorylated state the actin-activated ATPase activity is increased and crossbridge cycling occurs,
which shortens/contracts the VSMC (Momotani and Somlyo, 2012). The kinase is Ca2+-calmodulin
dependent and activated by rise in cytosolic Ca2+ concentrations whereas the phosphatase is Ca2+
independent. Thus inactivation of MLCP results in Ca2+ sensitization of the system (fig. 4). The
regulation of cytosolic Ca2+ and Ca2+ sensitization occurs mainly through activation of GPCRs, which
are coupled to Gαq and Gα12/13. Gαq activates PLC and subsequently Ca2+ is released from intracellular
stores and flows in from the extracellular lumen (de Gasparo et al., 2000; Balakumar and Jagadeesh,
2010). In parallel RhoGEFs are activated by either Gαq/11 or Gα12/13, which induce Ca2+ sensitization
via RhoA and its target ROCK. Upon activation of ROCK MLCP is phosphorylated, which reduces its
catalytic activity (Uehata et al., 1997). This causes higher sensitivity of MLC for Ca2+ and therefore
more pronounced contraction in the presence of small cytosolic Ca2+ concentrations (Loirand and
Pacaud, 2014). In Japan a ROCK inhibitor, Fasudil, is in clinical use for treatment of cerebral
vasospasm (Morgan-Fisher et al., 2013).
In interest of simplicity additional regulators like NO or RhoGAPs are neglected in the further
discussion on the role of the GPCR Gα RhoGEF Rho axis in vascular tone. Until now several different
RhoGEFs are shown to be involved in vascular tone regulation depending on the model of
hypertension studied (Loirand and Pacaud, 2014). In arterial smooth muscle cells p63RhoGEF is the
most abundant, but also p115-RhoGEF, PDZ-RhoGEF and LARG are expressed in conductance and
resistance arteries (Ying et al., 2004; Jin et al., 2006; Hilgers et al., 2007; Wirth et al., 2008; Momotani
et al., 2011; Cario-Toumaniantz et al., 2012). Gαq knock-out mice showed no aorta contraction upon
Ang II stimulation, but aorta of Gα12/13-deficient mice contracted almost complete (Wirth et al., 2008).
This emphasizes p63RhoGEF´s role in response to Ang II, since p63RhoGEF is the only RhoGEF of
the four activated by Gαq. Additionally p63RhoGEF was found upregulated in hypertensive patients
(Calò et al., 2014). Due to these and other observations p63RhoGEF was implicated as major regulator
of basal blood pressure (Momotani and Somlyo, 2012). S1P stimulation activates LARG in vascular
smooth muscle cells and salt-induced hypertension was abolished by LARG knock-out mice (Wirth et
al., 2008; Medlin et al., 2010). According to a recent study, LARG and PDZ-RhoGEF mediate Ca2+
sensitization in arterial smooth muscle cells simultaneously upon stimulation of Gα12/13 coupled
Txa2-R and ET-1-R, but if one of the RhoGEFs was missing the half time until full contraction was
prolonged (Artamonov et al., 2013). In our opinion this showed the importance of exact knowledge on
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the kinetics of activation and inactivation of individual RH-RhoGEFs. Therefore LARG activation by
Gα12/13 was studied in detail in the present work (see 6.1).
An influence of RGS2 on vascular tone is most likely, since RGS2 knock-out mice have increased blood
pressure and are hyperresponsive to vasoconstrictors (Heximer et al., 2003). Additionally NO induced
relaxation is reduced in these mice, since no RGS2 is present, which could be activated downstream of
NO production (Tang et al., 2003; Sun et al., 2005). Interestingly also in human changes in RGS2
expression influence the blood pressure as several SNPs in RGS2 were associated with hypertension in
patients and decreased RGS2 levels were described for hypertensive patients (Riddle et al., 2006;
Semplicini et al., 2006; Bodenstein et al., 2007; Freson et al., 2007; Gu et al., 2008; Kohara et al., 2008).
This finding underlined RGS2´s function as regulator of vascular tone.
Noteworthy, in a human syndrome of normo- or hypotension in the presence of high renin and
aldosterone plasma levels, the inhibitor of Ang II signaling RGS2 was found up and the signaling
mediators, p115RhoGEF and p63RhoGEF, downregulated (Calò et al., 2004, 2011; Pagnin et al.,
2005; Fremont and Chan, 2012). The regulation of p63RhoGEF by RGS2 in single living cells was
investigated as part of the present study (see 6.2).
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4.8 Aim of the study
Regulation of Rho activity by G protein coupled receptors is important for many physiological and
pathophysiological conditions, including regulation of vascular tone (Wirth et al., 2008; Momotani et
al., 2011; Balakumar and Jagadeesh, 2014). GPCRs regulate RhoA mainly via RhoGEFs, which are
directly activated by Gαq and Gα12/13. The best established signaling cascades link activation of Gαq
and Gα13 to p63RhoGEF and RH-RhoGEFs, respectively (fig. 10B).
Until now the GPCR G protein RhoGEF Rho axis was mainly studied at endpoints, like active
RhoA-GTP concentrations, SRE.L reporter gene assays or cytoskeletal changes (fig. 10A). With
these methods the importance of this signaling axis was shown on the level of single cells as well as
for regulation of important physiological parameters, like synaptic plasticity or blood pressure. The
GPCR G protein Rho signaling pathway will interfere with other pathways to give rise to an
integrated cellular response. Therefore it is important to study the temporal dynamics of the GPCR
induced Rho signaling pathway. In the present study we aimed to elucidate the interaction of
p63RhoGEF and the RH-RhoGEF LARG with Gαq and Gα13, respectively, with high temporal and
spatial resolution for the first time. As this information might give insight as to why RhoGEFs are
activated downstream of two different Gα subfamilies and how information is integrated within one
or between the two signaling pathways. Of note, this signal integration dictates the sensitivity as
well as duration of the signaling upon stimulation of GPCRs by physiological agonists.
Accordingly, several FRET assays were developed and the speed of RhoGEF inactivation was
determined as kinetics of complex dissociation (koff).
Fig. 10 GPCR signaling towards RhoGEFs
A RhoA is activated upon activation of both Gαq and Gα13. In this study Gαq signaling towards RhoA via p63RhoGEFwas resolved in single cells with high temporal resolution. Additionally the regulation of this interaction by the PLCβ
antagonist RGS2 was studied in detail. Further activation of leukemia-associated RhoGEF (LARG) by Gα13 wasinvestigated with the same temporal and steric resolution. LARG was chosen as representative for the important family of
RH-RhoGEFs. Also RhoA activation itself and gene expression was determined downstream of these pathways, in order
to gain a complete picture on regulation of RhoA signaling by GPCRs. By the flow chart in B the parallel steps for both
pathways are illustrated. The Gβγ subunit was neglected in interest of simplicity.
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Recently adenylyl cyclase V regulation was found more sensitive towards stimulation with small
agonist concentrations than the activation of its regulator Gαi (Milde et al., 2013). Thus we tested
whether or not the concentration response relationships of the LARG Gα13 and the p63RhoGEF Gαq
interaction differed in sensitivity compared to the respective G protein activation. Such sensitivity
differences between steps in the same signal transduction cascade would have to be considered for
the emerging pharmacological targeting of the GPCR G protein RhoGEF Rho axis and are thus of
great importance.
For sure this signaling pathway has to be tightly regulated by endogenous mechanisms besides the
regulation by pharmacological tools. RGS2 was implicated as regulator for effector activation by Gαq
for example in vascular smooth muscle cells. Therefore we wondered whether the kinetic and
sensitivity of p63RhoGEF activation is regulated by RGS2, which expression is modulated by several
stimuli, and used our new FRET tools in addition to well-established methods to study this in detail.
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5 Material and methods
5.1 Material
5.1.1 Plasmids
DAG sensor rat Addgene (plasmid 14865)
(Violin et al., 2003)
FLAG-LARG human cloned during this thesis
GIRK4-YFP rat L. Pott, Universität Bochum
(Mintert et al., 2007)
Gα13 Q226L
(Gα13 QL)
T. Wieland, Universität Heidelberg
(personal communication)
Gα13-mTur2 mouse A.-L. Krett in the workgroup of M. Bünemann
(personal communication)
Gα13-wt mouse A.-L. Krett in the workgroup of M. Bünemann
(personal communication)
Gα13-YFP mouse A.-L. Krett in the workgroup of M. Bünemann
(personal communication)
Gαi1-CFP rat M. Bünemann, University Würzburg
(Hein and Bünemann, 2009)
Gαq-CFP murine C. Berlot, Yale University School of Medicine
(Hughes et al., 2001)
Gαq-wt murine C. Berlot, Yale University School of Medicine
(Hughes et al., 2001)
Gαq-YFP murine C. Berlot, Yale University School of Medicine
(Hughes et al., 2001)
Gβ1-Cer human M. Bünemann, University Würzburg
(Frank et al., 2005)
Gβ1-wt human M. Bünemann, University Würzburg
(Bünemann et al., 2003)
Gγ2-wt bovine M. Bünemann, University Würzburg
(Bünemann et al., 2003)
H1-R human T. Wieland, Universität Heidelberg
(Lutz et al., 2005)
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LARG-insYFP human E.-L. Bodmann in the workgroup of M. Bünemann
(Bodmann, diploma thesis)
M3-R human Missouri S&T cDNA Resource Center
(http://www.cdna.org; #MAR030TN00)
mCFP M. Bünemann, University Würzburg
(Hein et al., 2005)
mTur2 V. Wolters in the workgroup of M. Bünemann
(Wolters et al., under revision)
p63RhoGEF human
(580aa; NP_891992)
T. Wieland, University Heidelberg
(personal communication)
p63RhoGEF-CFP human cloned during this thesis
p63RhoGEF-CFP
F471E L475A
human cloned during this thesis
pcDNA3-mRFP Addgene
(plasmid 13032 from Doug Golenbock)
pcDNA3 Invitrogen
pcDNA3-LARG human cloned during this thesis
pCMV T. Wieland, University Heidelberg
(personal communication)
pGex Rho/RBD R. Grosse, University Marburg
(Brandt et al., 2002)
pHyg-LARG human T. Wieland, University Heidelberg
(personal communication)
PLCβ3 mouse P. Gierschick, University Ulm
(Illenberger et al., 2003)
pRL-TK Promega
pSRE.L Provided by T. Wieland, University Heidelberg
(Hill et al., 1995)
RGS2 human Missouri S&T cDNA Resource Center
(http://www.cdna.org)
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RGS2-mRFP human cloned during this thesis
RGS2-YFP human S. Heximer, University of Toronto
(Gu et al., 2008)
Si-eYFP-β2AR human V. Wolters in the workgroup of M. Bünemann
(Wolters et al., under revision)
Si-eYFP-β2AR-mTur2 human cloned during this thesis
Si-Venus-β2AR-CFP human cloned during this thesis
Tax2-R human T. Wieland, University Heidelberg
(personal communication)
Venus-p63RhoGEF
(V-p63RhoGEF)
human
(580aa; NP_891992)
A. Rinne in the workgroup of M. Bünemann
(Bodmann et al., 2014)
V-p63RhoGEF F471E human A. Rinne in the workgroup of M. Bünemann
(Bodmann et al., 2014)
V-p63RhoGEF F471E
L475A
human A. Rinne in the workgroup of M. Bünemann
(Bodmann et al., 2014)
V-p63RhoGEF L475A human A. Rinne in the workgroup of M. Bünemann
(Bodmann et al., 2014)
YFP-LARG
(LARG N-terminally
tagged with eYFP)
human E.-L. Bodmann in the workgroup of M. Bünemann
(Bodmann, diploma thesis)
YFP-LARG F1098A
I1100E
human cloned during this thesis
YFP-PLCβ3 human M. Frank in the workgroup of M. Bünemann
(personal communication)
α2A-AR murine M. Bünemann, University Würzburg
(Bünemann et al., 2001)
β2AR-CFP human C. Krasel, University Würzburg
(Krasel et al., 2005)
β2AR-Tur human C. Krasel in the workgroup of M. Bünemann
(personal communication)
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5.1.2 Bacteria and cell lines
Two Escherichia coli strands were used. The chemically competent E. coli strain DH5α was used for
plasmid amplification and the E. coli strain Rosetta2 (DE3) (Novagen, Darmstadt) for protein
expression. All experiments were performed in human embryonic kidney cells. In most cases
HEK293TSA cells were used and for indicated experiments HEK293 cell stably transfected with
murine H1 histaminergic receptor, which were a kind gift from Roland Seifert, Medizinische
Hochschule Hannover.
5.1.3 Primers
The primers were ordered from Eurofins Genomics. They synthesize the oligomers by solid phase
synthesis with phosphoramidite chemistry (Caruthers et al., 1983). All primers used for
QuickChange® mutagenesis or with a size longer than 29 bases were purified with a liquid
chromatography based method, the High Purity Salt Free method by Eurofins Genomics. Before use
all primers were dissolved to a final concentration of 100pmol/µL in ultrapure water.
5.1.3.1 Primers used for cloning
Primer name Sequence Cloning project Melting
temperature
5´-Flag-Larg-Bam aaaaggatccatggattataaggatgatgatgataaaaat
gagtggcacacagtctac
Flag-LARG 60°C
3´-YFP-Larg-Xho ggtactcgagctaacttttatctgagtgcttg Flag-LARG 60°C
5´-RGS2_Kpn1 aaaaaaggtaccatgcaaagtgctatgttcttggc RGS2-RFP 62°C
3´-RGS2_Not1 aaaaaagcggccgcggtgtagcatgaggctctgtgg RGS2-RFP 62°C
5´-BamHI-Si aaaaaaggatccatgaagacgatcatcgccctgagctac
atcttctgcctggtattcgccatggtgagcaagggcgag
Si-Venus-β2AR-CFP 60°C
3´-Venus-XbaI aaaaaatctagacttgtacagctcgtcc Si-Venus- β2AR-CFP 60°C
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5.1.3.2 Primers used for QuickChange® site-directed mutagenesis
Primer name Sequence Cloning project
5´-p63RhoGEF-FELA cgggacgaactcaacgcagcgcagtcacccattgag p63RhoGEF-CFP
F471E L475A
3´-p63RhoGEF-FELA ctcaatgggtgactgcgctgcgttgagttcgtcccg p63RhoGEF-CFP
F471E L475A
5´-mTurq2-TTC ctggagtacaactacttcagcgacaacgtc Si-eYFP-beta2AR-mTur2
3´-mTurq2-TTC gacgttgtcgctgaagtagttgtactccag Si-eYFP-beta2AR-mTur2
5´-LARG-F1098A caacagataacaaagctttagccgtcatttccatgtcagac YFP-LARG
F1098A I110E
5´-LARG-I1100E gataacaaagctttagccgtcgaatccatgtcagacaatggcgc YFP-LARG
F1098A I110E
5.1.3.3 Sequencing primers
In most cases standard primers form Eurofins Genomics were used, which are listed at
http://www.eurofinsgenomics.eu/media/968735/standard-vector-primer.pdf. Additional primers are
listed below and were also ordered from Eurofins Genomics.
Primer name Sequence Binds to LARG
Seq_Larg_1 caggactgactgtagcagtg from bp875
Seq_Larg_2 agtgaaagagcctcgaaatttg from bp1679
Seq_Larg_3 tttggagaaagtcaaagtgagg from bp2247
Seq_Larg_4r tgatttcccagaggtactcag until bp3594
5.1.4 Chemicals
1 kb ladder New England BioLabs, Frankfurt
Acetylcholine Sigma-Aldrich, Steinheim
Acrylamide/ Bisacrylamide Carl Roth, Karlsruhe
Agar Applichem, Darmstadt
Ammonium persulfate (APS) Sigma-Aldrich, Steinheim
Ampicillin Applichem, Darmstadt
Bovine serum albumin (BSA) Sigma-Aldrich, Steinheim
Bovine serum albumin (BSA) (delipidized) Sigma-Aldrich, Steinheim
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Bromophenol blue Sigma-Aldrich, Steinheim
Calcium chloride Sigma-Aldrich, Steinheim
Cheluminate-HRP PicoDetect Applichem, Darmstadt
cOmplete ULTRA Tablets, Mini, EDTA-free,
EASYpack (protease inhibitor cocktail)
Roche, Mannheim
Desoxyribonucleotides (dNTPs) New England BioLabs, Frankfurt
Dimethyl sulfoxide Sigma-Aldrich, Steinheim
DMEM high glucose Capricorn, Ebsdorfergrund
dNTP mix New England BioLabs, Frankfurt
DTT Sigma-Aldrich, Steinheim
EDTA Sigma-Aldrich, Steinheim
Effectene Transfection Reagent Qiagen, Hilden
Ethanol absolute Roth, Karlsruhe
Ethidium bromide Promega, Mannheim
FCS superior Biochrom, Berlin
G-418 Sulphate PAA, Pasching
Glycine Carl Roth, Karlsruhe
HEPES Sigma-Aldrich, Steinheim
Histamine Sigma-Aldrich, Steinheim
Isopropanol Roth, Karlsruhe
Isopropylβ-D-1-thiogalactopyranoside (IPTG) Applichem, Darmstadt
Kanamycin sulfate Roth, Karlsruhe
LB-medium powder according to Lennox Applichem, Darmstadt
LE Agarose Biozym, Hessisch Oldendorf
L-glutamine 200 mM Biochrom, Berlin
Magnesium chloride Sigma-Aldrich, Steinheim
Magnesium sulfate Sigma-Aldrich, Steinheim
Methanol Lenz-Chemie, Westerburg
Milk powder Carl Roth, Karlsruhe
Noradrenaline bitartrate Sigma-Aldrich, Steinheim
PBS Biochrom, Berlin
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PEG 3000 Sigma-Aldrich, Steinheim
Penicillin/Streptomycin (10.000 U/mL / 10mg/mL) Biochrom, Berlin
peqGOLD Protein Marker IVv PEQLAB Biotechnologie, Erlangen
Polyethylenimine (PEI, linear. 25kDa) Polysciences, Eppelheim
PolyFect Transfection Reagent Qiagen, Hilden
Poly-L-lysine-hydrobromide Sigma-Aldrich, Steinheim
Potassium chloride Sigma-Aldrich, Steinheim
Protino® Glutathione Agarose 4B
(Glutathione-coated agarose beads)
Machery-Nagel, Düren
Sodium chloride Sigma-Aldrich, Steinheim
Sodium deoxycholate Sigma-Aldrich, Steinheim
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe
TEMED Carl Roth, Karlsruhe
Tris Sigma-Aldrich, Steinheim
Tris-Acetat Sigma-Aldrich, Steinheim
Trition X-100 Sigma-Aldrich, Steinheim
Trypsin/ EDTA (1:250) Biochrom, Berlin
U46619 (Txa2-R agonist) Biomol, Hamburg
β-mercaptoethanol Sigma-Aldrich, Steinheim
5.1.5 Consumables
Cell culture dish 6 cm & 10 cm (coated) Greiner, Solingen
Cell culture plate 6-well (coated) Greiner, Solingen
Cell culture plate 96-well (coated) Greiner, Solingen
Cell scraper 16cm Sarstedt, Nümbrecht
Cover slips 25 mm VWR, Darmstadt
Cuvettes Bio-Rad, München
Parafilm Brand, Wertheim
Pasteur pipets Hartenstein, Würzburg
PCR-tubes 0,2 mL Brand, Wertheim
Petri dish (uncoated) Hartenstein, Würzburg
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Pipet tips 10 µL, 200 µL, 1000 µL Greiner, Solingen
Polyvinylidene fluoride (PVDF) membrane Roche, Mannheim
Reaction tubes 1,5 & 2,0 mL Hartenstein, Würzburg
Reaction tubes 15 mL & 50 mL Greiner, Solingen
Ritips for multipette Plus® Kobe, Marburg
Whatman paper VWR, Darmstadt
White 96-well plates Perkin Elmer, Waltham, USA
5.1.6 Kits
Dual-Luciferase® Reporter Assay System Promega, Mannheim
Plasmid Midi Kit Qiagen, Hilden
QIAquick Gel Extraction Kit Qiagen, Hilden
5.1.7 Enzymes
Phusion DNA polymerase New England BioLabs, Frankfurt
Restriction endonucleases, various New England BioLabs, Frankfurt
Ribonuclease A (RNAse A) Roth, Karlsruhe
T4 DNA ligase New England BioLabs, Frankfurt
T4 DNA polymerase New England BioLabs, Frankfurt
5.1.8 Antibodies
5.1.8.1 Primary antibodies
Against Produced in Catalog no. Company Dilution
Actin mouse 691001 MP Biomedicals, Santa Ana 1:100.000
Gα13 goat sc-26788 Santa Cruz, Heidelberg 1:200
GFP goat 600-101-215 Rockland, Gilbertsville 1:300
LARG (H-70) rabbit sc-25638 Santa Cruz, Heidelberg 1:2000
Rho rabbit 2117S Cell Signaling, Darmstadt 1:2000
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5.1.8.2 Secondary antibodies
All secondary antibodies are conjugated to horse radish peroxidase.
Against Produced in Catalog no. Company Dilution
Goat horse PI-9500 Vector Laboratories, Burlingame 1:3.500
Mouse horse 7076 Cell Signaling, Darmstadt 1:3.500
Rabbit goat 7074 Cell Signaling, Darmstadt 1:3.500
5.1.9 Equipment
300 Volt Electrophoresis Power Supply Labnet, Ried im Innkreis
Autoclav VX-95 Systec, Bergheim
Cell chamber Attofluor Invitrogen, Darmstadt
ChemiDoc (gel analyzer) Bio-Rad, München
Digital Sonifier Branson
F100 Compact Ice flaker Icematic, Düsseldorf
Feinwaage 770 (precision balance) KERN & Sohn, Balingen-Frommern
FLUOstar OPTIMA BMG Labtech, Ortenberg
Freezer (-80 °C) FORMA 900 Series Thermo Scientific, Waltham, USA
Freezer Premium NoFrost Liebherr, Biberach an der Riss
Fridge Profiline Liebherr, Biberach an der Riss
Hamilton pipet Hamilton company, Reno, USA
Heraeus Fresco 17 Centrifuge Thermo Scientific, Waltham, USA
Heraeus Megafuge 16R Centrifuge Thermo Scientific, Waltham, USA
Horizontal shaker 3015 GFL, Burgwedel
Incubator APT.lineTM C150 Binder, Tuttlingen
Laminar flow NU-437-400E INTEGRA Biosciences, Fernwald
Magnetic stirrer MR Hei-Standard Heidolph, Schwabach
Microwave R-202 SHARP, Hamburg
Mini Trans-Blot® Cell Bio-Rad, München
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Mini-PROTEAN® Tetra Cell Bio-Rad, München
Mini-PROTEAN® Tetra Cell Casting Module Bio-Rad, München
Multilabel Reader EnVision Perkin Elmer, Waltham,USA
Multipette Plus® Eppendorf, Hamburg
Nano photometer Implen, München
pH meter FiveEasy Mettler Toledo, Giessen
Pipet Gilson Pipetman Gilson, Limburg-Offheim
PipetHelp Accumax, India
Sorvall RC5B Plus with Sorvall GSA rotor Thermo Scientific, Waltham, USA
Spectrophotometer SmartSpec Plus Bio-Rad, München
Thermocycler SensoQuest, Göttingen
Thermomixer comfort Eppendorf, Hamburg
Ultra Clear UV plus (ultrapure water device) SG, Hamburg
UV light table Eurofins MWG Operon, Ebersberg
Vortex – Genie2 Scientific Industries, Bohemia, USA
5.1.10 Microscopes
5.1.10.1 Microscope for most FRET measurements: Visitron set-up
The devices are labeled according to their primary function. False excitation or bleed through is
neglected at this point and will be described in detail later (see 5.2.6). In figure 12 the spectra of YFP
and CFP are shown together with the filters used during FRET measurements and figure 13 illustrates
how the filters are principally installed into the microscopes.
All FRET measurements, except the ones mentioned in 5.1.10.2, have been conducted with this set-up.
Device Type Supplier
inverted microscope Axiovert 100 Zeiss, Oberkochen
micromanipulator MM 33 Merzhäuser, Wetzlar
perfusion system VC3-8xP Series ALA Scientific Instruments,
Farmingdale, USA
light source CFP excitation2 precisExcite-100, 440nm CoolLED, Andover, UK
2 The intensity was set to 10%.
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light source YFP excitation3 precisExcite-100, 500nm CoolLED, Andover, UK
high performance CCD-camera SPOT Pursuit SPOT Imaging solutions, Sterling
Heights, USA
objective Plan/Apo N 60x/1.45 Oil Nikon, Düsseldorf
air-cushioned optical table Vision IsoStationTM Newport, Stahnsdorf
software VisiView Visitron Systems, Puchheim
Filters used during FRET measurement
excitation filter CFP 436/20 Chroma Technology, Bellows Falls,
USA
dichroic 458LP Semrock, Rochester, USA
beam splitter (separates YFP
emission from CFP emission)
505LP and
416;500;582;657
Chroma Technology, Bellows Falls,
USA
CFP emission filter 470/24 Chroma Technology, Bellows Falls,
USA
YFP emission filter 525/39 Semrock, Rochester, USA
Filters used to search for cells and during direct YFP measurement
dualband excitation filter
CFP/YFP
416;501 Semrock, Rochester, USA
dichroic 440;520 Semrock, Rochester, USA
dualband emission filter CFP/YFP 464;547 Semrock, Rochester, USA
3 The intensity was set to 4%.
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5.1.10.2 Microscope for some FRET measurements: Nikon set-up
This microscope was used for the FRET experiments shown in figures 31, 34, 35, 37. The devices
are labeled according to their primary function. False excitation or bleed through is neglected at this
point and will be described in detail later (see 5.2.6). The filters are installed in the set-up according
to figure 13.
Device Type Supplier
inverted microscope Eclipse Ti Nikon, Düsseldorf
micromanipulator MM 33 Merzhäuser, Wetzlar
perfusion system VC3-8xP Series ALA Scientific Instruments,
Farmingdale, USA
light source4 Lambda DG4 Sutter, Novato. USA
high performance CCD-camera Evolve512 Photometrics, Tucson, USA
objective Plan/Apo VC 100x/1.40
Oil ∞/0.17 Dic N2
Nikon, Düsseldorf
air-cushioned optical table Vision IsoStationTM Newport, Stahnsdorf
software NIS Elements AR Laboratory Imaging
Filters used during FRET measurement
excitation filter CFP 430/24 Chroma Technology, Bellows Falls,
USA
dichroic T455LP Chroma Technology, Bellows Falls,
USA
beam splitter (separates YFP
emission from CFP emission)
z488/800-1064 Chroma Technology, Bellows Falls,
USA
CFP emission filter 480/40 Chroma Technology, Bellows Falls,
USA
YFP emission filter 535/30 Chroma Technology, Bellows Falls,
USA
Filters used to search for cells and during direct YFP measurement
dualband excitation filter
CFP/YFP
≈425; 500 (Item number
F59-017)
Chroma Technology, Bellows Falls,
USA
4 The intensity was set to 30%.
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dichroic ≈470;550; 690; 950 (Item
number F58-017)
Chroma Technology, Bellows Falls,
USA
dualband emission filter CFP/YFP ≈475;525 (Item number
F57-017)
Chroma Technology, Bellows Falls,
USA
5.1.10.3 Microscope for confocal and translocation studies: VisiTech Set-up
Device Type Supplier
inverted microscope IX 71 Olympus, Hamburg
micromanipulator MM 33 Merzhäuser, Wetzlar
perfusion system VC3-8xP Series ALA Scientific Instruments,
Farmingdale, USA
light sources 405nm and 491nm lasers VisiTech International, Sunderland,
UK
high performance CCD-camera EM-CCD Digital Camera Hamamatsu, Herrsching am
Ammersee
objective UPlanSApo 100x/ 1.40
Oil
Olympus, Hamburg
air-cushioned optical table Vision IsoStationTM Newport, Stahnsdorf
software VoxCell Scan VisiTech International
FRAP imaging system VT-HAWK VisiTech international
dichroic T495lpxr Chroma Technology, Bellows Falls,
USA
beam splitter (separates YFP
emission from CFP emission)
Optosplit II with FF560-
FDi01, FF01-525/39 and
FF01-593/46
Semrock, Rochester, USA
CFP emission filter ET 470/40 Chroma Technology, Bellows Falls,
USA
YFP emission filter ET 535/30 Chroma Technology, Bellows Falls,
USA
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5.1.11 Databases, software
5.1.11.1 Databases
National Centre for Biotechnology Information http://www.ncbi.nlm.nih.gov
Pubmed http://www.ncbi.nlm.nih.gov/pubmed
5.1.11.2 Software
ApE – A plasmid Editor M. Wayne Davis
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi
corelDRAW X4 Corel Cooperation, Ottawa, Canada
Fluorescence SpectraViewer http://www.lifetechnologies.com/de/de/home/life-science/cell-
analysis/labeling-chemistry/fluorescence-spectraviewer.html
GraphPad Prism 5 for Windows GraphPad Software, La Jolla, USA
ImageJ Wayne Rasband, National Institutes of Health, USA
Mendeley Desktop Mendeley, Washington, USA
Microsoft Office 2010 (Word,
Excel, PowerPoint)
Microsoft, Unterschleißheim
NSI-Elements AR 64bit laboratory Imaging, Prag, Czech Republic
Optima BMG Labtech, Ortenberg
Origin Pro OriginLab Corporation, Northampton, USA
PCR Primer Design Tool https://ecom.mwgdna.com/services/manage-primers/design-
primer.tcl
PrimerX http://www.bioinformatics.org/primerx/
QuantityOne Bio-Rad, München
VisiView Visitron Systems, Puchheim
VoxCell Scan VisiTech International, Sunderland, UK
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5.1.12 Buffer, media
Standard buffers and media are listed here. Buffers only are used for one method are listed with the
according method.
FRET buffer
137mM NaCl
5,4mM  KCl
10mM   HEPES
2mM     CaCl2
1mM     MgCl2
in ultrapure water, pH = 7,3
LB medium
20g LB medium powder according to Lennox
ad 1 L Ultrapure water
autoclaved
RIPA buffer (Alcaraz et al., 1990)
50 mM       Tris-Base, pH 7.5
500 mM     NaCl
10 mM       MgCl2
1% (v/)       Triton X-100
0.1% (w/v) SDS
0.5% (w/v)  Sodium Deoxycholate
1 mM          EDTA
Added fresh:
1pill/10mL buffer protease inhibitor
2mM DTT
5x SDS gel-loading buffer
250 mM      Tris, pH 6.8
10 % (w/v)  SDS
0.5 % (w/v) Bromophenol blue
20 % (w/v)  Glycerol
200mM β-mercaptoethanol
in ultrapure water
TE buffer (Tris/EDTA)
10 mM Tris-HCl pH7,4
1 mM   EDTA
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5.2 Methods
5.2.1 Cell culture
Human embryonic kidney (HEK) cells were cultured at 37°C, 90-95% humidity and 5-10% CO2 in an
incubator. The cells were split every three to five days according to their growth rate. During the
culture HEK293TSA cells were maintained in full medium, which consisted of DMEM medium
(Dulbecco´s modified eagle´s medium high glucose) with 10% (v/v) fetal calf serum (FCS), 2mM
L-glutamine, 100U/mL penicillin and 0.1mg/mL streptomycin. If the same medium was mixed with
0.5% (v/v) FCS instead of 10%, this is entitled as DMEM 0.5% FCS. Further DMEM without
supplements (DMEM w/o) was used for two transfection methods (5.2.1.2.2 and 5.2.1.2.3).
Additionally mH1-R-HEK293T cells were used for the experiments shown in figure 33A, B and 36.
These cells stably express the murine H1-R and a G-418 resistance. Therefore cells expressing these
genes were protected against G-418 induced cytotoxicity and were selected for this property by culture
in full medium additionally containing 1mg/mL G-418.
5.2.1.1 Cell splitting
Cells were detached from a cell culture dish by incubation with trypsin/EDTA for one to three
minutes. Afterwards they were collected by washing of the dish with full medium and centrifugation at
1.000rpm for three minutes (Heraeus Fresco 17 centrifuge). Finally the cell pellet was resuspended
with medium and seeded at a suitable density.
5.2.1.2 Transient transfection of eukaryotic cells
DNA transfer into eukaryotic cells is called transfection. Several different protocols have been
invented in order to increase transfection efficiency. The method of choice depends on cell type,
transfection scale and specific use of the cells after transfection. In this thesis HEK293T cells were
transfected with Effectene transfection reagent for live cell imaging, with PolyFect transfection
reagent for SRE.L reporter gene assays and with polyethylenimine (PEI) for affinity purification of
active Rho and Western Blot.
5.2.1.2.1 Effectene transfection
Cells were plated on 6cm dishes one to three days prior to transfection. At the day of transfection the
cells showed a density of 50 to 70% and in the evening they were transfected according to the
manufacturer´s protocol: Briefly, the DNA mixture described for each experiment was mixed with
GC buffer to a total volume of 150µL and incubated with 16µL Enhancer and 20µl Effectene.
Afterwards the transfection solution was mixed with 500µl full medium and everything was added
dropwise to the cells.
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5.2.1.2.2 PolyFect transfection
The PolyFect transfection was used as inverse transfection method. So the DNA was added to a
96well plate first and then transfection reagent and cells were added. The DNA composition used for
each condition can be found in the results part and the volume was filled up with DMEM without
supplements (DMEM w/o) to 10µL. Afterwards 1.25µl PolyFect plus 8.75µL DMEM w/o were added
and everything was incubated for ten minutes. Finally 100µL cell suspension (DMEM 0.5% FCS) was
added. In the next hours cells were transfected while they settled down.
5.2.1.2.3 PEI transfection
Large scale transfection (one 10cm dish per condition) was done with unbranched, linear, 25kDa
polyethylenimine (Polysciences) (Boussif et al., 1995). Therefore DNA was mixed with PEI in a
stoichiometry of 1:3 (w/w) in a total volume of 1mL DMEM w/o and incubated in the dark at 20°C for
30min. Afterwards the mixture was added dropwise to the cells in full medium and medium was
exchanged after six hours for DMEM 0.5% FCS.
5.2.1.3 Cell transfer onto coverslips
Cells were transferred onto coverslips in order to examine them by fluorescence microscopy on the
following day. In advance coverslips were placed one to one into wells of a 6-well plate and
pretreated. The coverslips were incubated with approximately 100µL poly-L-lysine for 30min and
then washed with PBS once. The cells were split (see 5.2.1.1) onto coverslips in full medium and low
density. The low density should allow for single cell measurements on the next day.
5.2.2 Molecular biology
5.2.2.1 Casting agar plates
Bacteria colonies were grown on agar plates. Therefore 1.5% (w/v) agar was solved in LB medium
and autoclaved. The solution was chilled to approximately 40°C and if necessary supplemented with
an antibiotic (ampicillin 100µg/ml, kanamycin 50µg/ml). Afterwards the solution was poured on Petri
dishes and coagulated at room temperature. Agar plates are good for some weeks at 4°C.
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5.2.2.2 Production of chemically competent E. coli
If bacteria should be transformed with DNA, they have to be made competent in advance (Chung
et al., 1989).
E. coli (strain DH5α) were cultured on an antibiotic-free agar plate at 37°C overnight. From this plate
one colony was picked and culture in 10mL LB medium (37°C, overnight). This preculture was filled
up with LB medium to 250mL and cultured. The growth was monitored by absorptiometry (see.
5.2.2.3). At an OD600 of 0.5-0.7 bacteria were harvested in the logarithmic growth phase by
centrifugation at 5.000rpm for ten minutes (Heraeus Fresco 17 centrifuge). The pellet was carefully
resuspended in 25mL ice-cold TBS buffer and incubated on ice for one to two hours. Subsequently
bacteria were aliquoted and frozen in liquid nitrogen. Competent bacteria were stored at -80°C.
TSB buffer
10 % (w/v) PEG 3000
5 % (v/v)    DMSO
20 mL         MgCl2
in LB medium
5.2.2.3 Absorptiometry of bacteria suspensions
The concentration of bacteria within a suspension can be estimated by absorptiometry. Therefore the
absorbance at 600nm was measured with a Smart Spec Plus spectrophotometer. First pure LB medium
was measured as blank and afterwards the bacteria culture every 30 min.
5.2.2.4 Transformation of bacteria
Plasmid DNA can be amplified in E. coli (strain DH5α). These chemically competent E. coli
(5.2.2.2) were transformed by the modified heat-shock method (Chung et al., 1989). Therefore DNA
(0.2 to 5µL dependent on concentration) was incubated with 20µl KCM buffer, 100µl chemically
competent E. coli and ad 200µL ultrapure water on ice for 20min. Afterwards the mixture was
incubated at room temperature for 10min. After addition of LB medium the bacteria were grown
shaking, at 37°C for 50min and then plated on an agar plate supplemented with either ampicillin or
kanamycin. Overnight only bacteria, which expressed a resistance against the antibiotic on the plate,
grew into colonies at 37°C.
KCM buffer (potassium calcium magnesium buffer)
500 mM KCl
150 mM CaCl2
250 mM MgCl2
Protein expression was done in the E.coli strain Rosetta2 (DH3). These bacteria have to be
transformed by the heat-shock method according to the manufacturer. Therefore 0.2µg DNA was
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mixed with one aliquot E.coli and incubated on ice for 30min. Then a heat-shock of 42°C for 30s was
applied, which was followed by 5min on ice. After addition of 950µL LB medium the bacteria were
grown shaking at 37°C for an hour and then plated on agar as described before.
5.2.2.5 Production of glycerol stocks of bacteria
E.coli carrying a plasmid can be stored for long term at -80°C, if they are kept in a glycerol stock. The
glycerol protects the frozen bacteria from cell membrane damage. For this method fresh bacteria
culture was mixed 1:1 with a glycerol solution (glycerol (65% (v/v)), 0.1M MgSO4 and 25mM
TrisHCl, pH8) and frozen at -80°C.
5.2.2.6 DNA preparation: Midi
Plasmid DNA was extracted from bacteria in large scale with the Qiagen Plasmid Midi Kit according
to the manufacturer´s protocol. This kit makes use of the alkaline lysis method (Birnboim and Doly,
1979). In the end the dry DNA pellet was resuspended in ultrapure water.
5.2.2.7 DNA preparation: Mini
The small scale DNA extraction makes also use of the alkaline lysis. This time the DNA was not
extracted with a kit, but with self-made buffers (see below) and a modified version of Birnboim and
Doly´s protocol for DNA extraction (Birnboim and Doly, 1979; Sambrook and Russel, 2001)
(Birnboim and Doly, 1979). Thus the DNA was not purified with a column. Consequently the DNA
yield of a Mini preparation is not as pure as the one from a Midi preparation. Mini preparations were
not used for sequencing, cloning, transformation or transfection, only for control of cloning by control
digestion with restriction enzymes (5.2.2.8).
For a mini preparation 4ml LB medium were incubated with one E.coli colony at 37°C, shaking
overnight. At the next day 2mL of this culture were centrifuged (2min, 13.300rpm, Heraeus Fresco 17
centrifuge5) and the leftover was stored for further use at 4°C. The bacteria pellet was resuspended in
100µL resuspension buffer and then the bacteria were lysed by alkaline lysis with 200µL lysis buffer.
Already the first buffer contains RNAse to ensure complete digestion of RNA before the DNA
precipitation step. Upon addition of 150µL neutralization buffer the pH changed quickly. Proteins and
genomic DNA precipitated during 5min incubation on ice and subsequent centrifugation (10min,
13.300rpm). Then the supernatant was mixed with 450µL isopropanol. The salt in the solution
neutralize the negative charges in the sugar phosphate backbone of the nucleotide chain and the
isopropanol assists the interaction of the two. Since this makes the nucleotide chains more
hydrophobic, a DNA pellet occurred upon 10min centrifugation with 12.000rpm. The pellet was
washed with 70% (v/v) ethanol once, then air-dried and resuspended in ultrapure water.
5 This centrifuge was used for the whole procedure.
60
Material and methods
Resuspension buffer
50 mM Glucose
10 mM EDTA
25 mM Tris(base), pH 8.0
in ultrapure water
Added fresh:
200µg/ml RNAse
Lysis buffer
0,2M        NaOH
1 % (w/v) SDS
in ultrapure water
Neutralization buffer
60 mL    Potassium acetate (5 M)
11,5 mL Acetic acid (96 %)
28,5 mL ultrapure water
5.2.2.8 DNA digestion with a restriction enzyme
Restriction endonucleases, also known as restriction enzymes, are used by bacteria to cut DNA at
specific sites. In most cases they recognize four to eight bases long, palindromic sequences and cut at
these sites, which may result in an overhang depending on the enzyme used. An overhang allows for
some specificity in the ligation step (see 5.2.2.12). In this step a ligase connects nucleotide chains.
During this thesis restriction enzymes were used for cloning and to control plasmids by their
digestions pattern. In both case the DNA fragments were separated according to their size by agarose
gel electrophoresis (see 5.2.2.9).
2µg DNA were mixed with 0.5µl restriction enzyme, 2µl 10-fold buffer, if necessary 0.2µg 100-fold BSA
and ad 20µl ultrapure water and digested at 37°C for one hour. The buffer version and BSA were used
according to the manufacturer’s protocol. Where indicated two restriction enzymes were used at the same
time and their activity in the same buffer was checked with the manufacturer’s protocol beforehand.
5.2.2.9 Agarose gel electrophoresis
DNA fragments can be separated according to their size by gel electrophoresis. Therefore agarose gels
were cast with a density of 0.8% or 1% (w/v) agarose in TAE buffer. The density was adjusted to the
expected fragment size. The cooled gel was loaded with 2µg DNA per slot, which was mixed with
loading buffer (10-fold) to a final volume of 20µL. In addition a 1kb DNA ladder was loaded, which
enabled evaluation of the fragment size. The separation occurred due to a voltage of 100V and the
pore size of the agarose matrix. Smaller DNA fragments ran faster than larger ones. Afterwards the gel
was illuminated with UV light and DNA fragments glowed due to the fluorescent ethidium bromide,
which was added during gel casting. The DNA intercalating agent ethidium bromide binds specifically
to DNA and is therefore enriched and glowing in DNA-rich regions of the gel. If needed DNA bands
were cut out and DNA isolated (see 5.2.2.10) for ligation.
TAE buffer (Tris Acetate EDTA)
40 mM Tris-acetate pH 8,0
0.1 mM EDTA
in ultrapure water
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5.2.2.10 DNA isolation from an agarose gel
DNA was isolated from an agarose gel if the DNA fragment was used further, for example for ligation
(see 5.2.2.12). Therefore the QIAquick Gel Extraction Kit was used according to the manufacturer´s
protocol and the DNA eluted with 30µL ultrapure water. Before the ligation, the DNA concentration
had to be determined (see 5.2.2.11).
5.2.2.11 Determination of DNA concentration
The DNA concentration was determined with the Nano Photometer. The absorbance at 280nm and
320nm was measured for ultrapure water as blank and the DNA sample. From these values the
concentration of the sample was calculated.
5.2.2.12 Ligation
The ends of DNA fragments can be reconnected with a phosphodiester bound by a ligation reaction.
This is an enzymatic process mediated by T4 DNA ligase, for example. In the present work this
process was used for cloning of small DNA fragments, also described as inserts, into vectors. A ligase
works with higher efficiency if two compatible DNA ends overlap and such overlaps were produced
with restriction enzymes at the insert and the vector of a cloning project (see 5.2.2.8). Nevertheless a
T4 DNA ligase is also able to reconnect fragment, which do not have overhangs or which have
mismatching overhangs.
In this thesis the small insert was used in a molecular excess of four to one over the large vector, in
order to prevent closure of the vector without insert insertion. The reaction was mixed as follows and
incubated for one to three hours at 16°C.
Volume/Amount Component
0,5 µL T4 DNA ligase
1 µL 10-fold T4 DNA
ligase buffer
see above insert
ca. 50 ng vector
ad 10 µL ultrapure water
5.2.2.13 DNA amplification
In 1986 Kary Mullis invented the polymerase chain reaction (PCR) as tool for DNA amplification
(Mullis et al., 1986). The DNA amplification consists of several cycles of the same three steps and
causes a monoexponential increase in DNA strands under perfect conditions. One cycle consists of
melting of the template double strand, annealing of a small DNA sequence, also entitled as primer,
onto the template and last but not least the elongation step. After such the cycle a next cycle is started.
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For the PCRs performed during this thesis 30 cycles were conducted with a thermocycler
(SensoQuest). In the first step the sample was heated to 98°C for 30s. This step leads to dissociation of
the double-stranded template and therefore the single strands are accessible for the primers now. The
primers anneal to their template with the matching nucleotides at a temperature, which depends on the
sequence of the primer. The annealing temperature was calculated as follows:
Annealing temperature=2°C*number of T and A+4°C*number of C and G
For the primer annealing the thermocycler is set to the calculated annealing temperature for 30s.
The primers were designed with an annealing temperature of 60°C to 62°. The primers used can
be found in 5.1.3.1. In one PCR two primers are used each binding to one strand of the
double-strands. Similar annealing temperatures were favored during the design of primer pairs for
the same PCR and complementary sequences were avoided as far as possible, since this could
induce primer dimerization.
For the next step the temperature is increased to the optimum temperature of the polymerase to ensure
perfect elongation conditions. During the elongation step the polymerase binds one
deoxyribonucleotide by another to the 3´-end of the primer matching with the template strand. DNA
polymerases, which are used for PCR, have to be thermo-stable. The polymerase, Phusion, used here
has 3´to 5´exonuclease activity, which allows for proof-reading. So mismatches, which occur during
the polymerization, are promptly removed by the polymerase itself. The Phusion polymerase
polymerizes 2kb per minute at 72°C. Therefore the duration of this step is adjusted to the length of the
amplified fragment.
Afterwards the sample is heated to 98°C again and the next cycle starts. In the last cycle elongation is
prolonged to ten minutes and then the reaction mix is stored at 4°C for further use.
The reaction mix was prepared for the PCRs in this thesis on ice as follows:
Volume/ amount Component
200 ng template DNA
20 pmol forward primer
20 pmol reverse primer
500 pmol dNTP mix
0,1 µL Phusion
4 µL 5-fold polymerase
buffer
ad 20 µL ultrapure water
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5.2.2.14 QuickChange® site-directed mutagenesis
By QuickChange® site-directed mutagenesis a DNA sequence can be mutated or in other words a base
in the sequence can be exchanged. This method is evolved from ideas of Braman and colleagues
(Braman et al., 1996) and inserts mutations by means of conventional PCR (see 5.2.2.13), but with the
following differences: The elongation step is greatly extended; the primers have a mismatch to the
annealing sequence and just 50ng template
DNA is used.
In a conventional PCR the template portion
between the two primers is elongated,
whereas in a QuickChange mutagenesis the
whole plasmid is amplified. Therefore the
elongation time is extended.
In order to insert the mutation into the
plasmid, the primer has this mutation flanked by matching sequences on both sides (fig. 11). This
allows the primer to bind to the template and then the polymerase elongates the rest of the plasmid
sequence to the primer. The mutagenesis primers are design with “PrimerX” and listed in 5.1.3.2.
After the PCR the mutated strands have to be separated from the wild type template. This separation is
facilitated if fewer templates are added in the beginning. The template present is destroyed by DpnI
digestion (see 5.2.2.8). DpnI is a restriction enzyme, which recognizes and cuts the sequence GATC
but only when the A is N6-methylated. Only the template DNA is digested, since DNA is not
methylated during PCR, but during amplification in E.coli DH5α.
The digestion efficiency was enhanced by precipitation of the DNA from the PCR mix with ethanol in
advance. Then the pellet was air-dried and resuspended in ultrapure water. After the digestion 5µl of
the reaction mix was directly transformed into E.coli (see 5.2.2.4) and after DNA preparation
(see 5.2.2.6) the mutagenesis was controlled by sequencing (see 5.2.2.15).
5.2.2.15 Sequencing
The sequence of all cloned constructs was controlled by sequencing. Sequencing was done with the
Sanger method by Eurofins MWG Operon (Sanger et al., 1977). The samples were prepared as
follows: 0.75 to 1.5µg DNA, if necessary 15pmol primer, ad 15µl ultrapure water.
Eurofins Genomics supplies a range of standard primers, which were used if possible. Otherwise
sequencing primers were designed using the “PCR Primer Design Tool” (see 5.1.3.3).
The results were aligned to reference sequences by means of “ApE” and the “Basic Local Alignment
Search Tool“.
Fig. 11 Localisation of the mismatch within a
QuickChange® site-directed mutagenesis primer
This shows the alignment of 5´-LARG-F1098A primer (upper
row) with wild type LARG (lower row) by “ApE”. The
mutation of phenylalanine to alanine in the amino acid
sequence requires the exchange of two bases in the DNA
sequence. In these two bases the primer and the template do
not align (red asterisk).
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5.2.3 Western Blot
5.2.3.1 Sample preparation
Cells were grown and transfected on 10cm dishes, medium was removed, cells were lysed with 600µl
RIPA lysis buffer on ice and collected by scratching with cell scrapers. The cell lysate was cleared by
centrifugation at 13.300rpm for four minutes (4°C, Heraeus Fresco 17 centrifuge) and removal of the
cell debris. At this step further steps were added for “affinity purification of active Rho” (5.2.5).
Otherwise immediately the cell lysate was boiled at 95°C for ten minutes and 5-fold SDS gel-loading
buffer (5.1.12) was added. The last two steps destroy quaternary, tertiary and secondary structures of
the proteins and SDS adds negative charges to the proteins according to their size. Β-mercaptoethanol
destroys disulfide bonds. The polyacrylamide gel was loaded with 20µl to 40µl sample per slot and
10µl peqGOLD protein marker.
5.2.3.2 Preparation and running a discontinuous SDS PAGE
Proteins can be separated by a discontinuous sodium dodecyl sulfate (SDS) polyacrylamide gel
electrophoresis (PAGE) as invented by Laemmli (Laemmli, 1970). This method allows separation of
the proteins into distinct bands according to their size. The PAGE is casted in two steps, which leads
to a quick pH shift in the gel during the electrophoresis.
In the upper part of the PAGE, the so called stacking gel, the isotachophoresis takes place and all
proteins are focused in one band. The pH 6.8 in the stacking gel is close to the isoelectric point of
glycine. Therefore glycine is uncharged and migrates slowly, whereas chloride is charged and migrates
fast. Between glycine and chloride an electric field occurs and all proteins stay within this field. Since
proteins with high mobility explore a weak field force and proteins with low mobility explore a strong
field force, all proteins are focused in one band.
The lower resolving gel has a higher pH of 8.8 and upon entering glycine gets charged immediately.
Thus glycine passes the proteins and the electric field disappears. So now the speed of each protein
depends only on its charge, which is proportional to its size due to SDS.
The PAGE was cast into a Mini-PROTEAN® Tetra Cell Casting Module. The polymerization is
initiated by addition of a free radical source, ammonium persulfate (APS), and a catalyst, TEMED.
These two substances led to the formation of acrylamide polymers. The reaction mixture contained
bisacrylamide, which allowed for crosslinks between the acrylamide branches. First the resolving gel
was cast and overlayed with isopropanol. After polymerization the isopropanol was removed, the
stacking gel was poured on top and a comb was added.
The gel was installed into a Mini-PROTEAN® Tetra Cell and running buffer was added. After sample
loading with a Hamilton pipet, the SDS PAGEs were run at 60V until the samples entered the
resolving gel and then at 125V.
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Resolving gel (10%)
4mL      Ultrapure water
2.5mL   1.5M Tris, pH 8.8
0.1mL   10 % (w/v) SDS
3.3mL   30% Acryl/Bis (37,5:1)
0.05mL 10%(w/v) APS
0.01mL TEMED
Stacking gel (3.3%)
6.2mL   Ultrapure water
2.5mL   0.5M Tris, pH 6.8
0.1mL   10 % (w/v) SDS
1.2mL   30% Acryl/Bis (37,5:1)
0.05mL 10% (w/v) APS
0.01mL TEMED
Running buffer
192mM       Glycine
25mM        Tris
0.1% (w/v) SDS
5.2.3.3 Wet Blot
In order to detect the separated proteins with antibodies, the proteins were transferred to
polyvinylidene fluoride (PVDF) membranes by electrophoresis. This can be achieved in a semi-dry
fashion or as Wet Blot within a buffer-filled tank. All Western Blots shown were done by means of
Wet blotting, which is a modified version of tank transfer invented by Towbin and colleagues (Towbin
et al., 1992). A Mini Trans-Blot® Cell was used according to the manufacturer´s protocol. Briefly, a
sandwich was made from a gel holder cassette, two sponges, two Whatman papers, the SDS PAGE
and a methanol-activated PVDF membrane. The methanol activation for two minutes enhances protein
binding to the membrane. The sandwich was put into the Mini Trans-Blot® Cell, which was filled
with transfer buffer and the transfer was conducted with a constant current of 220mA for 2.5h.
Afterwards the membrane was cut into pieces according to the desired protein detections. Of note, for
all antibodies specificity was first tested on complete membranes. The membranes were blocked with
TBST containing 5% (w/v) BSA or milk powder for one hour, rotating at room temperature. The
blocking with BSA was only done for the RhoA antibody. Next the membranes were incubated with
primary antibodies overnight at 4°C. The antibodies were diluted in blocking solution and antibody
dilutions are mentioned with the antibodies (see 5.1.8).
The next day the membranes were washed three times for five minutes with TBST and then the
according horse radish peroxidase (HRP) -conjugated, secondary antibody was added for another hour
at room temperature. Finally the membranes were washed three times for 15min with TBST.
The membranes were incubated with the HRP substrate and developed with ChemiDoc. Images were
saved and processed with “QuantityOne” and “ImageJ”.
Transfer buffer
25mM    Tris
192mM glycine
20% (v/v) methanol
TBST
20mM         NaCl
20mM Tris
0.05% (v/v) Tween-20
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5.2.4 SRE.L reporter gene assays
The SRE.L reporter gene assay was used to determine transcriptional activity downstream of RhoA
(see 4.4.1) (Hill et al., 1995; Mao et al., 1998). The reporter gene construct pSRE.L consists of the
Photinus pyralis luciferase gene under the control of a modified serum response element (SRE), which
cannot bind the transcription factor TCF anymore (see 4.4.1 Amongst others, ROCK is activated by the
Rho subfamily for details). Therefore luminesce at 570nm is a surrogate parameter for transcriptional
activity downstream of RhoA activation. Besides the pSRE.L the constitutive active reporter gene
construct pRL-TK was transfected. This plasmid encodes for Renilla reniformis luciferase and
transcription is regulated by the constitutive active Herpes simplex thymidine kinase promoter. Thus
luminescence at 475nm was used to correct for transfection efficiency, cell number and cell viability.
Each condition was transfected with PolyFect Transfection Reagent in triplicates in a 96well plate and
further processed with the Dual-Luciferase® Reporter Assay System according to manufacturer´s
protocol. Luminescence was detected for both wavelengths by the multilabel reader EnVision.
Briefly all conditions were transfected with the same DNA amount (125ng/well): pSRE.L (21.6),
pRL-TK (3.4) and as indicated RhoGEF, receptor, G protein, empty vector. Agonist-stimulated assays
were lysed after 48h with 20µL passive lysis buffer per well, whereas the other assays were lysed after
24h. In response to transfection efficiency 2 to 10µL lysate was transferred to a white 96-well plate. In
all cases volume of at least 2µL were pipetted in order to reduce pipetting errors. To every well 25µL
LARII and after the first measurement 25µL Stop´n´Glow was added with a multipette Plus®. The
ratio of luminescence at 570nm and 475nm was calculated and normalized to control. These values are
depicted as relative luciferase activity (mean±S.E.M.) for every condition. The data were processed by
“MARS” and “Excel”. As control condition three wells were transfected with both reporter gene
constructs and 100ng empty vector on every plate. For each condition the leftover lysate of all three
wells was collected and the complete volume was loaded on SDS PAGE as described (see 5.2.3).
5.2.5 Affinity purification of active RhoA
In 1999 Ren and colleagues developed a method to determine active RhoA in cells (Ren et al., 1999).
The main principle of this method is specific binding of a Rho binding domain (RBD) to active RhoA
and precipitation of this complex. Therefore RBD, which is fused to a Glutathione-S-transferase
(GST) -tag, was transformed into E.coli Rosetta2 (DE3) (5.2.2.4) and several colonies were
inoculated in at least 10mL LB overnight. At the next day the overnight culture was diluted 1:100 in
1L LB medium and grown until an OD600 of 0.4 was measured (5.2.2.3). Then RBD expression was
induced by addition of 300µM isopropylβ-D-1-thiogalactopyranoside (IPTG). The bacteria were
centrifuged (5000rpm, 15min, 4°C, Sorvall RC5B Plus) and the pellet was resuspended in 10mL
bacteria lysis buffer on ice. Next the bacteria suspension was sonified for 10min (Digital Sonifier , 1s,
1s break, 10% intensity) in order to homogenize the bacteria lysate. Upon centrifugation (10.000g,
30min, 4°C, Heraeus Megafuge 16R) the cell debris was precipitated and all soluble proteins were
found in the supernatant. The supernatant was incubated with glutathione-coated agarose beads
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(20µl/condition) for 30min, rotating at 4°C. The beads had been washed in lysis buffer beforehand
according to the manufacturer´s protocol. Afterwards the bead-bound RBD (RBD beads) was
harvested by centrifugation (500g, 5min, 4°C, Heraeus Megafuge 16R) and washed three times with
lysis buffer. In the meantime RIPA buffer (5.1.12) was prepared freshly. The RBD beads were
distributed equally to as many reaction tubes as conditions. Per condition one 10cm dish HEK293T
cells had been transfected with PEI on the previous day as described (5.2.1.2.3). The medium was
removed from the cell culture dish, 600µL RIPA buffer was added and cells collected with a cell
scraper. Next the HEK293T cell lysate was cleared by centrifugation (13.300rpm, 4min, 4°C,
Heraeus Fresco 17) and the supernatant was transferred to the RBD beads. During rotation for 30 to
45min at 4°C, the active RhoA was bound by RBD beads. Therefore active RhoA could be harvested
by centrifugation (500rpm, 5min, 4°C, Heraeus Fresco 17) next. After this step the supernatant
contained inactive RhoA and all other cellular protein. 100µL of this were used as loading control
and supplemented with 5x SDS gel loading buffer (5.1.12). The pellet was washed three times with
RIPA buffer and finally resolved in Laemmli buffer. The loading control and precipitate were further
analyzed by Western Blot (5.2.3).
Bacteria lysis buffer
50 mM             Tris-Base, pH 7.5
500 mM           NaCl
1% (w/v)          Triton X-100
2%-10% (w/v) Glycerol
2 mM               EDTA
Added fresh:
1pill/10mL buffer protease inhibitor
4mM                DTT
Laemmli buffer
125mM    TrisHCl
4% (w/v)  SDS
20% (v/v) Glycerol
0,004%     Bromophenol blue
pH 6.8
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5.2.6 Fluorescence microscopy
For all fluorescence microscopic experiments HEK293T cells were transfected (5.2.1.2.1) two days in
advance. On the day before the measurements the cells were split onto poly-l-lysine coated coverslips
(5.2.1.3) and shortly before the measurement a coverslip was fixed in an Attofluor cell chamber. The
chamber was filled with FRET buffer (5.1.12). During the measurement the cells were continuously
superfused with FRET buffer by a perfusion system, which exchanged solutions at the cell within
10ms. Also the agonists were applied with this device at the time points indicated in the graphs as
black bar. All agonists were freshly diluted in FRET buffer, except U46619. This Txa2-R agonist was
delivered in methyl acetate. Methyl acetate was evaporated and the substance was dissolved in ethanol
(100%) at a final concentration of 2.5mM and stored in aliquots at -20°C. At the day of experiment
U46619 was diluted in FRET buffer containing 0.1% (w/v) delipidized bovine serum albumin (BSA).
In this case the corresponding amount of ethanol and delipidized BSA was added to FRET buffer and
used as wash buffer. For all experiments with U46619 only one cell was measured per coverslip. In
the other cases three cells were measured at most per coverslip. Further agonist solution was applied
once per cell, if not mentioned otherwise.
5.2.6.1 FRET measurement
5.2.6.1.1 Theoretical background of FRET measurement
Protein protein interactions can be measured by Förster/fluorescence resonance energy transfer.
Simplified FRET occurs, if two fluorophores are in close proximity and the emission spectrum of the
donor fluorophore overlaps with the
excitation spectrum of the acceptor
fluorophore, because in this case the
donor does not emit light, but rather
excites the acceptor radiation free
(Förster, 1948). This phenomenon is
used to study protein-protein
interactions (intermolecular FRET) and
conformational changes of a protein
(intramolecular FRET) (Vilardaga et
al., 2009). The most popular
fluorophore pair is YFP and CFP for
studies between biomolecules
(Miyawaki, 2011). These two proteins
are engineered from the green fluorescence protein (GFP), which is a monomeric, fluorescent protein
and was found in the jellyfish Aequorea victoria (Prasher et al., 1992; Heim and Tsien, 1996).
Unfortunately the FRET amplitude does not allow for distance estimations, because the FRET
Fig. 12 Spectra of YFP and CFP
Excitation and emission spectra of YFP and CFP were overlayed with
the CFP excitation filter (1), CFP emission filter (2) and YFP
emission filter (3) of the Visitron set-up. Direct excitation of YFP is
shown in area A and bleed through in area B. The spectra were plotted
and modified using the “Fluorescence SpectraViewer” and
“CorelDRAW”.
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amplitude depends on three factors (Jares-Erijman and Jovin, 2003): (I) the distance of the fluorophores
(<10nm), which enters into FRET with the sixth power. (II) The spectral overlap of the used
fluorophores is important, since the acceptor has to emit the excitation energy, which is needed by the
donor. (III) The FRET amplitude is maximal with parallel dipoles. But engineering the dipole orientation
is complicated by flexibility in the linker between fluorophore and protein of interest and fast rotation of
the fluorophore (Lohse et al., 2012). In the FRET application of sensitized emission also the
stoichiometry of fluorophores influences the FRET amplitude: if the donor is expressed in excess over
the acceptor, the FRET ratio will decrease. Since the acceptor fluorescence will grow whereas the donor
fluorescence will not change and thus the FRET ratio of donor over acceptor will decrease.
FRET can be measured in several ways. In this thesis donor recovery after acceptor photobleaching
(5.2.6.1.10) and sensitized emission are conducted. In order to simplify nomenclature all sensitized
emission measurements were termed as FRET measurements (5.2.6.1.2) and donor recovery after
acceptor photobleaching experiments were termed as such. If sensitized emission is measured, several
aspects have to be controlled: Two factors add unto the actual YFP emission due to FRET (Berney and
Danuser, 2003): The light used to excite of the donor, CFP, excites to some extent also directly the
acceptor, YFP. This is termed “direct excitation of YFP” and is illustrated as area A in figure 12. In
the same figure also bleed through is visualized (area B). Bleed through describes the CFP emission,
which is collect together with the YFP emission. This is again caused by spectral overlap, but this time
of their emission spectra. In this thesis all FRET measurements were corrected for bleed through and
direct excitation (see 5.2.6.1.2). Additionally the proteins of interest could be harmed by the
fluorophore tag, since the GFP derivatives have a size of 27kDa. Previously or in this thesis the
functionally was shown for all fluorophore-labeled used constructs, besides the downstream signaling
of the LARG constructs (see. 7.1).
5.2.6.1.2 FRET measurements (Sensitized emission)
The FRET measurements were conducted at room temperature at one of two inverse microscopes, as
specified in 5.1.10.1, 5.1.10.2 and figure 13. In dual excitation mode (fig. 13B) cells were chosen
which expressed YFP and CFP in the region of the cells corresponding to the localization of the
untagged version of the protein. Then the light path was changed to the FRET measurement mode
(fig. 13A) and the cells were superfused as described in 5.2.6. The cells were illuminated with 2Hz or
0.5Hz for 60 or 30ms (Visitron and Nikon set-up, respectively) and the FYFP(440nm,535nm) and
FcFP(440nm,480nm) fluorescence was detected separately with a CCD-camera. At the end of the
measurement the light path was changed to dual excitation mode and FYFP(500nm,535nm) was measured
upon excitation at 500nm. This information was needed for every measured cell during data
processing, in order to correct for direct excitation of YFP by 440nm. In the results section the term
“excitation at 500nm/440nm” described the excitation spectrum reaching the sample as filtered by the
CFP excitation filter or Dualband for CFP and YFP excitation, respectively.
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The images were displayed with VisiView or NIS Elements AR, respectively and stored. Than the
data were processed using Excel and Origin as follows:
First the intensity of a background region was subtracted for both fluorescences and then FYFP was
corrected for direct excitation and bleed through:
FYFP(corr)= FYFP(440nm,535nm) - BT*FCFP(440nm,480nm) - DE*FYFP(500nm,535nm)
The correction constants for direct excitation (DE) and bleed through (BT) were measured for both
FRET set-ups on a regular basis as described in 5.2.6.1.2.
Then the ratio was calculated of corrected FYFP over FCFP. Further bleach correction had to be done for
all cells measured with 2Hz or faster at the Visitron set-up (5.2.6.1.4).
5.2.6.1.3 Detection of correction factors for bleed through and direct excitation
For the direct excitation correction constant (DE) cells were transfected only with YFP. Intensity was
measured for the same cell in FRET measurement mode (excitation 440nm) as well as dual excitation
mode (excitation 500nm) and the ratio of these intensities makes the DE. A cell transfected only with
CFP was used to determine the bleed through correction constant (BT). The cell was measured in
FRET measurement mode, is excited at 440nm. The intensity in YFP and CFP channel were measured
and the ratio of this makes BT. For both correction factors mean of ten cells were measured and
evaluated approximately every six month.
5.2.6.1.4 Correction for photo bleaching effects
All cells measured at 2Hz or faster at the Visitron set-up had to be corrected for photo bleaching, since
repetitive excitation with high intensity harms the fluorophores and this leads to a decrease in
fluorescence over time. The decrease in FRET ratio over time due to bleaching is best described by a
Fig. 13 Light paths for FRET measurement and dual excitation of CFP and YFP
In A the light path is depicted during FRET measurement and B shows the light path in dual excitation mode, which is
used for direct excitation of YFP and bleaching experiments.
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monoexponential function. Therefore a monoexponential function was fitted to the baseline of the
FRET ratio trace and the fitted function was subtracted from the FRET ratio trace. In some cases also
the FRET ratio before agonist application is of interest. Therefore the mean basal value before agonist
application of the original trace was added to the FRET ratio trace at every time point. The whole
procedure is visualized in figure 14.
5.2.6.1.5 Plotted Δ(FYFP/FCFP) and determination of FRET response Δ(FYFP/FCFP)
For most FRET traces Δ(FYFP/FCFP) is plotted, which depicts the FRET ratio at every given time point
subtracted by the mean FRET ratio 15s before agonist application. The FRET response was evaluated
as difference of mean FRET ratio 15s before agonist application and mean FRET ratio within the
agonist plateau.
5.2.6.1.6 Normalization
Some traces are depicted as normalized FYFP/FCFP. In these cases a high and variable FRET ratio was
observed before agonist application, which was caused by the transfected FRET pair. Therefore cells
measured under these conditions were normalized: FYFP/FCFP of every given time point was divided by
the mean FRET ratio before agonist application.
Also some traces were normalized to maximal response in order to emphasize the kinetic differences
between conditions. Therefore the Δ(FYFP/FCFP) at every given time was divided by the Δ(FYFP/FCFP) in
the plateau of agonist application.
5.2.6.1.7 Measurement and evaluation of concentration response curves
Concentration response curves were measured as described for regular FRET measurements. But two
agonist concentrations were applied to the same cell immediately after each other. The same reference
concentration was used for all cells and test concentrations of one transfection condition. For both
concentrations the response amplitude was determined and the response amplitude of the test
concentration was shown relative to the reference concentration. For each data point at least three cells
Fig. 14 Bleach correction
A shows the ratio trace of FRET between Gαq-YFP and p63RhoGEF-CFP before correction together with the fittedmonoexponential function in red. In B the bleach corrected traces of the same cell is shown.
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were measured and the data were plotted with “GraphPad Prism”. Afterwards a concentration response
curve was fitted by the following “dose-response curve” with “GraphPad Prism”:
Y = Bottom + (Top-Bottom) / (1 + 10((logEC50 - X)*Hill Slope))
During the fit only the Bottom was constrained and Top, Hill Slope as well as EC50 were set variable.
X gives the logarithm of the test concentration and Y the relative response amplitude.
5.2.6.1.8 Evaluation of kinetics
The kinetics of wash-in or -out were evaluated with “OriginPro”. A monoexponential function
y = A0*e-x/t1 + y0 was fitted to the graph (fig. 15). In this function y described the FRET ratio at a given
time point x and t1 shows the time
constant in seconds. For all fits R2
values were calculated and fits worse
than 0.70 were excluded from further
evaluation. The arithmetic mean was
plotted for the inverse of t1, which is
k. For wash-in kinetics (kon) the graph
was fitted from the start of wash-in
until the plateau was reached.
Accordingly for wash-out kinetics
(koff) the graph was fitted from the
start of wash-out until the baseline
plateau was reached. For kon and koff
cells were measured with 2Hz and
stimulated with supersaturating (1µM U46619) and saturating (10nM U46619; 10µM His) agonist
concentrations, respectively.
5.2.6.1.9 Area under the curve
The influence of RGS2 on the steady state of Gαq p63RhoGEF was studied by evaluation of the area
under the curve (AUC) until agonist wash-out (fig. 15, grey area). In “GraphPad Prism” the AUC was
evaluated for individual cells with the flowing settings: the baseline y=0, a minimum peak height of
less than 10% of the distance between minimal and maximal Y, all peaks must be broader than 9 data
points and go above baseline. Then the AUC was plotted as arithmetic mean.
Fig. 15 Evaluation of kinetics and area under the curve
As an example the koff of FRET between Gα13 and Gβ was fitted with amonoexponential function (y=A1*exp(-x/t1)+y0). For this curve a t1 of
15.856s was found with an adjoint R-Square of 0.9544. The fitted
monoexponential curve is shown in red. For the same cell the area
under to curve was evaluated and is shown as grey area.
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5.2.6.1.10Donor recovery after acceptor photobleaching
Two proteins may show FRET before agonist
application. The magnitude of FRET under such
steady state conditions can be estimated by bleaching
of the acceptor and monitoring the increase in donor
fluorescence. The measurement was done in dual
excitation mode at the Visitron set-up (fig. 13B) and
the intensity was increased to 70% for the 500nm light
source. The cells were bleached for 100s and FCFP was
monitored every 1.5s. For the control condition
(mCFP) FCFP was detected a short period before and
after the bleaching whereas for the other conditions a
more complex protocol was chosen (fig. 16). This
protocol allows for detection of steady state FRET
(Δunstim) and absolute FRET upon agonist application
(Δstim). Further the data were divided by FCFP before
agonist application and this normalized change in FCFP
was plotted as %. These calculations were conducted
with “Excel”.
5.2.6.1.11Stoichiometry
The measured YFP and CFP fluorescence can be correlated to the number of fluorophores expressed
in the cell. This is of special importance if the amplitude of the FRET signal is evaluated, see above
(5.2.6.1.1). Control constructs were cloned, which express a yellow and a blue fluorophore at the N-
and C-terminus of β2 adrenergic receptor. So the fluorophores are located at different sites of the
plasma membrane and this prevents FRET between the fluorophores (Dorsch et al., 2009).
Accordingly, acceptor photobleaching experiments show little to no FRET between the two
fluorophores (C. Krasel, personal communication). For every fluorophore pair tested a control
construct was cloned with the exact fluorophores of this pair, e.g. Venus and CFP. Cells were
transfected with 1µg of the control construct and FCFP was measured in FRET mode (fig. 13A) at
440nm excitation and FYFP in dual excitation mode at 500nm excitation. The background was
subtracted and the mean of FYFP(500nm) over FCFP(400nm) were calculated, which gives an stoichiometry
factor for a one to one expression of the fluorophores. In general for all measured cells FYFP(500nm) and
FCFP(400nm) was recorded either as direct excitation for correction or during the FRET measurement. For
the measured cells FYFP(500nm) over FCFP(400nm) was calculated and then this cell specific stoichiometry
factor was divided by the stoichiometry factor of the control constructs. By this the fluorophore ratio
was calculated for individual cells and then averaged as geometric mean for each condition. These
calculations were done with “Excel”.
Fig. 16 Protocol for donor recovery after
acceptor photobleaching
The standard protocol is shown for a condition with
pronounced basal FRET and FRET increase upon
stimulation with agonist. The stimulation with
agonist led to an increase in FYFP and decrease inFCFP. If the plateau is reached, the bleaching startedand took 120s. In the meantime FYFP decreases dueto photobleaching and FCFP increases. The FCFPincrease is caused by the loss of FRET, due to loss
of FRET acceptor YFP. After the bleaching the
agonist is washed-off in order to check for residual
FRET. The cells were measured in dual excitation
mode.
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5.2.6.1.12Localization of fluorophore-labeled constructs
For overview images three consecutive pictures were taken from a FRET measurement at Nikon
set-up and were stored with “NIS elements”. From the same cell tree, three consecutive pictures were
collected in dual excitation mode with excitation only at 500nm. Further processing was done in
“ImageJ”. The background was subtracted for each image and then the three images were combined
with the “Z-projection by sum slices” tool of “ImageJ”.
5.2.6.2 Confocal microscopy
The measurements were done at the VisiTech set-up with VT-HAWK. This system allows for
confocal imaging and was used with a 100x oil objective as specified before (5.1.10.3). The samples
were excited with the 491nm laser, since only YFP-labeled proteins were monitored.
The cells were prepared as usual (3.2.6.) and superfused with FRET buffer.
5.2.6.2.1 Localization of YFP-labeled constructs
For overview confocal images three pictures were taken within 1000ms with an illumination time of
300ms and 30% laser intensity and data were stored with “VoxCell Scan”. Further processing was
done in “ImageJ”. The background was subtracted for each image and then the three images were
combined with the “Z-projection by sum slices” tool of “ImageJ”.
5.2.6.2.2 Translocation measurements
The cells were illuminated with 0.5Hz or 0.03Hz as indicated for
30ms and images were stored by “VoxCell Scan”. For evaluation
three regions of interest (ROIs) were set, as shown in figure 17.
The intensities of these regions were exported to “Excel” and
further processed:
Fcytosol/Fcell = (Fcytosol – Fbackground) / (Fcell – Fbackground)
The background (ROI3) was subtracted from intensities of
cytosol (ROI1) and the whole cell (ROI2) for every time point.
In figure 24A both intensities are plotted for a representative cell
together with the ratio trace of cytosol over whole cell of the
same cell. The ratio was plotted subtracted with the mean ratio
before the first agonist application. Agonist applications were indicated by black bars.
Fig. 17Measurement of translocation
For every cell three ROIs were set:
One in the cytosol, one around the
whole cell and the last one into the
background. In figure 24A the
calculated intensities are plotted for
the same cell over time.
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5.2.7 Statistics
The data were statistically evaluated with “GraphPad Prism”. The following statistical tests were
performed in response to the data type: one way ANOVA with Dunnet´s or Bonferroni´s multiple
comparison test, Student´s t-test after Welch´s correction, extra sum-of squares F-test. Dunnet´s
multiple comparison test was used if several conditions were compared to one control condition,
whereas Bonferroni´s multi comparison test compares all condition with each other. The Welch´s
correction was needed if the variances differed between conditions. The number of cells per condition
is given in brackets in the graph or as n=x in the legend.
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6 Results
Rho activation upon stimulation of GPCRs occurs mainly through two parallel pathways: Gαq
activates p63RhoGEF and Gα13 activates RH-RhoGEFs. Both pathways are implicated for example in
Ca2+ sensitization in vascular smooth muscle cells. It had not been studied so far why two pathways
evolved in parallel and how the signal is integrated within each and between both pathways. Thus in
the following the temporal as well as special dynamics of the Gα RhoGEF interactions of both
pathways were elucidated and correlated to effects on downstream signaling: The LARG Gα13
interaction was studied as model for RH-RhoGEFs (6.1). Further the p63RhoGEF Gαq interaction was
studied on its own and in the context of the Regulator of G protein signaling 2 (6.2).
6.1 Dynamic of the LARG Gα13 interaction and its influence on agonist sensitivity
6.1.1 YFP-LARG translocated to the plasma membrane in single living cells
In order to investigate the activation of a RhoGEF of the RH-RhoGEF family by Gα13 in living cells
LARG was chosen as model RhoGEF. For live cell imaging two LARG constructs were used, which
have been cloned during my diploma thesis (Bodmann, diploma thesis). They have a yellow
fluorescent protein (YFP) either tagged to the N-terminus of LARG or inserted between the RH
domain and the DH-PH domain (behind amino acid 623). YFP and the later used mTur2, Venus, CFP
and Cer are derivatives of green fluorescent protein (GFP (Watkins et al., 2013)).
The RH-RhoGEFs were described to be cytosolic in their inactive state and to translocate to the
plasma membrane upon activation. For all RH-RhoGEFs Gα13 activation is implicated as stimulus for
the translocation (Carter et al., 2014). Therefore LARG translocation is most likely a good hint for
physiological Gα13 LARG interaction. Nevertheless until now translocation in living cells was only
investigated for p115RhoGEF (Meyer et al., 2008). We previously found YFP-LARG and
LARG-insYFP in the cytosol in unstimulated cells and at the membrane upon coexpression of Gα13QL
(Bodmann, diploma thesis). Therefore, we hoped to establish YFP-LARG as functional effector of
Gα13 and to get insight into the kinetics of translocation, by investigation of the localization of LARG
in response to activation of a receptor, which couples to Gα13.
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In order to visualize translocation and understand the kinetics of LARG translocation HEK293T cells
were transfected with Txa2-R, Gα13-wt, Gβ-wt, Gγ-wt and YFP-LARG. The translocation was monitored
by confocal microscopy of single living cells with a region of interest (ROI) in the cytosol and one
around the whole cell (see fig. 17 and 5.2.6.2.2 for further information). The cells were excited at 500nm
every 5s for 30ms and the thromboxane A2 receptor (Txa2-R) was stimulated with 10nm U46619. The
agonist was applied in this study at indicated times (black bars) and exchanged for FRET buffer within
10ms at the cell by a pressure operated superfusion device. The fluorescence in the cytosol decreased
remarkably during agonist application, which was slowly reversible upon agonist wash-out (fig. 18A red
trace). The fluorescence of the whole cell permanently decreased during the measurement due to
photobleaching of the fluorophore (fig. 18A blue trace). For further analysis the ratio of Fcytosol over
Fwhole cell was used, as this corrects for bleaching. The translocation was also detectable by naked eye in
the images evaluated for the traces. For the cell evaluated in figure 18A an image at the beginning of the
measurement and after the first stimulation with agonist was shown (fig. 18B).
Fig. 18 YFP-LARG translocation to the plasma membrane is Gα13 dependentYFP-LARG translocated to the plasma membrane in HEK293T cells transfected with Txa2-R, Gα13-wt, Gβ-wt and Gγ-wtupon stimulation with U46619 (A, B and C). In A this is shown for the cell imaged in B (scale bar 5µm). The
fluorescence in the cytosol (red) and of the whole cell (blue) was monitored and the ratio (black) was calculated. The loss
of cytosolic fluorescence was also visible as mean±S.E.M. ratio trace of 12 individual cells. (D) No translocation upon
stimulation with 5nM and 500nM U46619 was observed in HEK293T cells transfected with Txa2-R and YFP-LARG, butwithout G protein. The same was true for cells transfected with M3-R, Gαq-wt, Gβ-wt, Gγ-wt, YFP-LARG and stimulatedwith 10µM acetylcholine (ACh) (E). Traces are mean±S.E.M. of eight individual cells for both conditions.
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As negative control translocation was monitored in the absence of Gα13 and upon stimulation of
muscarinic M3 receptor (M3-R). When Gα13 was not cotransfected, translocation of YFP-LARG did
not occur even after stimulation with 500nM U46619 (fig. 18D). Also stimulation of M3-R with
10µM acetylcholine and subsequent Gαq activation did not induce translocation of YFP-LARG
(fig. 18E). Evaluation of downstream signaling by either wild type or YFP-tagged LARG was
hindered by minor LARG expression in most experiments as discussed in detail later (6.1.7 and 6.1.8).
Taken together these results suggested, that YFP-LARG reversibly translocates to the plasma
membrane upon Gα13, but not Gαq activation and this hints towards a functional interaction of Gα13
and YFP-LARG.
6.1.2 FRET change between Gα13-mTur2 and YFP-labeled LARG
Since translocation of LARG upon stimulation of Gα13 coupled receptor did not monitor Gα13
LARG interaction directly, we established a FRET-based assay to study the Gα13 LARG
interaction in single living cells (see 5.2.6.1 for further information on FRET). Therefore, the
fluorescent protein mTurquoise2 (mTur2) was inserted into Gα13 behind amino acid 127 by A.-L.
Krett and the functionality was verified by her (unpublished data). In order to study the Gα13
LARG interaction in HEK293T cells, cells were transfected with cyan labeled Gα 13 (Gα13-mTur2)
and YFP-LARG, whose fluorophores have overlapping excitation and emission spectra.
Additionally, the Gα12/13 coupled thromboxane A2 receptor (Txa2-R), Gβ and Gγ were
cotransfected (Offermanns et al., 1994; Klages et al., 1999). Cotransfection of Gβ and Gγ was
necessary to assure balanced stoichiometry of the three members of the trimeric G protein. Two
days after transfection single cells were measured using an inverted microscope and a
high-performance CCD camera. During the measurement cells were excited at 440nm for 60ms
every 0.5s. After the measurement the cell was excited at 500nm for 60ms to excite YFP directly.
A single HEK293T cell, which was transfected with the mentioned plasmids, was stimulated with 10nM
U46619 resulting in an increase in YFP fluorescence and a decrease in CFP fluorescence (fig. 19A).
These changes were reflected in an increase in FRET ratio of the same cell and also in the averaged trace
of 30 individual cells (fig. 19A and B). The increase occurred within a half time (t1/2) of 3.9s as measured
in nine cells upon stimulation with a super-saturating concentration of 1µM U46619
(kon=0.271±0.023s-1, mean±S.E.M.). Upon wash-out of the agonist the ratio decreased very slowly. The
change in FRET could either reflect the change in distance between LARG and Gα13 or could arise
from bystander FRET, which is an unspecific change in distance between LARG or Gα13 and a
random fluorophore-labeled protein. To exclude this possibility, HEK293T cells were transfected with
Txa2-R, Gα13-wt, Gβ-wt, Gγ-wt, membrane bound mCFP and YFP-LARG. Hence, changes in FRET
upon agonist application would be due to YFP-LARG translocation to the membrane in these cells. As
visible in figure 19C, no change in FRET was observable. The same is true for cells expressing
Gα13-mTur2 and Venus-p63RhoGEF (fig. 19D) as for Venus-p63RhoGEF the interaction with Gαq,
but not Gα13 is described (see 4.5.2.1 and 6.2).
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In order to exclude artefacts in FRET between LARG and Gα13 due to the N-terminal localization of
YFP, the FRET experiments were repeated with LARG-insYFP (fig. 20A). The LARG-insYFP variant
has YFP inserted between RH domain and DH-PH domain. Also between LARG-insYFP and
Gα13-mTur2 an increase in FRET could be measured upon agonist stimulation, however the FRET
amplitude was approximately half the size of the FRET amplitude with YFP-LARG upon stimulation
with 10nM U46619. This is not due to the lower concentration, as both concentrations are saturating
(see concentration response curves in fig. 23).
Fig. 19 Agonist-dependent FRET change between Gα13-mTur2 and YFP-LARG upon activation of Txa2-RHEK293T cells were transfected with 0.5µg Txa2-R, 1µg Gα13-mTur2, 0.5µg Gβ-wt, 0.2µg Gγ-wt and 1µg YFP-LARG.Two days after transfection cells were measured on an inverted microscope with a high-performance CCD camera. During
the measurement cells were excited for 60ms at 2Hz with 440nm. Further the cells were continuously superfused with
FRET buffer and U46619 was applied using a pressure operated superfusion device were indicated by black bar. (A and B)
Stimulation of Txa2-R with 10nM U46619 led to an increase in FRET, as visible in FCFP decrease (blue), FYFP increase(yellow) and ratio increase (black) for a representative cell (A) and in a mean±S.E.M. trace of 30 individual cells (B). a.u.,
arbitrary unit(s). (C) Cells were transfected as before, only Gα13-wt and mCFP were used instead of Gα13-mTur2. These cellsshowed almost no increase in FRET upon agonist stimulation. (D) The same was true for cells transfected with
Venus-p63RhoGEF (V-p63) instead of YFP-LARG. Traces are mean±S.E.M. for at least 13 individual cells.
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In the case of LARG-insYFP a little increase in FRET was observed if Gα13 and mCFP were used
instead of Gα13-mTur2 (fig. 20B). This increase was most likely caused by bystander FRET between
plasma membrane bound CFP and LARG-insYFP upon agonist-induced LARG translocation.
Consequently, the increase in FRET was diminished if the trimeric G protein was excluded from the
transfection mixture, in other words if the cells were transfected with Txa2-R, mCFP and
LARG-insYFP alone (fig. 20C).
In summary, activation of Txa2-R lead to a fast and specific increase in FRET between Gα13-mTur2
and two different YFP-labeled LARG constructs.
Fig. 20 Agonist-dependent change in FRET between Gα13-mTur2 and LARG-insYFPA HEK293T cells were transfected with 0.5µg Txa2-R, 1µg Gα13-wt, 0.5µg Gβ-wt, 0.2µg Gγ-wt and 1µg LARG-insYFP.The mean trace±S.E.M. of nine individual cells showed an increase upon stimulation with 5nM U46619. A smaller
increase was observed for cells transfected with 1µg Gα13-wt and 1µg mCFP instead of Gα13-mTur2 (B) and no increasewas found for cells transfected only with Txa2-R and YFP-LARG (C). Shown are mean traces±S.E.M. of eleven cells forboth conditions.
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6.1.3 LARG dissociated slower from Gα13 than Gα13 reassociated with Gβγ
The activation and deactivation of Gα13 can be monitored by FRET in cells transfected with Gα13-YFP
and Gβ-Cer together with Txa2-R and Gγ-wt (unpublished data by A.-L. Krett). This allowed us to
compare the inactivation of the G protein with the dissociation of LARG from Gα13. Upon stimulation of
the Txa2-R with 1µM U46619 a rearrangement of the Gα13-subunits occurred as reflected by an increase
in FRET (fig. 21A). Wash-out of the agonist led to a fast decrease in FRET back to control level or even
below with t1/2 of 17.50s (n=5). As visible in the overlays of the agonist wash-out of both conditions in
figure 21B, the Gα13 inactivation occurred faster than the dissociation of LARG and Gα13.
Since the Gα13 and Gβγ are known to form a
trimeric complex in the basal state, we
wondered whether the inactive, unstimulated
trimeric G protein exhibits FRET. FRET under
such steady state conditions can be investigated
by donor recovery after acceptor photo
bleaching (5.2.6.10). This method is limited in
terms of sensitivity, nevertheless it is the only
way to estimate FRET under steady state
condition (Hein and Bünemann, 2009). For this
approach YFP was bleached by approximately
70% with high intensity at 500nm for 120s and
FCFP was monitored every 1.5s. If FRET was
present, the cyan fluorescence would increase
over time. The increase in FCFP for the
Gα13-YFP Gβ-Cer FRET pair was
Fig. 21 Inactivation of Gα13 occured faster than Gα13 LARG dissociationA HEK293T cells transfected with 0.5µg Txa2-R, 1µg Gα13-YFP, 0.5µg Gβ-Cer and 0.2µg Gγ-wt showed an increase inFRET upon stimulation with 1µM U46619. The increase was quickly reversible upon wash-out of the agonist. B shows
the G protein inactivation (grey) and dissociation of LARG and Gα13 (black) upon wash-out of the agonist. Shown aremean traces±S.E.M. of ten individual cells for A. B is an overlay of measurements of figure 21A and 19B normalized to
their maximal response.
Fig. 22 Acceptor photobleaching led to an increased FCFPfor the Gα13 Gβ FRET, but had no influence on FRETbetween Gα13 and YFP-LARGFRET under steady conditions would result in donor recovery
upon acceptor photo bleaching. The FRET assay between
Gα13-YFP and Gβ-Cer was tested in the absence and presenceof 1µM U46619 (unstim. and stim. Gα13-A, respectively), theFRET assay between Gα13-mTur2 and YFP-LARG in thepresence of 10nM U46619 (YFP-LARG) and as control
condition cells were transfected with 0.5µg β2-AR-mTur2 and0.5µg pcDNA3 (mTur2). Relative changes in FCFP due toacceptor bleaching are means±S.E.M. for n (in parantheses)
individual cells. ****P<0.0001, **P<0.01, ANOVA with
Bonferroni´s multiple camparison test.
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significantly higher in the absence and presence of 1µm U46619 (6.6±1.3% and 9.7±1.0%,
respectively (mean±S.E.M.)) than for the YFP-LARG Gα13-mTur2 FRET pair in the presence of
10nM U46619 (-0.1±1.0%, fig. 22). For YFP-LARG no significant donor recovery was observed
compared to control. Hence, FRET already takes place in the inactive Gα13-mTur2 Gβ-Cer Gγ
complex, but does not appear between Gα13-mTur2 and YFP-LARG in amounts detectable by this
method.
6.1.4 Left shift in concentration response relationship of the Gα13 LARG interaction compared
to Gα13 activation
Since the dissociation of LARG and Gα13 is remarkably slower than the inactivation of the G protein,
we wondered if this results in a shift in the concentration response relationship. In case of the Gα13
activation 300nM U46619 were used as reference concentration, whereas 10nM U46619 were used for
the Gα13 LARG interaction. On each cell two agonist concentrations were applied, first the test
concentration and second the reference concentration. For both stimulations the FRET amplitudes
were determined and afterwards they were compared. For each FRET pair a concentration response
curve was fitted by “GraphPad Prism” with constrained bottom and free hill slope (fig. 23, see
5.2.6.1.7 for details on fitting of concentration response curves). As the amplitudes of the Gα13-mTur2
LARG-insYFP FRET pair are small, evaluation of small concentrations was complicated and caused
probably the large variations observed for this FRET pair.
For FRET between Gα13-mTur2 and LARG-insYFP or YFP-LARG EC50 values of 0.048nM and
0.33nM were calculated, respectively. The Gα13 activation occurred with an EC50 value of 29.22nM.
So the EC50 values of the Gα13 LARG interaction and the Gα13 activation differed almost by two
Fig. 23 Concentration response curves of Gα13 activation and the Gα13 LARGinteraction
Cells were transfected as described for figure 20A (blue), 19A (black)and 21A (red).
Each cell was first stimulated with a test concentration and afterwards with 10nM or
300nM for the Gα13 LARG interaction or the Gα13 activation, respectively. Theconcentration response curve for Gα13 activation was measured by A.-L. Krett. Everyconcentration was tested in at least three cells, in most cases more than five cells were
evaluated. For every concentration mean±S.E.M. is depicted. “Dose-response curves”
were fitted to the measured values “GraphPad Prism” and are shown as continous lines.
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orders of magnitude. Also the extra sum-of-squares F-test, which compared logEC50 values, rejected
the null hypothesis of equal logEC50 values for all conditions.
As described in detail in the methods section (see 5.2.6.1.1) the amplitude of a FRET signal does not
increase exponentially with decrease in fluorophore distance, but is for example influenced by the ratio
of donor over acceptor fluorophores: If the donor is present in huge excess over the acceptor, the
FRET amplitude will be saturated even if not all acceptors are excited. Even more, the FRET
amplitude would decrease with further increase in donor fluorescence, because FCFP, the donor
fluorescence intensity, functions as the denominator of the FRET ratio. Due to this an excess in
Gα13-mTur2 would be a possible explanation for the shift in concentration response relationship,
because partial interaction of LARG and Gα13 would be interpreted as full interaction. Did we
overestimate the Gα13 LARG interaction induced by small concentrations, due to this problem? In
order to investigate this possibility, we evaluated the stoichiometry of YFP-LARG and Gα13-mTur2 of
the cells analyzed for the concentration response curve.
For the evaluation a control construct was needed, which expresses the same fluorophores as used in
the YFP-LARG Gα13-mTur2 FRET pair in a one to one stoichiometry and in a distance, which
abolishes FRET (see 5.2.6.1.11 for details, (Dorsch et al., 2009)). This construct was a β2 adrenergic
receptor (β2-AR) with eYFP at its N-terminus and mTur2 at its C-terminus.
The control construct was cloned as follows: First β2-AR-mTur (C. Krasel, personal communication)
was mutated to β2-AR-mTur2 by QuickChange® mutagenesis (see 5.1.3.2 for mutagenesis primers).
Next SI-eYFP-β2-AR from V. Wolters and β2-AR-mTur2 were digested with HpaI and HindIII. HpaI
cuts within the β2-AR and HindIII in front of the ORF of both constructs. So the N-terminal part of
β2-AR-mTur2 was substituted by the N-terminal part of SI-eYFP-β2-AR by ligation of the right
fragments. Through this procedure SI-eYFP-β2-AR-mTur2 was produced.
The fluorescence intensity of YFP and CFP was evaluated for cells expressing
Si-eYFP-β2-AR-mTur2, each fluorophore excited directly with 500nm and 440nm, respectively.
Also the cells, which were analyzed for the YFP-LARG Gα13-mTur2 concentration response curve,
were evaluated the same way. Afterwards the stoichiometry of YFP-LARG and Gα13-mTur2 was
extrapolated from the control construct. By this method approximately two YFP-LARGs per three
Gα13-mTur2s were predicted for the analyzed cells (0.66±0.56 (geo. mean±S.D.)). So a pronounced
excess in Gα13 was probably not the reason for shift in concentration response relationship between
LARG-Gα13 interaction and Gα13 activation.
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6.1.5 LARG´s interaction with Gα13 and its translocation to the plasma membrane is slowly
reversible
Next we tested whether the shift in the
concentration response relationship was
caused by irreversible interaction of LARG
and Gα13. The LARG Gα13 interaction and
LARG translocation was monitored over ten
minutes of agonist wash-out and then agonist
was applied for a second time (fig. 24). The
mean FRET traces in figure 24A and B are
not corrected for bleaching, because
correction could have led to overestimation of
decrease in FRET during wash-out and
thereby overestimation of the LARG Gα13
dissociation. Also no comparison was done
between the first and second amplitude, since
loss in amplitude can be caused by photo
bleaching as well. In order to facilitate
comparison of kinetics the translocation trace
was mirrored along the time axis (fig. 24C).
Further, the sampling rate was reduced to one
image every 30s to exclude underestimation
of the second translocation due to bleaching.
In all three assays a second increase could be
observed after ten minutes. In the
translocation experiment the first and second
amplitude were not significantly different as
evaluated by a paired t-test. From these data
we assume a reversible translocation of
LARG as well as interaction of the same with
Gα13. Noteworthy, the mean traces of
YFP-LARG translocation in the presence of
unlabeled and mTur2-labeled Gα13 were
comparable (fig 24C).
Fig. 24 LARG´s translocation and interaction with Gα13 isslowly reversible
HEK293T cells were transfected as described in figure 19A,
20A and 18A for Gα13 LARG interaction (A and B) andYFP-LARG translocation (C, black trace). Additionally,
translocation of YFP-LARG was monitored in the presence of
Gα13-mTur2 instead of Gα13-wt (C, grey trace). Wash-out ofagonist was monitored for 10 minutes and afterwards U46619
was applied for a second time. The translocation was detected
with 0.03Hz and the interaction with 0.2Hz. Mean
traces±S.E.M. of at least nine individual cells. For better
comparison the translocation was mirrored at the time axis.
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6.1.6 Does RhoA-GTP stabilize the LARG Gα13 interaction?
All Lbc-RhoGEFs bind RhoA-GTP and
this binding is discussed to participate in
a positive feedback loop (Medina et al.,
2013). Therefore we wondered whether
the interaction of RhoA-GTP with
LARG is the reason for the prolonged
interaction of Gα13 and LARG. We
mutated LARG to prevent RhoA-GTP
binding, as described before (F1098A
and I1100E (Medina et al., 2013)). The
mutations were introduced in two cycles
of QuickChange® site-directed
mutagenesis (see 5.1.3.2 for primer
sequence) and verified by sequencing.
The FRET change between Gα13-mTur2
and YFP-LARG F1098A-I1100E upon stimulation with 5nM U46619 is shown in figure 25. There is no
obvious difference between this trace and the mean trace for YFP-LARG wild type (fig. 19B) in terms of
wash-out kinetics even though a smaller agonist concentration was applied.
6.1.7 Overexpression of LARG in HEK293T cells
For functional comparison of downstream effects of the fluorophore tagged LARG variants and wild
type LARG equal expression is essential. The wild type plasmid with pHyg as backbone was a kind
gift by T. Wieland, Mannheim. Full cell lysates were separated by 10% SDS PAGE and afterwards
transferred to a PVDF membrane by Western Blot. The membrane was incubated with antibodies
against LARG, Gα13 and as loading control an antibody against RhoA was used (see 5.1.8 for a list of
Fig. 25 Interaction of Gα13 with a LARG mutant deficient in Rho-GTP binding
HEK293T cells were transfected with 0.5µg Txa2-R, 1µgGα13-mTur2, 0.5µg Gβ-wt, 0.2µg Gγ-wt and 1µg YFP-LARGF1098A-I1000E and stimulated with agonist. The mutant is described
to be deficient in RhoA-GTP binding and therefore should not
participate in a putative positive feedback loop. Shown is the mean
trace±S.E.M. of twelve cells.
Fig. 26 Localization and overexpression of LARG constructs
A HEK293T cells were transfected with 1µg/6cm dish YFP-LARG and fluorescence was detected with a confocal FRAP
imaging system (Visitech) two days after transfection. Scale bar, 5µm (B and C) Expression of differing LARG
constructs (Flag-LARG, pcDNA3-LARG, pHyg-LARG and YFP-LARG) and constitutive active Gα13QL as well asGα13-YFP were investigated by SDS PAGE and Western Blot. 10cm dishes of HEK293T cells were transfected with10µg LARG constructs or 2µg Gα13. After blotting PVDF membranes were incubated with a-LARG, a-Gα13 and a-Rho(B) as well as with a-GFP and a-Rho (C) antibodies.
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antibodies). In the two lanes on the left of figure 26B and C 2µg constitutive active Gα13QL and
YFP-labeled Gα13 were transfected in HEK293T cells with polyethylenimine (PEI), respectively.
These constructs expressed rather equally. Whereas 10µg per 10cm dish of pHyg-LARG was far less
expressed than the same amount of YFP-LARG (fig. 26B).
If LARG wild type transcription were controlled by the same promoter as YFP-LARG transcription,
both constructs should be transcribed with the same rate. Therefore, LARG was cloned into pcDNA3,
which is also the vector of YFP-LARG:
The plasmids YFP-LARG and empty pcDNA3 were digested with the restriction enzymes BamHI and
XhoI. Thereby the LARG cDNA was separated from YFP. Afterwards LARG was ligated into
pcDNA3.
But also LARG in pcDNA3 was as weakly expressed as LARG in pHyg (fig. 26B). For this reason we
tried to enhance protein stability by fusion of a Flag-tag to the N-terminus of LARG. We chose this
approach, because YFP-LARG is better expressed and it differs only by its N-terminal YFP from
pcDNA3-LARG. But nevertheless, Flag-LARG expressed as weakly as wild type LARG (fig. 26B).
The described major differences in expression, hindered comparison of LARG and YFP-LARG in
respect to downstream signaling as discussed in detail in 6.1.8.
LARG cDNA was amplified from YFP-LARG with an N-terminal primer featuring the coding
sequence for a Flag-tag (see 5.1.3.1 for a list of cloning primers). Afterwards the PCR product and
empty pcDNA3 were digested with BamHI and XhoI, ligated and sequenced.
To estimate stoichiometry of LARG and Gα13 the same cell lysates as used for figure 26B were blotted
and the membrane was incubated with an antibody against GFP (fig. 26C). The GFP antibody should
detect YFP equally well no matter if it´s fused to LARG or to Gα13. Thus this should allow for
comparison of YFP-LARG and Gα13-YFP expression. Transfection of either 10µg YFP-LARG or 2µg
Gα13-YFP cDNA led to the same amount of YFP-labeled protein (fig. 26C). Differences in DNA
amount were balanced with empty pcDNA3 and RhoA was used as loading control.
6.1.8 Determination of active RhoA and SRE.L activation by LARG
Next, we tried to monitor RhoA and SRE.L signaling downstream of LARG. Activation of RhoA can
be measured by affinity purification of active GTP-bound RhoA from full cell lysates (Ren and
Schwartz, 2000). In a mammalian cell the total amount of RhoA should exceed the portion of active
RhoA and therefore total RhoA should not be significantly altered by precipitation of active RhoA.
The RhoA binding domain (RBD) of Rhotekin has high affinity for active RhoA and can be expressed
in E. coli as fusion protein with Glutathione-S-transferase (GST). The GST-RBD was incubated with
glutathione coated agarose beads and this “predator” was used to isolate its “prey” RhoA-GTP from
full cell lysates. The left over lysate was tested for expression of transfected constructs and equal
amounts of total RhoA. The precipitated, active RhoA and the RhoA from the full cell lysate were
detected with the same antibody, which should bind equally well to active and inactive RhoA.
HEK293T cells were transfected with PEI with or without 1µg constitutively active Gα13QL,
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10µg YFP-LARG or pcDNA3-LARG. Differences in DNA amounts were balanced with empty
pcDNA3. 24 hours after transfection cells were lysed and active RhoA was isolated.
In theory cells only transfected with empty vector should show no or only a faint RhoA band in the
precipitate fraction, which represents the active RhoA fraction under basal conditions. Further
expression of either Gα13QL or LARG should increase the signal of the active RhoA fraction and this
should be even enhanced by coexpression of both.
In most experiments transfection of Gα13QL increased the amount of RhoA in the precipitate compared
to active RhoA under basal conditions
whereas the active RhoA upon LARG
transfection alone or together with Gα13QL
varied considerably, which paralleled the
again very low LARG expression in most
experiments. For the affinity purification of
active RhoA experiment with the highest
LARG expression the Western Blot result is
shown in figure 27. In this case transfection
of YFP-LARG alone led to the highest
amount of RhoA in the precipitate fraction.
This was even higher than if YFP-LARG
was cotransfected with Gα13QL. The
amount of RhoA in the full cell lysate was
in the same range for all conditions.
In addition to the described transfection conditions also other G protein RhoGEF ratios were tested,
but no reliable Gα13QL-dependent LARG mediated Rho activation could be observed. The same
problem occurred in the SRE.L reporter gene assay.
As described previously the transcription factor SRF is activated downstream of Rho activation
(see 4.4.1 Amongst others, ROCK is activated by the Rho subfamily and 5.2.4). SRF binds together
with another transcription factor, MRTF, to the serum response element (SRE) and thus the SRE.L
reporter gene assay is used to determine RhoGEF activity.
In theory Gα13 should activate LARG and this should lead to increased SRE.L transcription, which
would be measured as increase in firefly luciferase activity. So transfection of Gα13 alone and LARG
alone should cause lower luciferase activities than cotransfection of both. To test this 50ng/well
LARG, YFP-LARG, LARG-insYFP or empty vector were cotransfected with increasing amounts of
Gα13QL (0ng (control) to 2.5ng). Luciferase activity is depicted normalized to cells transfected only
with the reporter plasmids and empty pcDNA3. All conditions are measured in triplicates. This is true
for all SRE.L reporter gene assays presented in this thesis.
Fig. 27 RhoA activation by YFP-labeled and wild type LARG
Active Rho was determined using a GST-tagged Rho binding
domain (RBD). HEK293T cells were transfected with or without
1µg Gα13QL, 10µg YFP-LARG or LARG in pcDNA3. 24h aftertransfection cells were lysed and incubated with RBD. Active
Rho was precipitated and analyzed by Western Blot (upper row,
a-Rho). Full cell lysates were also investigated by Western Blot
in order to check for expression of the transfected constructs
(a-LARG and a-Gα13) and equal loading (a-Rho).
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Gα13QL was detectable in Western Blot (fig. 28 lower panel) only if 2.5ng/well were transfected.
For the Western Blot the lysates of triplicates per condition were pooled and the complete lysates
were loaded on a 10% SDS PAGE. Even though 0.7ng/well Gα13QL were not detectable in Western
Blot, an increased luciferase activity was already present. For all Gα13QL concentrations no
significant difference in luciferase activity between Gα13QL alone and together with LARG was
measured. In line with this, LARG expression was found equal for cells transfected with and
without LARG. Thus, LARG transfection did not enhance LARG expression over endogenous
levels. For YFP-LARG an overexpression could be validated in the Western Blot. Also
LARG-insYFP was expressed, as shown by the double band, but only in the range of endogenous
LARG. For YFP-LARG and LARG-insYFP a significant effect compared to basal was found in the
conditions with 1.25ng and 2.5ng Gα13QL (fig. 28 upper panel). This luciferase assay is
representative for many others, with differing concentrations in Gα13QL and the LARG variants.
Especially unlabeled LARG could not be reliably expressed.
Fig. 28 SRE.L transcription due to activation of LARG and the two YFP-labeled LARG
constructs by increasing amounts of Gα13QLIn 96-well format HE293T cells were transfected as indicated with or without 50ng/well LARG
(red), YFP-LARG (blue), LARG-insYFP (purple) or empty vector (basal, white), as well as
differing amounts of Gα13QL, if indicated, and empty pcDNA3 for equal DNA amounts. Further allconditions were transfected with the reporter gene plasmids: 21.6ng/well pSRE.L and 3.4ng/well
pRL-TK, which is constitutively active. Results are relative (rel.) mean±S.E.M. luciferase activities
after normalization **P<0.01, ***P<0.001, ****P<0.0001, ANOVA with Bonferroni´s multiple
comparison test, comparisons between different Gα13QL concentrations of one LARG version werecolored according to the LARG version. Expression of the transfected proteins was confirmed by
Western Blot (lower panel, a-Rho as loading control).
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In one case transfection of 50ng/well LARG and YFP-LARG led to a pronounced overexpression
(fig. 29B). For this experiment 50ng/well Gα13QL was used. Later on the amount of Gα13QL was
reduced stepwise to the amounts used in figure 28 in order to get an excess of the LARG variants over
Gα13QL. Significantly, with LARG and YFP-LARG overexpressed a significant increase in luciferase
activity was observed for Gα13QL coexpression compared to the LARG variants alone (fig. 29A).
In summary, we could not reliably investigate Gα13-dependent signaling downstream of LARG, due to
minor LARG expression in most experiments. Thus also the validation of downstream signaling by the
YFP-tagged LARG was prohibited. Noteworthy, they behaved as expected for wild type in regard to
interaction with Gα13: YFP-LARG translocated to the plasma membrane upon activation of wild type
and mTur2-tagged Gα13 (fig. 24C). In addition, translocation was reflected also in terms of kinetics by
an increase in FRET between Gα13-mTur2 and two LARG constructs, which were tagged with YFP at
different sights (fig. 24A and B).
Fig. 29 SRE.L transcription due to activation of LARG and YFP-LARG by Gα13QLIn 96-well format HE293T cells were transfected as indicated with 50ng/well LARG (red), YFP-LARG (blue) or
empty vector (basal, white), as well as with or without 50ng/well Gα13QL. All conditions were transfected with thereporter gene plasmids. (A) Results are relative (rel.) mean±S.E.M. luciferase activities after normalization
**P<0.01, ***P<0.001, ****P<0.0001, ANOVA with Bonferroni´s multiple comparison test. Expression of the
transfected proteins was confirmed by Western Blot (B, a-actin as loading control).
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6.2 Dynamics of the Gαq p63RhoGEF interaction and its regulation by RGS2
In order to compare the mainly Gα13-regulated LARG with the Gαq-regulated p63RhoGEF, we further
studied the interaction of p63RhoGEF and Gαq in detail. p63RhoGEF´s domain structure (fig. 9) is much
simpler than LARG´s structure (fig. 5) as it misses the PDZ domain and the RH domain. The interaction
with Gαq occurs via its PH domain and parts of its DH domain (fig. 30, (Lutz et al., 2007)). This
interaction involves only Gαq´s effector binding site, but leaves its RGS binding site free for further
interaction partners, which is in contrast to PLCβ´s binding to Gαq (fig. 8, (Lyon et al., 2014)). This free
interaction site on Gαq can be occupied by RGS2 in a trimeric complex with p63RhoGEF, as shown in
this section. Most of the results described in the following have been published (Bodmann et al., 2014).
6.2.1 The Gαq p63RhoGEF interaction can be monitored by FRET
The RhoGEF p63RhoGEF as effector of Gαq has not been studied in living cells. Therefore a FRET
assay was established to study the p63RhoGEF Gαq interaction. HEK293T cells were transfected with
the histaminergic H1 receptor (H1-R), Gαq-CFP, Gβ-wt, Gγ-wt and N-terminally Venus-labeled
p63RhoGEF (V-p63). Both, Venus-p63RhoGEF and Gαq-CFP were found at the plasma membrane
under basal conditions (fig. 31A). The H1-R is known to couple to Gαq and was stimulated with 10µM
histamine (Li et al., 1995). This led to a pronounced and fast increase in FYFP, which was mirrored by
decrease in FCFP. After withdrawal of agonist FYFP and FCFP slowly recovered (fig. 31B). Accordingly, the
ratio trace of the same cell and the mean trace of fifteen individual cells showed a reversible response to
stimulation (fig. 31B and C). In order to verify this FRET assay with another Gαq coupled receptor, the
Fig. 30 Crystal structure of p63RhoGEF´s DH-PH domain in complex with RhoA and Gαi/qThe crystal structure by Lutz and colleagues shows the interaction of RhoA (green) with p63RhoGEF´s
DH domain (yellow). Gαq (blue) interacts with both DH (yellow) and PH (purple) domain. The lastdepicted amino acid of each domain is indicated with N and C, respectively, Gαi/q´s three switchdomains are shown in red (Lutz et al., 2007). The viewer looks from the plasma membrane towards the
complex.
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muscarinic M3 receptor (M3-R) was cotransfected with the FRET pair. Also with this receptor an
increase in FRET was observed (fig. 31C). An increase in FRET was visible in approximately 75% of all
cells. Absence of a FRET change was probably due to lack of receptor in these cells.
Unspecific FRET is possible as described previously for the FRET between YFP-LARG and
Gα13-mTur2 (see 6.1.2). Therefore Venus-p63RhoGEF was also cotransfected with Gαi-CFP, Gβ-wt,
Gγ-wt and the Gαi coupled α2A adrenergic receptor (α2A-AR). For this condition no change in FRET
was observed upon stimulation with a saturating noradrenaline (NA) concentration of 100µM
(fig. 31E). Also HEK293T cells, which were transfected with H1-R, Gαq-CFP, Gβ-wt, Gγ-wt and
GIRK4-YFP instead of Venus-p63RhoGEF, did not show a change in FRET ratio (fig. 31F). So
activation of Gαq coupled receptors and subsequent Gαq activation leads to a reversible and specific
increase in FRET between Gαq-mTur2 and Venus-p63RhoGEF.
Fig. 31 FRET change between Gαq–CFP and Venus-p63RhoGEF upon receptor stimulationHEK293T cells were transfected with 1µg H1-R, 1.5µg Gαq-CFP, 0.5µg Gβ-wt, 0.2µg Gγ-wt and 0.3µgVenus-p63RhoGEF. A In these cells Venus-p63RhoGEF and Gαq-CFP localized to the plasma membrane under basalconditions. Both fluorophores were excited independently. Scale bar, 5µm. B Upon stimulation with 10µM histamine
(His) FYFP (yellow) increased and FCFP (blue) decreased rapidly in a representative cell. This was also reflected in anincrease in ratio trace of the same cell (black) and mean±S.E.M. trace for 15 individual cells (C). a.u., arbitrary unit(s).
D Activation of M3-R instead of H1-R with acetylcholine (ACh) had the same effect. E For activation of Gαi-CFP by theα2A adrenergic receptor (α2A-AR) with noradrenaline (NA) no change in FRET with Venus-p63RhoGEF was observed.The same was true for FRET between Gαq-CFP and GIRK4-YFP upon activation of H1-R (F). Traces are means±S.E.M.of at least nine individual cells.
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6.2.2 The interface of the Gαq p63RhoGEF interaction
The interaction of p63RhoGEF with Gαq is described to rely on p63RhoGEF´s PH domain. Therefore
two mutations were inserted in this domain (F471E and L475A). Thus we wondered whether a loss in
interaction abolished downstream signaling. We could show previously reduced FRET amplitude and
significantly reduced fraction of responding cells upon mutation of one of the two sites (Bodmann,
diploma thesis). A complete loss in FRET was observed between Venus-p63RhoGEF F471E-L475A
and Gαq-CFP.
As described previously (see 6.1.8) SRE.L reporter gene assays are widely used to determine RhoGEF
activity. Since the H1-R is known to have relatively high basal activity, the high luciferase activity by
H1-R alone was expected (Bakker et al., 2000). The single mutants as well as the double mutant
showed a significant loss in luciferase activity compared to wild type p63RhoGEF upon H1-R
activation (fig. 32A). The luciferase activity of the mutants was comparable with receptor alone. The
reduction in RhoGEF activity of the mutants was not caused by lower expression as determined by
Western Blot (fig. 32B). We concluded that p63RhoGEF´s PH domain is crucial for Gαq-binding and
activation of downstream signaling.
For PLCβ3 the Gαq-binding site was described, which overlaps with the binding sites for RGS2 and
p63RhoGEF (see 4.5.2.1 PLCβ3 overlaps with p63RhoGEF and RGS2 binding to Gαq, (Lyon et al.,
2014)). RGS2 and p63RhoGEF bind to different sites on Gαq (Shankaranarayanan et al., 2008).
Therefore we wondered, if RGS2 would inhibit interaction of Gαq and PLCβ3 and thereby would
inhibit production of the second messenger diacylglycerol (DAG). Further we wondered how far
p63RhoGEF and PLCβ3 would interfere with each other during signaling.
Fig. 32 Decreased SRE.L activation by Gαq binding deficient p63RhoGEF variantsA In 96-well format HEK293T cells were transfected with differing 10ng/well Venus-p63RhoGEF mutants alone (basal,
open bars) or together with 50ng/well H1-R and stimulated with 10µM histamine (hatched bars). Further all conditionswere transfected with the reporter gene plasmids. Results are relative (rel.) mean±S.E.M. luciferase activities after
normalization **P<0.01, ***P<0.001, ANOVA with Dunnett´s multiple comparison test, which compared all conditions
with p63RhoGEF wild type. B Equal expression of Venus-p63RhoGEF was confirmed by Western Blot and actin
expression was used as loading control (lower panel).
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The interaction of Gαq and PLCβ3 can be monitored by FRET between the two proteins as studied in
detail by T. Pollinger (Pollinger, 2012). The interaction of Gαq–CFP and YFP-PLCβ3 was greatly
abolished by cotransfection of RGS2 in HEK293T cells, which stably express murine H1-R
(mH1-R-HEK293T, fig. 33A). For this experiment RGS2 was tagged with a red fluorescent protein
(RFP) at its C-terminus and only RGS2 expressing cells were measured.
RGS2-RFP was cloned as follows: RGS2 was PCR amplified from RGS2-YFP with the primers listed
in 5.1.3.1. A KpnI and a NotI restriction site were N- and C-terminally, respectively, introduced into
RGS2 with this step. Next the PCR product and pcDNA3-mRFP were digested with KpnI and NotI
and the fragments were ligated.
Active PLCβ hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3)
and diacylglycerol (DAG). Thus, DAG levels are an established surrogate parameter for PLCβ
activity. The cellular DAG levels can be measured with a FRET-based sensor (Violin et al., 2003). An
increase in FRET reflects an increase in cellular DAG concentrations. Cotransfection of RGS2-RFP
with the DAG sensor reduced the agonist dependent increase in FRET in mH1-R-HEK293T cells
(fig. 33B). Hence, RGS2 cotransfection disrupts the PLCβ3 Gαq interaction and production of the
second messenger DAG.
Fig. 33 Influence of RGS2 and p63RhoGEF on PLCβ3 signaling
HEK293T cells stabily expressing murine H1-R (mH1-R) were cotransfected with 1µg Gαq-CFP and 1µg YFP-PLCβ3alone (black) or together with 0.5µg RGS2-RFP (grey) and stimulated with 10µM histamine (A). B The production of
diacylglycerol (DAG) was monitored in mH1-R-HEK293T cells transfected with a FRET-based DAG sensor (0.5µg) and0.5µg pcDNA3. An increase in FRET reflects an increase in DAG levels. DAG levels were drastically reduced in the
presence of 0.5µg RGS2-RFP (grey). For C HEK293T cells were transfected with 1µg H1-R and the DAG sensor (0.5µg)in the absence (black) and presence of 0.3µg p63RhoGEF (grey). D HEK293T were transfected like in figure 31A (black)
or additionaly with 1µg PLCβ3 (grey). All traces are mean±S.E.M., n (in parentheses).
94
Results
p63RhoGEF coexpression with the DAG sensor and H1-R in HEK293T cells reduced also the
histamine-induced increase in DAG (fig. 33C). In contrast, the amplitude in FRET between Gαq and
p63RhoGEF was not changed by PLCβ3 coexpression (fig 33D). Since the amplitude in the plateau
phase of agonist stimulation reflects the steady state of protein interaction, this result indicates no
influence of PLCβ3 on the steady state of the Gαq p63RhoGEF interaction. This is also reflected in
unchanged dissociation of Gαq and p63RhoGEF in the presence of PLCβ3: For all cells shown in
figure 33D the dissociation kinetics were determined by fitting of a monoexponential function to the
wash-out curve. The koff did not significantly differ as analyzed with Student´s t-test after Welch´s
correction (koff=0.064±0.047 and in the presence of PLCβ3 0.040±0.006, n ≥7, mean±S.E.M.).
In summary the PH domain is crucial for p63RhoGEF´s binding to and activation by Gαq. Furthermore
p63RhoGEF and RGS2 can compete with PLCβ3 for binding to Gαq.
6.2.3 RGS2 accelerated Gαq inactivation and the Gαq p63RhoGEF dissociation
RGS2 belongs to the GTPase activating protein family and accelerates GTP hydrolysis of active Gα
subunits. Therefore we wondered how RGS2 influences the p63RhoGEF Gαq interaction. In
HEK293T cells, which were transfected with H1-R, Gαq-CFP, Gβ-wt, Gγ-wt and Venus-p63RhoGEF,
we studied the area under the curve (AUC) and decline upon agonist wash-out in the absence and
presence of RGS2. The steady state of the Gαq p63RhoGEF interaction was not altered by RGS2 as
Fig. 34 RGS2 accelerates the Gαq p63RhoGEF dissociation without an influence on steady stateHEK293T cells were transfected with 1µg H1-R, 1.5µg Gαq-CFP, 0.5µg Gβ-wt, 0.2µg Gγ-wt and 0.3µgVenus-p63RhoGEF. If indicated (grey) 0.5µg RGS2 was added to the transfection. A Cells were stimulated with 10µM
histamine for one minute and area under the curve (AUC) until agonist wash-out was evaluated (B). The same cells were
normalized to maximal response and plotted since agonist wash-out (C). In cells with RGS2 p63RhoGEF and Gαqdissociated faster than in cells without RGS2. Also stimulation with agonist for five minutes was followed by faster
dissociation in the presence of RGS2 (D) and unchanged area under the curve until wash-out (E). Traces are
mean±S.E.M., n (in parentheses).
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indicated by the unchanged area under the curve upon stimulation with 10µM histamine for either one
or five minutes (fig. 34B and E). The dissociation was analyzed by fitting a mono-exponential
function to the decline after agonist wash-out. For the cells summarized in the raw and normalized
mean trace depicted in figure 34A and C koff values were evaluated. This analysis showed that the
dissociation in the presence of RGS2 was three times faster than under control conditions. The koff for
the two conditions differed significantly, as analyzed by an unpaired Student´s t test after Welch´s
correction (P<0.01, (Bodmann et al., 2014)).
The activation cycle of Gαq can be monitored by FRET. Since RGS2 accelerates Gαq´s
inactivation, we wondered if this is reflected in faster off-rate of FRET between Gαq-YFP and
Gβ-Cer. Further we wondered if p63RhoGEF exhibits GAP activity towards Gαq and/or modulates
RGS2´s GAP activity.
Therefore HEK293T cells were transfected with H1-R, Gαq-YFP, Gβ-Cer, Gγ-wt and either
p63RhoGEF, RGS2, none of them or both. The reassociation of Gαq and Gβγ is reflected in an
increase in FRET between Gαq-YFP and Gβ-Cer upon agonist wash-out. The increase can be analyzed
by fitting of a mono-exponential curve, as described above. RGS2 accelerated the reassociation
significantly (koff=0.058s-1) compared to the trimeric G protein alone (koff=0.024s-1), as it can be seen
in the wash-out traces of representative cells (fig. 35). Whereas cotransfection of p63RhoGEF did not
significantly change the reassociation of Gαq and Gβγ (koff=0.031s-1). In cells expressing RGS2 and
p63RhoGEF the reassociation occurred with the same speed as for RGS2 alone (koff=0.058s-1).
Fig. 35 Gαq reassociation is accelerated by RGS2 independent of p63RhoGEF expressionGαq activation and inactivation was investigated in the absence or presence of either p63RhoGEF (0.3µg), RGS2 (0.5µg)or both in HEK293T cells additionally transfected with 1µg H1-R, 1.5µg Gαq-YFP, 0.5µg Gβ-Cer and 0.2µg Gγ-wt.Reassociation kinetics were estimated by fitting a deactivation mono-exponential function. A Normalized representative
traces of the cells, which showed the koff closest to the mean, for each condition. The traces are plotted since wash-out of10µM histamine. p63RhoGEF did not affect Gαq reassociation, but RGS2 did as indicated by calculated koff (B).Mean±S.E.M. n (in parentheses). *P<0.05, **P<0.01, ANOVA with Bonferroni´s multiple comparison test. ns, not
significant.
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6.2.4 Concentration response curves of Gαq activation and its interaction with p63RhoGEF
superimpose independent of RGS2 expression
RGS2 accelerates Gαq inactivation and Gαq p63RhoGEF dissociation. For the LARG Gα13 interaction
compared to Gα13 inactivation we described a prolonged interaction. This might be the reason for the
left shift in concentration response relationship described in 6.1.4. Because of that we wondered if
shortened Gαq activation or Gαq p63RhoGEF interaction would lead to a right shift in concentration
response curve.
In order to guarantee constant receptor levels for all cells and conditions, we used again a HEK293
cell line stably expressing murine H1-R. The cells were transfected similarly to conditions in figure 34
and 35, but without additional receptor. The measurements were evaluated as described for the
concentrations response curves (6.1.4 and 5.2.6.1.7). For the Gαq activation and the Gαq p63RhoGEF
interaction with and without RGS2 we found the same logEC50 values, as analyzed by extra
sum-of-squares F-test. Histamine activated all conditions with an EC50 of around 0.5µM. As discussed
in 6.1.4 we analyzed the stoichiometry of G protein and RhoGEF in the cells used for the
concentration response curve. We calculated 0.56±0.11 (geo. mean±S.D.) Venus-p63RhoGEFs per
Gαq-CFP for the analyzed cells with SI-Venus-β2-AR-CFP as control construct. Therefore Gαq
proteins were expressed approximately in a 2:1 stoichiometry in respect to p63RhoGEFs.
The control construct was cloned as follows: Venus was PCR amplified from Venus-p63RhoGEF with
the primers listed in 5.1.3.1. By this PCR a BamHI restriction site and a SI-sequence were added at the
Fig. 36 Concentration response curve of Gαq activation and the Gαq p63RhoGEFinteraction in the presence and absence of RGS2
For the concentration response curve HEK293T cells stabily expressing murine H1-Rwere used. The single cells were transfected similarly to figure 34 and 35, respectively,
but without receptor. Every cell was first stimulated with a test concentration and
afterwards with 10µM histamine. Every concentration was tested in at least five
individual cells. For every concentration mean±S.E.M. is depicted. To the measured
values “dose-response curves” were fitted by “GraphPad Prism” and are shown as
continous lines.
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N-terminus of Venus and a XbaI restriction site at the C-terminus. Next the PCR product and
SI-eYFP-β2-AR were digested with BamHI and XbaI and ligated. With this step a SI-Venus-β2-AR
was created. Next this construct was digested with HpaI and HindIII in parallel with β2-AR-CFP
(Krasel et al., 2005). With these fragments SI-Venus-β2-AR-CFP could be ligated.
6.2.5 Interaction of Gαq and RGS2 is not altered by p63RhoGEF
The Gαq inactivation was accelerated by RGS2 in the presence of p63RhoGEF. Also the dissociation
of Gαq and p63RhoGEF was faster in the presence of RGS2. Thus we wondered whether the Gαq
RGS2 interaction can be monitored by FRET in cells expressing p63RhoGEF. Control HEK293T cells
were transfected with H1-R, Gαq-CFP, Gβ-wt, Gγ-wt and RGS2-YFP and a second population was
transfected additionally with p63RhoGEF. p63RhoGEF was transfected in the same amounts as used
for FRET between Gαq and p63RhoGEF. Upon stimulation with 10µM histamine FRET increased
rapidly and also declined rapidly with wash-out of the agonist (fig. 37A). The kinetics of interaction
were not obviously changed by p63RhoGEF and also the FRET amplitude was not significantly
different (fig. 37B, P=0.18) for the two conditions.
Fig. 37 p63RhoGEF did not change FRET between Gαq-CFP and RGS2-YFPFRET between Gαq and RGS2 was measured in HEK293T cells transfected with 1µg H1-R, 1.5µg Gαq-CFP, 0.5µgGβ-wt, 0.2µg Gγ-wt and 0.5µg RGS2-YFP with (grey) or without (black) 0.3µg p63RhoGEF. p63RhoGEF did not
change kinetics or amplitude of FRET between Gαq and RGS2 as visible in the mean±S.E.M. trace (A) and in theamplitude evaluation of the same cells (B). Mean±S.E.M., n (in parentheses).
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6.2.6 Increase in FRET between p63RhoGEF-CFP and RGS2-YFP upon agonist stimulation
The convergence of p63RhoGEF and RGS2 upon activation of Gαq has never been shown in living
cells. In order to reveal their juxtaposition by means of FRET, we tagged p63RhoGEF C-terminally
with CFP and cotransfected it together with RGS2-YFP.
p63RhoGEF-CFP was cloned as follows: β2-AR-CFP (Dr. C. Krasel) and Venus-p63RhoGEF were
digested with HindIII and XbaI and ligated in order to obtain Venus-p63RhoGEF-CFP. This construct
was then digested with HindIII and BspEI, because restriction sites for this enzymes flank Venus. Next
the barbed ends were blunted with a T4 DNA polymerase and the larger fragment was religated.
Functionality of p63RhoGEF-CFP was verified by SRE.L reporter gene assay (data not shown) and
FRET with Gαq-YFP (fig. 38E).
For the FRET measurement HEK293T cells were transfected with H1-R, Gαq-wt, Gβ-wt, Gγ-wt and
RGS2-YFP as well as p63RhoGEF-CFP. A fast increase in FRET occurred upon stimulation with
10µM histamine and was reversible with agonist wash-out (fig. 38A and B). The change in FRET was
rather small, but specific, which was indicated by three experiments: Firstly, no change in FRET was
observed between p63RhoGEF-CFP and GIRK4-YFP, which localizes at the plasma membrane
(fig. 38C). Secondly, no change in FRET was observed between p63RhoGEF-CFP and cytosolic
Venus (data not shown). Since RGS2 translocates from the cytosol to the membrane, cytosolic and
membrane bound YFP was used. Thirdly, no change in FRET occurred between RGS2-YFP and Gαq
Fig. 38 Specific histamine-induced FRET change between p63RhoGEF-CFP and RGS2-YFP
Stimulation with histamine led to a fast, reversible FRET increase in HEK293T cells transfected with 0.3µg
p63RhoGEF-CFP, 0.5µg RGS2-YFP, 1µg H1-R, 1.5µg Gαq-wt, 0.5µg Gβ-wt and 0.2µg Gγ-wt (A and B). FYFP (yellow),FCFP (blue) and ratio trace (black) of a representative cell and mean±S.E.M. of 16 individual cells. No change in FRETwas observed in cells transfected with GIRK4-YFP (0.4µg) instead of RGS2-YFP (C) or Gαq binding deficientp63RhoGEF (p63-CFP F471E-L475A) instead of wild type p63RhoGEF (D). E Also p63RhoGEF-CFP showed
agonist-dependent FRET changes with Gαq-YFP, DNA amounts transfected as described in figure 31. (B-E) Shown aremean±S.E.M. traces of at least eight individual cells, a.u. arbitrary unit(s).
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binding deficient p63RhoGEF (p63RhoGEF-CFP F471E-L475A, fig. 38D, see fig. 32 for
characterization of the mutant). Thus the increase in FRET between RGS2 and p63RhoGEF reflects
the specific convergence of the two in a trimeric complex with Gαq.
6.2.7 Monitoring the Gαq p63RhoGEF RGS2 complex in living cells
In section 6.2 we examined FRET within the trimeric Gαq protein (fig. 35), between Gαq and
p63RhoGEF (fig. 34), between Gαq and RGS2 (fig. 37) and between p63RhoGEF and RGS2 (fig. 38).
In order to understand the kinetics of the trimeric complex in more detail, we compared the different
assays by an overlay of the
respective experiments (fig. 39).
All experiments expressed Gαq,
p63RhoGEF and RGS2 either
labeled or unlabeled.
Differences in terms of kinetics
were observed between the
upper and the lower two sets of
experiments. In the lower two
sets, RGS2 is used in its
fluorophore-labeled variant and
functions as FRET partner.
Therefore only complexes which
include RGS2 are measured.
The upper two sets of
experiments have RGS2
cotransfected without a label. In
these FRET measurements
complexes with and without
RGS2 are monitored, which
results in a mixed phenotype for
the overall FRET signal. Hence,
the effect of RGS2 on Gαq
inactivation and the Gαq
p63RhoGEF interaction is
probably underestimated in
FRET assays with unlabeled
RGS2 (e.g. fig 39 upper panel).
With the described FRET assays
Fig. 39 Overlay of the four FRET assays monitoring the p63RhoGEF GαqRGS2 complex
Traces are mean±S.E.M. of the cells shown in figure 35B (black), 34A (red),
37A (blue) and 38B (purple) in the conditions transfected with Gαq,p63RhoGEF and RGS2, either labeled or unlabeled.
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we demonstrated a dynamic complex of RGS2 and Gαq-activated p63RhoGEF in living cells for the
first time. Formation of this complex depends strictly on activation of and binding to Gαq. In the
presence of RGS2 Gαq inactivates faster and consequently presence of RGS2 in the trimeric complex
accelerates its dissociation.
6.2.8 RGS2 negatively regulated signaling downstream of p63RhoGEF
The sensitivity towards histamine of Gαq activation and its interaction with p63RhoGEF is not altered
by RGS2. But RGS2´s influence on signaling downstream of p63RhoGEF was not determined jet.
Together with Dr. D. Brandt (AG Grosse, bpc, Marburg) we investigated Rho activation by
p63RhoGEF in the presence of RGS2 (Bodmann et al., 2014): As explained in 6.1.2 activation of
RhoA can be measured by affinity purification of active GTP-bound RhoA. In this assay p63RhoGEF
coexpression increased Rho activity under basal conditions and after stimulation for five minutes with
10µM histamine. This p63RhoGEF-mediated response was reduced by RGS2 coexpression.
RhoGEF activity can also be estimated by SRE.L reporter gene assay (see 6.1.2). Therefore HEK293T
cells were transfected in 96well format with H1-R, with or without Venus-p63RhoGEF and/or
RGS2-YFP. Fluorophore labeled constructs were used to control for equal expression by Western Blot
with an antibody against GFP (fig. 40B).
RGS2 coexpression also reduced luciferase activity in cells with and without p63RhoGEF
significantly (18.44 and 40.73, respectively, compared to 1.19 and 12.22, respectively, with RGS2;
fig. 40A) indicating negative regulation of p63RhoGEF-mediated downstream signaling by RGS2.
Fig. 40 SRE.L transcription upon p63RhoGEF activation is reduced by RGS2 coexpression
(A) In 96-well format HEK293T cells were transfected with 45ng/well H1-R and stimulated with 10µMhistamine. If so cotransfection is indicated for RGS2-YFP (45ng/well, RGS2) and/or Venus-p63RhoGEF
(5ng/well, p63RhoGEF hatched bars). Further all conditions were transfected with the reporter gene plasmids.
Results are relative (rel.) mean±S.E.M. luciferase activities after normalization. ****P<0.0001, ANOVA with
Dunnett´s multiple comparison test. (B) Equal expression of Venus-p63RhoGEF (at 100kDa) and RGS2-YFP (at
60kDa) was confirmed for different conditions by Western Blot with a-GFP antibody and actin expression was
used as loading control (lower panel).
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7 Discussion
The activation of p63RhoGEF and RH-RhoGEFs by Gαq and Gα13 were shown by different
groups. For both pathways several physiology and pathological functions have been described,
including chemotactic migration and progressive bone loss upon Pasteurella multocida infection
for p63RhoGEFs (Hayashi et al., 2013; Siegert et al., 2013). The RH-RhoGEF LARG has been
described as central player during pressure-overload induced cardiac hypertrophy and was shown
to be important for synaptic plasticity for example (Takefuji et al., 2013; Kempf et al., 2014).
Additionally, both pathways were shown to regulate vascular smooth muscle tone.
In contrast to this broad functional knowledge, only little was known about why RhoGEFs are
activated by two different Gα subtypes and how the signal is integrated within each as well as
between both pathways. Even though, this dictates the sensitivity and duration of the cellular
response to GPCR activation. Such limited information on kinetics and sensitivity of the different
steps in the signaling cascade is a common phenomenon in the research on G protein effector
interactions (4.3.1.2). Thus we successfully established FRET assays for both interactions, Gα13
with LARG and Gαq with p63RhoGEF, and resolved formation and dissociation of these
complexes with high temporal and spatial resolution in the present work. Key findings were
prolonged interaction between LARG and Gα13, which was accompanied by a higher sensitivity of
the LARG Gα13 interaction compared to Gα13 activation. Contrastingly, the p63RhoGEF Gαq
interaction closely resembled Gαq activation kinetics and sensitivity. This was also true for a
trimeric complex of p63RhoGEF and Gαq together with RGS2, which dissociated fast due to
accelerated Gαq inactivation by RGS2.
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7.1 Activation of RH-RhoGEFs by Gα13
In the first part of this study we were able to elucidate the dynamics of the interaction between a
RH-RhoGEF and Gα13 in intact, living cells for the first time. Interestingly, upon agonist wash-out the
dissociation of LARG and Gα13 is more than 20-fold delayed compared to Gα13 inactivation (long
effector binding in fig. 41). Such a prolonged effector binding influences the equilibrium of Gα-GDP
and Gα-GTP towards Gα-GTP compared to the absence or short binding of an effector. This results in
a left shift of the concentration response curve (fig. 41). Thus we think the prolonged interaction is the
most likely reason for the observed almost 100-fold higher sensitivity towards Txa2-R activation of the
RH-RhoGEF G protein interaction compared to the G protein activation (II). Noteworthy, this new
insights on the LARG Gα13 interaction were acquired with carefully validated FRET assays (I).
(I) The FRET between YFP-LARG and Gα13-mTur2 increased rapidly and robust upon stimulation
with small concentrations of U46619 (10nM, fig. 19A-C). This FRET increase reflects the interaction
between LARG and Gα13 with high temporal and spatial specificity and the used LARG constructs
behave most likely like wild type in regard to Gα13 interaction as shown in the following:
Upon agonist stimulation a robust increase in FRET was observed between Gα13-mTur2 and
YFP-LARG. Nevertheless no increase in FRET was observed between either YFP-LARG and
membrane bound CFP in the presence of Gα13 or between Gα13-mTur2 and the Gαq effector
Venus-p63RhoGEF (fig. 19C and D). These data point towards a FRET signal caused by interaction of
Gα13 and LARG rather than by close proximity at the plasma membrane, which would be described as
bystander FRET.
LARG was found cytosolic in the absence of an agonist, which activates Gα13 coupled receptors, and
at the plasma membrane upon stimulation (Meyer et al., 2008). Also YFP-LARG as well as
LARG-insYFP were found in the cytosol if transfected alone (fig. 26A, (Bodmann, diploma thesis)) or
if YFP-LARG was transfected together with Txa2-R, Gα13-wt, Gβ and Gγ in the absence of agonist
(fig. 18B). Thus before stimulation YFP-LARG and Gα13-mTur2 are localized in two different regions
Fig. 41 Long effector binding results in left shift in concentration response curve
During activation Gα is balanced between three states (left to right): the GTP- and effector-bound, the GTP-bound and
the GDP-bound state. If an effector exhibits short Gα bind (blue), the equilibrium between the GTP-bound and the
GDP-bound state is not influenced and thus the concentration response curve is unchanged compared to no effector
binding (purple). But if an effector exhibits prolonged Gα binding (red), the equilibrium is shifted towards the left and
thus also the concentration response curve.
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of the cell, cytosol and plasma membrane, respectively. This is of great importance as Carter and
colleagues showed recently enhanced RhoGEF activity of PDZ-RhoGEF and p115-RhoGEF by their
artificial translocation to the plasma membrane (Carter et al., 2014).
YFP-LARG translocated reliably to the plasma membrane upon stimulation with U46619 (fig. 18A
and B). This translocation depended strictly on activation of a substantial quantity of Gα13 proteins as
no translocation was detected with endogenous Gα13 alone (fig. 18C and D). In line with this no
agonist dependent bystander FRET was observed between LARG-insYFP and membrane bound CFP
in the absence of Gα13 (fig. 20C). Whereas bystander FRET was shown between both proteins, if Gα13
was cotransfected (fig. 20B). This is caused by LARG-insYFP translocation to the plasma membrane
upon activation of cotransfected Gα13 and thus LARG-insYFP and mCFP were close enough for FRET
to occur. Of note, the FRET amplitude of the LARG-insYFP Gα13-mTur2 FRET was larger than the
one between LARG-insYFP and mCFP, suggesting a closer proximity between LARG-insYFP and
Gα13-mTur2 due to direct interaction. Thus we were able to monitor the LARG Gα13 interaction with
two LARG constructs. Since both constructs behaved similarly in terms of kinetic of the FRET signal
with Gα13 (fig. 24), the measured kinetics are most likely not changed by the localization of the
fluorophore within LARG (see (II) for further validation of kinetics).
In order to characterize Gα13-dependent signaling downstream of LARG we tried to detect RhoA
activation and SRE.L transcription. In most experiments we could not reliably express wild type LARG
over levels of endogenous expression, whether a Flag-tagged or one of two different wild type constructs
were transfected (fig. 26). Consequently no stable Gα13 dependent transcriptional activation downstream
of LARG could be detected and we were not able to directly compare our fluorophore-labeled LARG
versions to wild type LARG (fig. 28). Only in one SRE.L reporter gene assay wild type LARG was
expressed over endogenous levels and in this assay a clear Gα13 dependent transcription was induced by
wild type LARG as well as YFP-LARG (fig. 29). Also the determination of active RhoA was impeded
by the variable wild type LARG overexpression level (fig. 27). In addition this assay is prone to artefacts
due to unequal amounts of the predator of RhoA affinity purification, RBD, between different conditions
within one assay. To the author´s knowledge only a few studies were published so far using
overexpressed wild type LARG, but considerably more studies on LARG knock-down (e.g. (Goulimari
et al., 2008; Guilluy et al., 2010; Chiu et al., 2012; Lessey-Morillon et al., 2014)): Two studies used wild
type LARG overexpression in SRE.L reporter gene assays, but they did not show overexpression by
Western Blot (Aittaleb et al., 2009; Pfreimer et al., 2011). Further one study showed LARG
overexpression in HEK293T cells, but in this case neither the LARG plasmid used nor the DNA amount
was described (Mikelis et al., 2013). Since this low number of studies contrasts the total number of
studies on LARG, overexpression of LARG might be challenging. In summary, we could characterize
signaling downstream of LARG neither in general nor could compare wild type and YFP-labeled LARG
in this regard. Thus it remains open whether YFP-LARG behaves exactly like wild type for the whole
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signaling pathway from GPCR to RhoA and further downstream. But we are confident, that our LARG
Gα13 FRET assay reflects their interaction in living cells.
The activation of Gα13 was elucidated and validated by A-L. Krett (unpublished data). Also we found
a robust increase in FRET between Gα13-YFP and Gβ-Cer (fig. 21A). Most data on trimeric G proteins
suggested the dissociation of Gα and Gβγ upon stimulation, but different approaches showed a
rearrangement for Gαi rather than dissociation (4.3.1.1, (Bünemann et al., 2003; Frank et al., 2005;
Digby et al., 2006; Galés et al., 2006)). The same seem to be the case for Gα13, as the FRET amplitude
increased upon activation of Gα13 by U46619. In line with the rearrangement of the trimeric G protein,
the unstimulated G protein already showed basal FRET, as elucidated by donor recovery after acceptor
photobleaching (fig. 22).
(II) Notably, the activation of Gα13 was quickly and completely reversible upon agonist wash-out
(t1/2 17.50s). This contrasted to the slow dissociation of LARG and Gα13 upon agonist wash-out
(fig. 22B). Nevertheless the fast inactivation measured for Gα13 was in line with the inactivation
kinetics measured for other G proteins (t1/2 Gαi: 30s (Bünemann et al., 2003), Gαq: 48s (Wolters et al.,
under revision)). The slow dissociation of Gα13 and LARG was validated by three approaches:
The slow dissociation between LARG and Gα13 was observed in two, individual FRET assays, which
used LARG constructs with YFP inserted in different sites (fig. 24A and B). Therefore if the YFP-tag
would increase affinity of LARG to Gα13, this effect would have to be independent of the place of
insertion. This is not likely, because for example the fluorophore-tag on p63RhoGEF did not lead to a
prolonged interaction with Gαq, as discussed in 7.2.
Additionally, the slow dissociation of LARG and Gα13 was mirrored by slow redistribution of LARG
into the cytosol upon agonist wash-out. This was monitored by translocation experiments with wild
type and mTur2-labeled Gα13 (fig. 24C). This excludes an artificial change in dissociation kinetic by
the mTur2 insertion into Gα13. Noteworthy, p115RhoGEF redistributed more quickly into the cytosol
upon inactivation of Gα13 with the PAR-1 antagonist SCH 79797 (Meyer et al., 2008).
Even though the dissociation of LARG and Gα13 is slow, this process is still reversible. As indicated
by a second FRET increase and translocation upon stimulation with agonist after wash-out for ten
minutes (fig. 24). Additionally the second translocation was not significantly different from the first
one. Further the Gα12 protein family is activated by a wide variety of agonists, which are for example
present in cell culture medium. Therefore most likely Gα13 had already been activated during cell
culture in preparation of the conducted experiments. Consequently irreversible interaction of Gα13 and
LARG would have led to constitutive localization of LARG to the plasma membrane, which we could
not detect (fig. 18A, and 24C).
Hence, Gα13 and LARG dissociate, but much slower than Gα13 inactivates. Such a kinetic difference in
G protein inactivation compared to effector G protein dissociation was not described before, except
recent findings for Gαi and adenylyl cyclase V (Milde et al., 2013). In this study they could show a left
shift in concentration response relationship of adenylyl cyclase V-Gαi interaction compared to Gαi
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activation. The authors suggested the prolonged interaction as reason for the sensitization of interaction
(Milde et al., 2013). Previous to these experiments cAMP-dependent signaling had been proven more
sensitive to agonist stimulation than G protein mediated processes (Li et al., 1994). Also RhoA, an
effector of RhoGEF activation by Gα13, was completely activated by small agonist concentrations (10nM
U46619) in mice platelets (Moers et al., 2003). Whereas Gα13 was activated with an EC50 of 600nM in
human platelets (Offermanns et al., 1994). So the EC50 values for Gα13 and RhoA activation differ in
platelets and we showed slow dissociation of Gα13 and LARG. Consequently, the interaction of Gα13 and
LARG was found more sensitive to U46619 than Gα13 activation in a concentration response curve
(fig. 23): The EC50 value for Gα13 activation was almost 100-fold higher than for the Gα13-mTur2
YFP-LARG interaction, as measured by FRET (32.55nM and 0.30nM, respectively). FRET between
Gα13-mTur2 and LARG-insYFP was even more sensible to agonist application, but this was maybe
overestimated. Since the maximal FRET amplitude of the LARG-insYFP Gα13-mTur2 FRET was
smaller than for the YFP-LARG Gα13-mTur2 FRET and thus the measurement error of amplitude
evaluation was larger for submaximal responses. The small amplitude could be caused either by the
distance of the fluorophores during LARG Gα13 interaction or by low expression of LARG-insYFP
compared to Gα13-mTur2. Since we could only detect LARG-insYFP in the range of wild type LARG by
means of Western Blot (fig. 26B), the latter problem could well have occurred. But we could neither
exclude the first because no LARG Gα13 crystal structure is available, which would allow for an
educated guess on the distance of the fluorophores within the complex. In future one could further
validate the shift in concentration response relationship by use of the FlAsH (fluorescein arsenical
hairpin binder) -tag technology (Hoffmann et al., 2005). This tag encodes for six amino acids binding
specifically the small fluorescent probe FlAsH, which can be used in a FRET pair with CFP. Thus the
findings with YFP-LARG/ LARG-insYFP and Gα13-mTur2 could be confirmed by FRET between
FlAsH-LARG and Gα13-mTur2.
For the first time the interaction between Gα13 and an effector was investigated in intact cells. Upon
activation of Txa2-R the RH-RhoGEF LARG translocates quickly to the plasma membrane, where it
interacts with active Gα13. This interaction is more sensitive to agonist stimulation than the G protein
activation, which is most likely caused by the observed prolonged interaction of LARG and Gα13
compared to Gα13 inactivation. We were not yet able to determine whether the prolonged interaction is
caused by delayed inactivation of Gα13 by LARG coexpression or if LARG is still bound to Gα13 after
deactivation. A crystal structure and biochemical data by others may indirectly support the latter idea:
Gα13-GDP seems to be able to bind PDZ-RhoGEF, since a crystal structure of both in complex was
resolved (Chen et al., 2008). Interestingly, Gα13 adopted despite GDP binding an active-like
conformation in this structure, and for PDZ-RhoGEF no GAP activity towards Gα13 could be shown,
which was shown for LARG (Kozasa et al., 1998; Wells et al., 2002; Suzuki et al., 2003). Thus the
direct correlation of this crystal structure to the prolonged Gα13 LARG interaction might be
challenging. Yet the accelerated Gα13 inactivation by LARG in vitro might support the interaction of
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Gα13-GDP and LARG by itself. Because if the Gα13 LARG interaction is strictly limited by Gα13
inactivation and LARG exhibits GAP activity towards Gα13 also in living cells, we should have seen
the opposite of what we saw. Precisely, the LARG Gα13 dissociation should have occurred faster than
the Gα13 inactivation in the absence of LARG. In future the influence of LARG on Gα13 activation
could be tested in our Gα13 Gβγ FRET. We were not able to reliably detect wild type LARG over
endogenous levels in HEK293T cells by means of Western Blot (fig. 26 upper panel and discussed
above). Thus it will be hard to control for a feasible proportion of wild type LARG transfected
together with the Gα13 Gβγ FRET pair. Therefore a LARG construct labeled with RFP might be used
to control for high LARG expression in the measured cells.
Interestingly, RhoA-GTP binds directly to the PH domains of Lbc-RhoGEFs and accelerates the
RhoGEF activity (Medina et al., 2013). Therefore we wondered if a LARG mutant deficient in
Rho-GTP binding (F1098A and I1100E) shows an increase in FRET upon stimulation with a small
agonist concentration (5nM U46619) and if the interaction with Gα13 is prolonged. Since the FRET
response appeared similar to wild type LARG in terms of amplitude and response, either RhoA-GTP
binding is not involved in the prolonged LARG Gα13 interaction or the mutant is not RhoA-GTP
binding deficient in living cells (fig. 25). Also mDia1 interaction with the C-terminus of LARG was
discussed as positive feedback loop (Goulimari et al., 2008). So maybe it would be worthwhile to
study the influence of mDia1 on the LARG Gα13 interaction. Nevertheless until now the mechanistic
reason for prolonged interaction of Gα13 and LARG remains elusive and should be studied in detail
next, e.g. with the Gα13 Gβγ FRET assay.
7.2 Dynamics of the Gαq p63RhoGEF RGS2 complex
GPCRs can activate RhoA not only through Gα13 and RH-RhoGEFs, but in addition through Gαq and
p63RhoGEF. Many GPCRs couple to both Gαq and Gα13 at the same time and thus we were also
interested in the RhoGEF activation downstream of Gαq (Riobo and Manning, 2005). Previous to this
study, biochemical data pointed towards an influence of RGS2 on Gαq and p63RhoGEF, thus we
investigated the putative p63RhoGEF Gαq RGS2 complex in detail (Shankaranarayanan et al., 2008;
Bodmann et al., 2014). The work resolved (I) the dynamics of the activation dependent interaction of
Gαq and p63RhoGEF and (II) the impact of RGS2 on this complex in single living cells. We found the
interaction of a portion of Gαq p63RhoGEF complexes with RGS2. In these trimeric complexes RGS2
accelerates the dissociation and partially inhibits signaling downstream of p63RhoGEF.
(I) We developed a FRET assay between the plasma membrane-bound proteins Gαq-CFP and
Venus-p63RhoGEF (fig. 31A). This FRET assay monitors the activity dependent interaction between Gαq
and p63RhoGEF (Shankaranarayanan et al., 2010). The activation of Gαq coupled receptors resulted in a
rapid and robust increase in FRET, which was fully reversible upon agonist wash-out (fig. 31A-D). The
spatial specificity of this FRET approach was verified by three means: First, upon stimulation with agonist
an increase in FRET was only observed between Gαq-CFP and V-p63RhoGEF, but neither between
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Venus-p63RhoGEF and CFP-labeled Gαi nor between Gαq-CFP and GIRK4-YFP (fig. 31D and F).
Second, DAG activation downstream of PLCβ was abolished by p63RhoGEF cotransfection (fig. 33C).
This was expected, since both proteins were described to bind to the canonical effector binding site at Gαq
(2.3.1.1, (Lutz et al., 2007; Waldo et al., 2010)). The affinity of p63RhoGEF towards this binding site
seems to be higher than PLCβ3´s affinity, as PLCβ3 cotransfection did not alter the Gαq p63RhoGEF
interaction as investigated by FRET (fig. 33D). Third, the FRET amplitude and rate of responding cells
was reduced by two mutations in p63RhoGEF (Bodmann, diploma thesis). These mutations lie within the
Gαq binding PH domain of p63RhoGEF and mutation of either of them abolished interaction of Gαq and a
truncated p63RhoGEF variant (amino acid 149-502) in vitro (Lutz et al., 2007; Rojas et al., 2007). Also
downstream signaling was reduced, as we observed significantly reduced SRE.L activation in the
presence of these mutations (fig. 32). These data validate the p63RhoGEF Gαq FRET assay as tool to
detect specifically and affinity-dependent the interaction of p63RhoGEF and Gαq in living cells.
Additionally, the p63RhoGEF activation was closely linked to receptor activation: In vitro only active
Gαq interacted with p63RhoGEF (Lutz et al., 2005, 2007). In line with this we could not detect donor
recovery after acceptor photo bleaching for the Gαq p63RhoGEF FRET pair in the absence of agonist
(Bodmann et al., 2014). Further the fast dissociation kinetic of Gαq and p63RhoGEF closely resembled
the Gαq inactivation, as measured by Gαq Gβγ FRET (fig. 31C and 35). The same was true for the
PLCβ3 Gαq dissociation, even though the dissociation and the Gαq inactivation were accelerated by
PLCβ3´s intrinsic GAP activity towards Gαq (fig. 33A and (Pollinger, 2012)). For p63RhoGEF this
shows again the low affinity towards inactive Gαq and fits to the observation of equal EC50 values of
Gαq activation and Gαq´s interaction with p63RhoGEF (fig. 36). Importantly, the Gαq activation cycle
is not altered by cotransfection of p63RhoGEF (fig. 35). Thus the Gαq p63RhoGEF FRET assay
reflects the real p63RhoGEF Gαq interaction in living cells, since the same amounts of p63RhoGEF
were used for both assays.
(II) Previously RGS2 was shown to reduce p63RhoGEF´s affinity to Gαq in vitro and to decrease
SRE.L activation downstream of p63RhoGEF activation by M3-R (Lutz et al., 2007;
Shankaranarayanan et al., 2010). Also we found reduced RhoA activation and SRE.L transcription
downstream of p63RhoGEF in response to RGS2 expression(fig. 40, (Bodmann et al., 2014)). These
studies were conducted with our fluorophore labeled constructs, which additionally validates their
functionality in respect to up- and downstream signaling. Thus RGS2´s GTPase activity towards Gαq
reduces p63RhoGEF signaling. Most likely RGS2 conducts its negative regulatory function in a
trimeric complex of RGS2 Gαq p63RhoGEF, as we could show such a complex with high steric and
temporal resolution: (A) Gαq inactivated faster in the presence of RGS2, due to RGS2´s GTPase
activity (fig. 35). This was also seen if p63RhoGEF was cotransfected in addition. Consequently,
RGS2 accelerated also the dissociation of p63RhoGEF and Gαq (fig. 34). Noteworthy, the accelerated
inactivation and dissociation did not result in changes in the EC50 values of Gαq activation or its
interaction with p63RhoGEF (fig. 36). (B) The interaction of RGS2 and Gαq occurred fast upon
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stimulation with agonist and was fully reversible upon agonist wash-out (fig. 37). This interaction is
not affected by p63RhoGEF, as neither the dissociation kinetic nor the amplitude was significantly
changed. Therefore, we conclude that p63RhoGEF does not, or only slightly, changes orientation of
RGS2 towards Gα, since this would most probably result in a change in FRET amplitude. (C) In
addition to interaction of either RGS2 or p63RhoGEF with Gαq, also the close proximity of RGS2 and
p63RhoGEF could be shown by means of FRET (fig. 38). Upon stimulation of H1-R with agonist the
trimeric complex was formed, which resulted in a small, robust and rapid increase in FRET between
RGS2-YFP and p63RhoGEF-CFP. This FRET change was fast reversible upon agonist wash-out and
dependent on the interaction of p63RhoGEF and Gαq. As a Gαq binding deficient p63RhoGEF mutant
did not show FRET with RGS2 (fig. 38D). The small amplitude of the FRET change is probably
caused by the big distance between the two fluorophores in the trimeric complex.
The formation of a trimeric p63RhoGEF Gαq RGS2 complex is in contrast to the inhibition of
PLCβ3´s Gαq binding by RGS2: PLCβ3 and RGS2 bind to an overlapping binding site at Gαq as
visible in crystal structures of both proteins with Gαq (fig. 8, (Waldo et al., 2010; Nance et al., 2013)).
This overlap excludes their simultaneous binding to Gαq. Consequently RGS2 abolished interaction of
Gαq and PLCβ3 and DAG production as determined by FRET (fig. 33A and B).
Within a living cell probably two populations of Gαq p63RhoGEF complexes exist. The one includes
RGS2 and the other does not. This cannot be observed by one FRET assay as FRET monitors the
overall populations of complexes in one cell instead of single complexes. Nevertheless the two
populations are visible if kinetics are compared for all four FRET assays, which monitor the members
of the trimeric complex with all three complex members cotransfected (fig. 39): FRET assays, which
use RGS2 as FRET partner, monitor exclusively RGS2 containing complexes. Whereas the other two
FRET assays monitor complexes with and without RGS2. In the second condition the observed
kinetics result from the mean of fast and slow Gαq inactivation, which are due to presence and absence
of RGS2 in the individual complexes within one measured cell. Consequently the FRET assays with
RGS2-YFP show faster kinetics than the other FRET assays.
For the first time we were able to analyze the p63RhoGEF Gαq interaction with the p63RhoGEF Gαq
FRET assay in intact, living cells. In the meantime Goedhardt and colleagues also developed a similar
FRET assay (Goedhart et al., 2013). They did not wash-out the agonist but used an inverse agonist
instead. With their study they focused on the localization of p63RhoGEF due to palmitoylation.
Whereas we elucidated the spatial as well as temporal behavior of this complex: The p63RhoGEF Gαq
interaction strictly depends on Gαq activation and is therefore terminated by Gαq inactivation. If RGS2
is expressed, the signaling downstream of this complex is diminished. This negative regulation does
not occur through competition of RGS2 and p63RhoGEF for the same binding site, as RGS2 and
p63RhoGEF were found in close proximity during Gαq activation. But rather through accelerated
inactivation of Gαq by RGS2 in a trimeric complex with p63RhoGEF.
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7.3 Differences and similarities in RhoGEF activation downstream of Gαq and
Gα13 and their physiological implications
Many receptors couple to Gαq/11 and Gα12/13 as reviewed in detail elsewhere (Riobo and Manning,
2005). Thus p63RhoGEF downstream of Gαq as well as RH-RhoGEFs downstream of Gα12/13 may be
activated by the same GPCR. LARG and p63RhoGEF are involved in many physiological and
pathophysiological pathways. LARG was found for example to repress synaptic plasticity, to be
overexpressed in patients suffering from the pre-leukemic Shwachman-Diamon syndrome and seemed
to be a central player during pressure-overload induced hypertrophy (Rujkijyanont et al., 2007;
Takefuji et al., 2013; Kempf et al., 2014). For p63RhoGEF involvement in chemotactic migration of
breast carcinoma cells was found and it was described as the target of a bacterial toxin, which can
cause atrophic rhinitis (Hayashi et al., 2013; Siegert et al., 2013). Both RhoGEFs and also the other
RH-RhoGEFs are involved in blood pressure regulation (see 2.7). Therefore contraction of vascular
smooth muscle cells was used as a model for their cross-talk in the following. The present work found
the p63RhoGEF Gαq interaction and therefore most likely activation of p63RhoGEF completely
dependent on Gαq activation. This included the duration of p63RhoGEF activation as well as the EC50
of the Gαq p63RhoGEF interaction, which is similar to the EC50 of Gαq activation. In contrast to this
the LARG Gα13 interaction is almost 100-fold more sensitive than the Gα13 activation and also the
interaction of LARG and Gα13 is substantially prolonged upon agonist wash-out compared to Gα13
inactivation. These studies were done with two different receptors and the H1-R is not of special
importance for regulation of vascular tone. Therefore, a study on both signaling pathways downstream
of a receptor coupling to both, Gαq and Gα12/13, would be interesting, for example the angiotensin 1
receptor. This receptor was implicated in vascular tone regulation by p63RhoGEF as well as
RH-RhoGEFs (Guilluy et al., 2010; Calò et al., 2014). With such a study one would get an idea about
the difference in agonist sensitivity and whether LARG activation leads to prolonged signaling
compared to p63RhoGEF activation. This would be of special interest, since both pathways are
regulated to different degrees:
p63RhoGEF is the primarily Gαq-activated RhoGEF in VSMCs, as such a function has not been
described for Trio or Kalirin yet (Schmidt and Debant, 2014). Further the activation of p63RhoGEF is
tightly, negatively regulated by RGS2, as elucidated in detail by the present study. Gαq and p63RhoGEF
interaction leads most probably to RhoA activation only if RGS2 is not part of a trimeric complex and
this is maybe dependent on RGS2 expression level (see 7.2). This would fit to the findings in
hypertensive patients: RGS2 expression is downregulated in hypertensive patients and SNPs, which
negatively influence RGS2 expression, are associated with hypertension (Calò et al., 2004; Riddle et al.,
2006; Semplicini et al., 2006; Bodenstein et al., 2007). Thus the expression level of RGS2 seems to be of
critical relevance for RhoA activation downstream of Gαq and p63RhoGEF.
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In contrast, redundancy was shown for the RH-RhoGEFs LARG and PDZ-RhoGEF in terms of Ca2+
sensitization in VSMCs (Artamonov et al., 2013). Additionally, RGS2 will not affect Gα13 signaling
directly, as it is a GAP specific for Gαq and probably to a smaller extent Gαi (Heximer et al., 1999). For
LARG and the other RH-RhoGEFs further regulatory mechanisms were described, but their impact on
vascular tone has not been studied yet.
Besides their relevance towards a better understanding of signaling upstream of RhoA, this data is also
important for the general understanding of G protein effector relationships. Because many G protein
effectors have been described, but the kinetics of their interaction with and activation by G proteins has
barely been studied. Of note, such direct correlations of G protein inactivation to G protein effector
interactions were challenging in regard to study design for a long time (4.3.1.2). As determination of
kinetics by biochemical assays might be distorted by experimental parameters, which can differ
substantially from intracellular conditions. For example in the first in vitro experiments inactivation of Gαt
and its effector PDE was considerably slow, but upon increase in protein concentration and temperature
towards more physiological levels, also inactivation kinetics were determined in the physiological range
(Arshavsky V. Yu. et al., 1989). In this regard G protein effectors, which are ion channels, were easier to
address as their activation and inactivation can be monitored by patch-clamp in living cells. For example
the activity of GIRK channels upon stimulation was measured by this method and resembled closely Gαi
activation as determined by FRET later (Dascal, 1997; Bünemann et al., 2003). Also the kinetics of Gαq
interaction with its effectors GRK2 and PLCβ3 resemble strictly Gαq activation as measured by means of
FRET (Wolters et al., under revision and (Pollinger, 2012)). Further we could show the same for the
p63RhoGEF Gαq interaction. But the G protein effector interactions do not necessarily have to resemble
G protein action as prolonged interaction was shown for adenylyl cyclase V with Gαi before (Milde et al.,
2013). Additionally, the LARG Gα13 interaction seems to be an example of prolonged interaction and
maybe other G protein effector pairs share this phenotype. Remarkably, in both cases of prolonged
interaction, a shift in concentration response relationship was found. Hence, this new described phenotype
might influence sensitivity of other G protein effector interactions as well. In the future kinetic and
sensitivity of other G protein effector pairs should be studied in order to reveal the prevalence and
physiological relevance of prolonged G protein effector interactions. Furthermore, data would be
desirable, which clarify the mechanism of prolonged interaction.
In summary, LARG either slows down Gα13 inactivation or stays in complex with inactive Gα13.
However, this prolonged interaction might result in higher sensitivity of the LARG Gα13 interaction.
Whether or not this phenotype is a common mode of G protein effector interaction has to be validated
with other G protein effector pairs in the future. In vascular smooth muscle cells LARG might induce
prolonged activation of downstream signaling in response to small changes in agonist due to this
phenotype. Whereas p63RhoGEF may ensure constant basal tone by quick and short responses to major
changes in physiological stimuli and this is further fine-tuned through the highly regulated RGS2. Of
course this hypothesis has to be tested in VSMCs in the future.
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